,docid,isValid,passage,passageid
0,AIMed.d0,False,"Cytokines measurements during IFN-alpha treatment showed a trend to decreasing levels of IL-4 at 4, 12, and 24 weeks.",AIMed.d0.s5
1,AIMed.d0,False,Levels of IFN-gamma were slightly increased following IFN-alpha treatment (P = 0.09).,AIMed.d0.s6
2,AIMed.d0,False,"In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.",AIMed.d0.s7
3,AIMed.d0,False,"In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.",AIMed.d0.s7
4,AIMed.d0,False,"In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.",AIMed.d0.s7
5,AIMed.d0,False,"In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.",AIMed.d0.s7
6,AIMed.d0,False,"In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.",AIMed.d0.s7
7,AIMed.d0,False,"In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.",AIMed.d0.s7
8,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
9,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
10,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
11,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
12,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
13,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
14,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
15,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
16,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
17,AIMed.d1,False,"This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing ""cartilage cap"" of osteochondroma.",AIMed.d1.s12
18,AIMed.d1,False,"BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and Col II, respectively.",AIMed.d1.s14
19,AIMed.d1,False,"BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and Col II, respectively.",AIMed.d1.s14
20,AIMed.d1,False,"BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and Col II, respectively.",AIMed.d1.s14
21,AIMed.d1,False,This is the first study to provide observational evidence of the involvement of BMP-2 signaling in the pathogenesis of cartilage cap of osteochondroma. and suggests the role of BMP-2 in the growth of cartilage cap in osteochondroma.,AIMed.d1.s16
22,AIMed.d2,False,The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.,AIMed.d2.s17
23,AIMed.d2,False,The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.,AIMed.d2.s17
24,AIMed.d2,False,The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.,AIMed.d2.s17
25,AIMed.d2,False,The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.,AIMed.d2.s17
26,AIMed.d2,False,The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.,AIMed.d2.s17
27,AIMed.d2,False,The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.,AIMed.d2.s17
28,AIMed.d2,False,OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.,AIMed.d2.s18
29,AIMed.d2,False,OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.,AIMed.d2.s18
30,AIMed.d2,False,OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.,AIMed.d2.s18
31,AIMed.d2,False,OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.,AIMed.d2.s18
32,AIMed.d2,False,OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.,AIMed.d2.s18
33,AIMed.d2,False,OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.,AIMed.d2.s18
34,AIMed.d2,False,"DESIGN: We took advantage of previously collected data during a randomised double-blind, placebo-controlled clinical trial to conduct a secondary analysis of the RBP/TTR ratio and its relationship to infection and VA status.",AIMed.d2.s19
35,AIMed.d2,False,MAIN OUTCOME MEASURES: RBP/TTR molar ratio after 7 days hospitalisation.,AIMed.d2.s23
36,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
37,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
38,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
39,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
40,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
41,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
42,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
43,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
44,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
45,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
46,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
47,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
48,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
49,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
50,AIMed.d2,False,"RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.",AIMed.d2.s24
51,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
52,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
53,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
54,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
55,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
56,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
57,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
58,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
59,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
60,AIMed.d8,False,"Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.",AIMed.d8.s60
61,AIMed.d8,False,"The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.",AIMed.d8.s61
62,AIMed.d8,False,"The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.",AIMed.d8.s61
63,AIMed.d8,False,"The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.",AIMed.d8.s61
64,AIMed.d8,False,"The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.",AIMed.d8.s61
65,AIMed.d8,False,"The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.",AIMed.d8.s61
66,AIMed.d8,False,"The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.",AIMed.d8.s61
67,AIMed.d8,False,"These cell lines showed mutations in K-ras and p53 at frequencies of 91% and 95%, respectively.",AIMed.d8.s63
68,AIMed.d8,False,"The most typical mutational profile involved K-ras, p53, and p16INK4a, concurrently aberrated in 20 cases (91%).",AIMed.d8.s66
69,AIMed.d8,False,"The most typical mutational profile involved K-ras, p53, and p16INK4a, concurrently aberrated in 20 cases (91%).",AIMed.d8.s66
70,AIMed.d8,False,"The most typical mutational profile involved K-ras, p53, and p16INK4a, concurrently aberrated in 20 cases (91%).",AIMed.d8.s66
71,AIMed.d9,False,We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor (CaR).,AIMed.d9.s73
72,AIMed.d9,False,We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor (CaR).,AIMed.d9.s73
73,AIMed.d9,False,We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor (CaR).,AIMed.d9.s73
74,AIMed.d9,False,Our results demonstrated that CaR was expressed in human gastrinoma cells and could be involved in the mechanism of calcium-evoked gastrin release.,AIMed.d9.s80
75,AIMed.d10,False,BMP-4 and BMP-6 involvement in the osteogenic properties of the HeLa cell line.,AIMed.d10.s81
76,AIMed.d10,False,We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins BMP-4 and BMP-6 by the grafted HeLa cells.,AIMed.d10.s84
77,AIMed.d12,False,Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.,AIMed.d12.s96
78,AIMed.d12,False,Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.,AIMed.d12.s96
79,AIMed.d12,False,Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.,AIMed.d12.s96
80,AIMed.d12,False,MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.,AIMed.d12.s102
81,AIMed.d12,False,MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.,AIMed.d12.s102
82,AIMed.d12,False,MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.,AIMed.d12.s102
83,AIMed.d12,False,"RESULTS: In the blister fluid of patients with TEN, we found significantly higher levels of sIL-2R than in patients with burns, whereas IL-1alpha levels were higher in the blister fluid of burned patients.",AIMed.d12.s103
84,AIMed.d12,False,"No significant differences were found in serum samples of patients with TEN and burns, in either sIL-2R or IL-1alpha.",AIMed.d12.s104
85,AIMed.d12,False,"In TEN we also found significantly higher levels of sIL-2R in the blister fluid compared with serum samples, pointing to a predominantly local production contrasting with the low concentration of sIL-2R in the blister fluid of burned patients.",AIMed.d12.s105
86,AIMed.d14,False,Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.,AIMed.d14.s117
87,AIMed.d14,False,Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.,AIMed.d14.s117
88,AIMed.d14,False,Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.,AIMed.d14.s117
89,AIMed.d14,False,Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.,AIMed.d14.s117
90,AIMed.d14,False,Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.,AIMed.d14.s117
91,AIMed.d14,False,Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.,AIMed.d14.s117
92,AIMed.d14,False,"Correlations between GFAp and NFL in CSF as markers for astrogliosis and neurodegeneration, and clinical and biological data were investigated.",AIMed.d14.s118
93,AIMed.d14,False,"Abnormal levels of GFAp and NFL were significantly associated with increasing CSF cell number and protein concentration, and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate.",AIMed.d14.s119
94,AIMed.d15,False,"We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.",AIMed.d15.s126
95,AIMed.d15,False,"We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.",AIMed.d15.s126
96,AIMed.d15,False,"We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.",AIMed.d15.s126
97,AIMed.d15,False,"We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.",AIMed.d15.s126
98,AIMed.d15,False,"We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.",AIMed.d15.s126
99,AIMed.d15,False,"We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.",AIMed.d15.s126
100,AIMed.d15,False,"MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.",AIMed.d15.s128
101,AIMed.d15,False,"MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.",AIMed.d15.s128
102,AIMed.d15,False,"MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.",AIMed.d15.s128
103,AIMed.d15,False,"MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.",AIMed.d15.s128
104,AIMed.d15,False,"MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.",AIMed.d15.s128
105,AIMed.d15,False,"MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.",AIMed.d15.s128
106,AIMed.d15,False,"Interferon-gamma, IL-2 and IL-10 levels were statistically greater in patients.",AIMed.d15.s131
107,AIMed.d15,False,"Interferon-gamma, IL-2 and IL-10 levels were statistically greater in patients.",AIMed.d15.s131
108,AIMed.d15,False,"Interferon-gamma, IL-2 and IL-10 levels were statistically greater in patients.",AIMed.d15.s131
109,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
110,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
111,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
112,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
113,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
114,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
115,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
116,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
117,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
118,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
119,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
120,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
121,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
122,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
123,AIMed.d16,False,"METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.",AIMed.d16.s136
124,AIMed.d16,False,"Expressions of TH, AADC and GCH were detected by Western blot analysis.",AIMed.d16.s137
125,AIMed.d16,False,"Expressions of TH, AADC and GCH were detected by Western blot analysis.",AIMed.d16.s137
126,AIMed.d16,False,"Expressions of TH, AADC and GCH were detected by Western blot analysis.",AIMed.d16.s137
127,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
128,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
129,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
130,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
131,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
132,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
133,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
134,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
135,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
136,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
137,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
138,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
139,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
140,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
141,AIMed.d16,False,"RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.",AIMed.d16.s139
142,AIMed.d16,False,"CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.",AIMed.d16.s141
143,AIMed.d16,False,"CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.",AIMed.d16.s141
144,AIMed.d16,False,"CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.",AIMed.d16.s141
145,AIMed.d17,False,This overview summarizes the current knowledge on plasminogen activator inhibitor-1 (PAI-1) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.,AIMed.d17.s146
146,AIMed.d17,False,"In addition, a possible role for Gas6, the product of growth arrest-specific gene 6, in atherosclerotic lesion development is put into perspective.",AIMed.d17.s147
147,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
148,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
149,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
150,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
151,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
152,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
153,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
154,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
155,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
156,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
157,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
158,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
159,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
160,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
161,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
162,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
163,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
164,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
165,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
166,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
167,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
168,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
169,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
170,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
171,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
172,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
173,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
174,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
175,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
176,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
177,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
178,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
179,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
180,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
181,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
182,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
183,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
184,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
185,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
186,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
187,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
188,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
189,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
190,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
191,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
192,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
193,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
194,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
195,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
196,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
197,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
198,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
199,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
200,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
201,AIMed.d18,False,"Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).",AIMed.d18.s151
202,AIMed.d18,False,Endothelin-1 and sP- and sE-selectin levels were not related to function of lymphocytes (by MDM data) as seen in both tests; it is probable that another cell-cell communication mechanism had been switched on.,AIMed.d18.s156
203,AIMed.d18,False,"We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, IL-6, and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.",AIMed.d18.s157
204,AIMed.d18,False,"We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, IL-6, and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.",AIMed.d18.s157
205,AIMed.d18,False,"We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, IL-6, and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.",AIMed.d18.s157
206,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
207,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
208,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
209,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
210,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
211,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
212,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
213,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
214,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
215,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
216,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
217,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
218,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
219,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
220,AIMed.d20,False,"Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.",AIMed.d20.s168
221,AIMed.d22,False,Present data concerning the renin-angiotensin system of extrarenal origin.,AIMed.d22.s181
222,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
223,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
224,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
225,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
226,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
227,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
228,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
229,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
230,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
231,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
232,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
233,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
234,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
235,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
236,AIMed.d22,False,"After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.",AIMed.d22.s182
237,AIMed.d22,False,"In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.",AIMed.d22.s184
238,AIMed.d22,False,"In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.",AIMed.d22.s184
239,AIMed.d22,False,"In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.",AIMed.d22.s184
240,AIMed.d22,False,"While the circulating RAS of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue RAS, in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.",AIMed.d22.s185
241,AIMed.d23,False,"In the present study, we examined the presence of glucocorticoid receptors (GRs) and cyclooxygenase-2 (COX-2) in the nasal polyps of nonallergic patients as compared with normal controls.",AIMed.d23.s189
242,AIMed.d23,False,"In contrast, in normal nasal tissues, COX-2 labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that COX-2 is upregulated in nasal polyps.",AIMed.d23.s194
243,AIMed.d23,False,"Therefore, 1) the presence of GRs and COX-2 in nasal polyps from nonallergic patients, as well as upregulation of COX-2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.",AIMed.d23.s195
244,AIMed.d25,False,"Assaying of tumor necrosis factor alpha, complement factors, and alpha-1-antitrypsin in the diagnosis of malignant serous effusions.",AIMed.d25.s203
245,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
246,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
247,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
248,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
249,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
250,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
251,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
252,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
253,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
254,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
255,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
256,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
257,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
258,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
259,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
260,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
261,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
262,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
263,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
264,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
265,AIMed.d25,False,"The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.",AIMed.d25.s204
266,AIMed.d25,False,"TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.",AIMed.d25.s206
267,AIMed.d25,False,"TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.",AIMed.d25.s206
268,AIMed.d25,False,"TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.",AIMed.d25.s206
269,AIMed.d25,False,"TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.",AIMed.d25.s206
270,AIMed.d25,False,"TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.",AIMed.d25.s206
271,AIMed.d25,False,"TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.",AIMed.d25.s206
272,AIMed.d25,False,"Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.",AIMed.d25.s210
273,AIMed.d25,False,"Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.",AIMed.d25.s210
274,AIMed.d25,False,"Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.",AIMed.d25.s210
275,AIMed.d25,False,"Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.",AIMed.d25.s210
276,AIMed.d25,False,"Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.",AIMed.d25.s210
277,AIMed.d25,False,"Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.",AIMed.d25.s210
278,AIMed.d25,False,"Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.",AIMed.d25.s212
279,AIMed.d25,False,"Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.",AIMed.d25.s212
280,AIMed.d25,False,"Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.",AIMed.d25.s212
281,AIMed.d25,False,"Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.",AIMed.d25.s212
282,AIMed.d25,False,"Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.",AIMed.d25.s212
283,AIMed.d25,False,"Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.",AIMed.d25.s212
284,AIMed.d26,False,Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.,AIMed.d26.s214
285,AIMed.d26,False,Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.,AIMed.d26.s214
286,AIMed.d26,False,Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.,AIMed.d26.s214
287,AIMed.d26,False,"Granulysin has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.",AIMed.d26.s215
288,AIMed.d26,False,"Granulysin has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.",AIMed.d26.s215
289,AIMed.d26,False,"Granulysin has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.",AIMed.d26.s215
290,AIMed.d26,False,The aim of the present study was to elucidate whether intracellular expression of granulysin and perforin by NK cells might be associated with progression of cancer.,AIMed.d26.s216
291,AIMed.d26,False,Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.,AIMed.d26.s217
292,AIMed.d26,False,Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.,AIMed.d26.s217
293,AIMed.d26,False,Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.,AIMed.d26.s217
294,AIMed.d26,False,Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.,AIMed.d26.s217
295,AIMed.d26,False,Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.,AIMed.d26.s217
296,AIMed.d26,False,Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.,AIMed.d26.s217
297,AIMed.d26,False,"In contrast, cancer patients exhibited significantly decreased levels of granulysin expression ( P<0.005), despite having equally high levels of perforin expression in comparison with healthy controls.",AIMed.d26.s218
298,AIMed.d26,False,"The tumor-free patients expressed granulysin at levels similar to healthy controls, while the progressive tumor-bearing patients expressed remarkably lower levels of granulysin compared to healthy controls ( P<0.0001).",AIMed.d26.s219
299,AIMed.d26,False,"In conclusion, impaired expression of granulysin by NK cells correlates with progression of cancer, and determination of granulysin expression might prove informative for assessing the immunological condition of cancer patients.",AIMed.d26.s223
300,AIMed.d27,False,"Activin A, a member of the TGFbeta superfamily, has various effects on diverse biological systems, including cell growth inhibition in many cell types.",AIMed.d27.s226
301,AIMed.d27,False,"Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.",AIMed.d27.s229
302,AIMed.d27,False,"Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.",AIMed.d27.s229
303,AIMed.d27,False,"Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.",AIMed.d27.s229
304,AIMed.d27,False,"Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.",AIMed.d27.s229
305,AIMed.d27,False,"Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.",AIMed.d27.s229
306,AIMed.d27,False,"Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.",AIMed.d27.s229
307,AIMed.d29,False,We have probed an epitope sequence (His18-Pro19-Lys20-Phe21) in interleukin-8 (IL-8) by site-directed mutagenesis.,AIMed.d29.s243
308,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
309,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
310,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
311,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
312,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
313,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
314,AIMed.d29,True,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
315,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
316,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
317,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
318,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
319,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
320,AIMed.d29,True,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
321,AIMed.d29,True,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
322,AIMed.d29,False,This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.,AIMed.d29.s244
323,AIMed.d29,False,These Ala mutants triggered neutrophil degranulation and induced calcium responses mediated by CXCR1 and CXCR2.,AIMed.d29.s245
324,AIMed.d29,False,"Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen.",AIMed.d29.s246
325,AIMed.d29,False,"Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen.",AIMed.d29.s246
326,AIMed.d29,False,"Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen.",AIMed.d29.s246
327,AIMed.d29,False,"This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.",AIMed.d29.s249
328,AIMed.d29,False,"This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.",AIMed.d29.s249
329,AIMed.d29,True,"This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.",AIMed.d29.s249
330,AIMed.d29,False,"This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.",AIMed.d29.s249
331,AIMed.d29,True,"This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.",AIMed.d29.s249
332,AIMed.d29,True,"This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.",AIMed.d29.s249
333,AIMed.d30,True,Isolation of human delta-catenin and its binding specificity with presenilin 1.,AIMed.d30.s250
334,AIMed.d30,True,"We screened proteins for interaction with presenilin (PS) 1, and cloned the full-length cDNA of human delta-catenin, which encoded 1225 amino acids.",AIMed.d30.s251
335,AIMed.d30,False,"Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.",AIMed.d30.s252
336,AIMed.d30,True,"Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.",AIMed.d30.s252
337,AIMed.d30,False,"Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.",AIMed.d30.s252
338,AIMed.d30,False,These results suggest that PS1 and PS2 partly differ in function.,AIMed.d30.s253
339,AIMed.d30,False,"We also found another armadillo-protein, p0071, interacted with PS1.",AIMed.d30.s255
340,AIMed.d30,True,"We also found another armadillo-protein, p0071, interacted with PS1.",AIMed.d30.s255
341,AIMed.d30,False,"We also found another armadillo-protein, p0071, interacted with PS1.",AIMed.d30.s255
342,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
343,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
344,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
345,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
346,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
347,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
348,AIMed.d32,True,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
349,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
350,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
351,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
352,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
353,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
354,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
355,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
356,AIMed.d32,False,Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.,AIMed.d32.s268
357,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
358,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
359,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
360,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
361,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
362,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
363,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
364,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
365,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
366,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
367,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
368,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
369,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
370,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
371,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
372,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
373,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
374,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
375,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
376,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
377,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
378,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
379,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
380,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
381,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
382,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
383,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
384,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
385,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
386,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
387,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
388,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
389,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
390,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
391,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
392,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
393,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
394,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
395,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
396,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
397,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
398,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
399,AIMed.d32,True,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
400,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
401,AIMed.d32,False,We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.,AIMed.d32.s269
402,AIMed.d32,True,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
403,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
404,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
405,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
406,AIMed.d32,True,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
407,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
408,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
409,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
410,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
411,AIMed.d32,False,"Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.",AIMed.d32.s270
412,AIMed.d32,False,We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.,AIMed.d32.s271
413,AIMed.d32,True,We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.,AIMed.d32.s271
414,AIMed.d32,False,We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.,AIMed.d32.s271
415,AIMed.d32,True,We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.,AIMed.d32.s271
416,AIMed.d32,False,We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.,AIMed.d32.s271
417,AIMed.d32,True,We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.,AIMed.d32.s271
418,AIMed.d32,False,"Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.",AIMed.d32.s273
419,AIMed.d32,False,"Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.",AIMed.d32.s273
420,AIMed.d32,False,"Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.",AIMed.d32.s273
421,AIMed.d32,False,"Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.",AIMed.d32.s273
422,AIMed.d32,False,"Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.",AIMed.d32.s273
423,AIMed.d32,False,"Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.",AIMed.d32.s273
424,AIMed.d32,False,"Thus, Phe93 and Phe205 are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.",AIMed.d32.s274
425,AIMed.d32,True,"Thus, Phe93 and Phe205 are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.",AIMed.d32.s274
426,AIMed.d32,True,"Thus, Phe93 and Phe205 are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.",AIMed.d32.s274
427,AIMed.d33,True,Native C8 and C9 formed a heterodimer in solution of physiological ionic strength with a free-energy change DeltaG degrees of -8.3 kcal/mol and a dissociation constant Kd of 0.6 microM (at 20 degrees C) that was ionic strength- and temperature-dependent.,AIMed.d33.s277
428,AIMed.d33,True,"A van't Hoff plot of the change in Kd was linear between 10 and 37 degrees C and yielded values of DeltaH degrees = -12.9 kcal/mol and DeltaS degrees = -15.9 cal mol-1 deg-1, suggesting that electrostatic forces play a prominent role in the interaction of C8 with C9.",AIMed.d33.s278
429,AIMed.d33,True,"Native C8 also formed a heterodimer with C5,and low concentrations of polyionic ligands such as protamine and suramin inhibited the interaction.",AIMed.d33.s279
430,AIMed.d33,False,Suramin induced high-affinity trimerization of C8 (Kd = 0.10 microM at 20 degrees C) and dimerization of C9 (Kd = 0.86 microM at 20 degrees C).,AIMed.d33.s280
431,AIMed.d33,False,Analysis of sedimentation equilibria and also of the fluorescence enhancement of suramin when bound to protein provided evidence for two suramin-binding sites on each C9 and three on each C8 in the oligomers.,AIMed.d33.s282
432,AIMed.d35,False,Most familial early-onset Alzheimer's disease cases are caused by mutations in the presenilin 1 (PS1) gene.,AIMed.d35.s292
433,AIMed.d35,False,"Although numerous studies revealed predominant localization of PS1 to endoplasmic reticulum and Golgi, there are conflicting reports on the localization of PS1 to the cell surface.",AIMed.d35.s294
434,AIMed.d35,True,"Cell surface PS1 formed complexes in vivo with actin-binding protein filamin (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.",AIMed.d35.s299
435,AIMed.d35,True,"Cell surface PS1 formed complexes in vivo with actin-binding protein filamin (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.",AIMed.d35.s299
436,AIMed.d35,False,"Cell surface PS1 formed complexes in vivo with actin-binding protein filamin (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.",AIMed.d35.s299
437,AIMed.d36,True,Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices.,AIMed.d36.s301
438,AIMed.d36,False,"In a previous work, we predicted and demonstrated that the 29-42-residue fragment of beta-amyloid peptide (Abeta peptide) has in vitro capacities close to those of the tilted fragment of viral fusion proteins.",AIMed.d36.s302
439,AIMed.d36,False,We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta(29-42) via a direct interaction.,AIMed.d36.s303
440,AIMed.d36,True,We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta(29-42) via a direct interaction.,AIMed.d36.s303
441,AIMed.d36,False,We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta(29-42) via a direct interaction.,AIMed.d36.s303
442,AIMed.d36,False,"Therefore, we suggested that this fragment is implicated in the neurotoxicity of Abeta and in the protective effects of apolipoprotein E in Alzheimer's disease.",AIMed.d36.s304
443,AIMed.d36,False,"In this study, we simulated interactions of all amphipathic helices of apolipoproteins E and A-I with Abeta and simian immunodeficiency virus (SIV) fusogenic fragments by molecular modeling.",AIMed.d36.s306
444,AIMed.d37,False,CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.,AIMed.d37.s310
445,AIMed.d37,True,"CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).",AIMed.d37.s311
446,AIMed.d37,True,"CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).",AIMed.d37.s311
447,AIMed.d37,True,"CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).",AIMed.d37.s311
448,AIMed.d37,False,"CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).",AIMed.d37.s311
449,AIMed.d37,False,"CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).",AIMed.d37.s311
450,AIMed.d37,False,"CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).",AIMed.d37.s311
451,AIMed.d37,False,"All CC-chemokines currently available were tested for their ability to compete with [(125)I]-MIP-1beta binding on a stable cell line expressing recombinant CCR5, and/or to induce a functional response in these cells.",AIMed.d37.s314
452,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
453,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
454,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
455,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
456,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
457,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
458,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
459,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
460,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
461,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
462,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
463,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
464,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
465,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
466,AIMed.d37,True,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
467,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
468,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
469,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
470,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
471,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
472,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
473,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
474,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
475,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
476,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
477,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
478,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
479,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
480,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
481,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
482,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
483,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
484,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
485,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
486,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
487,AIMed.d37,False,"We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.",AIMed.d37.s315
488,AIMed.d37,True,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
489,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
490,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
491,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
492,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
493,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
494,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
495,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
496,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
497,AIMed.d37,True,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
498,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
499,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
500,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
501,AIMed.d37,False,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
502,AIMed.d37,True,"Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.",AIMed.d37.s316
503,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
504,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
505,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
506,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
507,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
508,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
509,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
510,AIMed.d37,False,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
511,AIMed.d37,True,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
512,AIMed.d37,True,"Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.",AIMed.d37.s318
513,AIMed.d37,True,"MCP-3 could compete efficiently for gp120 binding but was, however, found to be a weak inhibitor of HIV infection, probably as a consequence of its inability to downregulate the receptor.",AIMed.d37.s319
514,AIMed.d39,True,Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.,AIMed.d39.s334
515,AIMed.d39,False,Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.,AIMed.d39.s334
516,AIMed.d39,False,Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.,AIMed.d39.s334
517,AIMed.d39,True,Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.,AIMed.d39.s334
518,AIMed.d39,False,Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.,AIMed.d39.s334
519,AIMed.d39,False,Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.,AIMed.d39.s334
520,AIMed.d39,False,Presenilin 1 (PS1) is the causative gene for an autosomal dominant familial Alzheimer's disease (AD) mapped to chromosome 14.,AIMed.d39.s335
521,AIMed.d39,True,"Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.",AIMed.d39.s336
522,AIMed.d39,False,"Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.",AIMed.d39.s336
523,AIMed.d39,False,"Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.",AIMed.d39.s336
524,AIMed.d39,False,"Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.",AIMed.d39.s336
525,AIMed.d39,True,"Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.",AIMed.d39.s336
526,AIMed.d39,False,"Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.",AIMed.d39.s336
527,AIMed.d39,True,We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/Jif-1 gene.,AIMed.d39.s337
528,AIMed.d39,False,We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/Jif-1 gene.,AIMed.d39.s337
529,AIMed.d39,True,We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/Jif-1 gene.,AIMed.d39.s337
530,AIMed.d39,False,"The binding of QM/Jif-1 to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.",AIMed.d39.s338
531,AIMed.d39,True,"The binding of QM/Jif-1 to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.",AIMed.d39.s338
532,AIMed.d39,True,"The binding of QM/Jif-1 to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.",AIMed.d39.s338
533,AIMed.d39,False,"Immunoelectronmicroscopic analysis showed that QM/Jif-1 and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.",AIMed.d39.s339
534,AIMed.d39,False,"Immunoelectronmicroscopic analysis showed that QM/Jif-1 and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.",AIMed.d39.s339
535,AIMed.d39,False,"Immunoelectronmicroscopic analysis showed that QM/Jif-1 and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.",AIMed.d39.s339
536,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
537,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
538,AIMed.d39,True,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
539,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
540,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
541,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
542,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
543,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
544,AIMed.d39,True,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
545,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
546,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
547,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
548,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
549,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
550,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
551,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
552,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
553,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
554,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
555,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
556,AIMed.d39,False,"Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.",AIMed.d39.s340
557,AIMed.d39,False,"By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).",AIMed.d39.s341
558,AIMed.d39,False,"By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).",AIMed.d39.s341
559,AIMed.d39,False,"By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).",AIMed.d39.s341
560,AIMed.d39,False,"PS1 suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.",AIMed.d39.s342
561,AIMed.d39,False,"PS1 suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.",AIMed.d39.s342
562,AIMed.d39,False,"PS1 suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.",AIMed.d39.s342
563,AIMed.d39,False,"Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.",AIMed.d39.s343
564,AIMed.d39,False,"Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.",AIMed.d39.s343
565,AIMed.d39,False,"Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.",AIMed.d39.s343
566,AIMed.d39,False,"Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.",AIMed.d39.s343
567,AIMed.d39,False,"Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.",AIMed.d39.s343
568,AIMed.d39,False,"Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.",AIMed.d39.s343
569,AIMed.d40,True,We have crystallized a complex between human FGF1 and a two-domain extracellular fragment of human FGFR2.,AIMed.d40.s347
570,AIMed.d41,False,Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.,AIMed.d41.s352
571,AIMed.d41,True,Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.,AIMed.d41.s352
572,AIMed.d41,False,Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.,AIMed.d41.s352
573,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
574,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
575,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
576,AIMed.d41,True,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
577,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
578,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
579,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
580,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
581,AIMed.d41,False,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
582,AIMed.d41,True,"HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.",AIMed.d41.s354
583,AIMed.d41,False,The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.,AIMed.d41.s355
584,AIMed.d41,False,The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.,AIMed.d41.s355
585,AIMed.d41,True,The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.,AIMed.d41.s355
586,AIMed.d41,True,The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.,AIMed.d41.s355
587,AIMed.d41,False,The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.,AIMed.d41.s355
588,AIMed.d41,False,The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.,AIMed.d41.s355
589,AIMed.d41,False,"On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.",AIMed.d41.s356
590,AIMed.d41,False,"On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.",AIMed.d41.s356
591,AIMed.d41,True,"On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.",AIMed.d41.s356
592,AIMed.d41,True,"The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.",AIMed.d41.s357
593,AIMed.d41,False,"The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.",AIMed.d41.s357
594,AIMed.d41,False,"The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.",AIMed.d41.s357
595,AIMed.d41,False,The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.,AIMed.d41.s358
596,AIMed.d41,False,The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.,AIMed.d41.s358
597,AIMed.d41,False,The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.,AIMed.d41.s358
598,AIMed.d41,True,The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.,AIMed.d41.s358
599,AIMed.d41,False,The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.,AIMed.d41.s358
600,AIMed.d41,False,The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.,AIMed.d41.s358
601,AIMed.d42,False,"The BMP receptors belong to the family of serine/threonine kinase receptors, whose activation has been investigated intensively for the transforming growth factor-beta (TGF-beta) receptor subfamily.",AIMed.d42.s361
602,AIMed.d42,False,"Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).",AIMed.d42.s364
603,AIMed.d42,False,"Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).",AIMed.d42.s364
604,AIMed.d42,False,"Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).",AIMed.d42.s364
605,AIMed.d42,False,"Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).",AIMed.d42.s364
606,AIMed.d42,False,"Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).",AIMed.d42.s364
607,AIMed.d42,False,"Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).",AIMed.d42.s364
608,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
609,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
610,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
611,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
612,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
613,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
614,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
615,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
616,AIMed.d42,True,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
617,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
618,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
619,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
620,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
621,AIMed.d42,True,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
622,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
623,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
624,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
625,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
626,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
627,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
628,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
629,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
630,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
631,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
632,AIMed.d42,True,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
633,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
634,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
635,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
636,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
637,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
638,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
639,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
640,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
641,AIMed.d42,True,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
642,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
643,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
644,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
645,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
646,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
647,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
648,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
649,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
650,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
651,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
652,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
653,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
654,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
655,AIMed.d42,True,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
656,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
657,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
658,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
659,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
660,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
661,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
662,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
663,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
664,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
665,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
666,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
667,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
668,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
669,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
670,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
671,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
672,AIMed.d42,False,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
673,AIMed.d42,True,"Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.",AIMed.d42.s367
674,AIMed.d42,True,"BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of BR-I).",AIMed.d42.s368
675,AIMed.d42,False,"BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of BR-I).",AIMed.d42.s368
676,AIMed.d42,True,"BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of BR-I).",AIMed.d42.s368
677,AIMed.d43,True,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
678,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
679,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
680,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
681,AIMed.d43,True,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
682,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
683,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
684,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
685,AIMed.d43,False,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
686,AIMed.d43,True,"Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.",AIMed.d43.s375
687,AIMed.d43,False,"In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.",AIMed.d43.s376
688,AIMed.d43,False,"In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.",AIMed.d43.s376
689,AIMed.d43,False,"In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.",AIMed.d43.s376
690,AIMed.d43,False,"In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.",AIMed.d43.s376
691,AIMed.d43,False,"In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.",AIMed.d43.s376
692,AIMed.d43,False,"In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.",AIMed.d43.s376
693,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
694,AIMed.d43,True,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
695,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
696,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
697,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
698,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
699,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
700,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
701,AIMed.d43,True,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
702,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
703,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
704,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
705,AIMed.d43,True,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
706,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
707,AIMed.d43,False,"The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.",AIMed.d43.s377
708,AIMed.d44,False,Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.,AIMed.d44.s379
709,AIMed.d44,True,Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.,AIMed.d44.s379
710,AIMed.d44,False,Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.,AIMed.d44.s379
711,AIMed.d44,True,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
712,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
713,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
714,AIMed.d44,True,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
715,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
716,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
717,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
718,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
719,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
720,AIMed.d44,False,CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.,AIMed.d44.s380
721,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
722,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
723,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
724,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
725,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
726,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
727,AIMed.d44,True,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
728,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
729,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
730,AIMed.d44,False,"Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.",AIMed.d44.s383
731,AIMed.d44,True,"CD30L binding by CD30 is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44).",AIMed.d44.s384
732,AIMed.d44,True,"Cluster Group B antibodies, including M67 and Ki-1, do not affect CD30L binding to CD30.",AIMed.d44.s385
733,AIMed.d44,False,The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling.,AIMed.d44.s386
734,AIMed.d44,False,The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling.,AIMed.d44.s386
735,AIMed.d44,False,The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling.,AIMed.d44.s386
736,AIMed.d44,False,"Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction.",AIMed.d44.s387
737,AIMed.d44,True,"Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction.",AIMed.d44.s387
738,AIMed.d44,False,"Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction.",AIMed.d44.s387
739,AIMed.d44,False,This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.,AIMed.d44.s388
740,AIMed.d44,False,This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.,AIMed.d44.s388
741,AIMed.d44,False,This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.,AIMed.d44.s388
742,AIMed.d46,False,BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.,AIMed.d46.s402
743,AIMed.d46,False,Bone morphogenetic protein-2 (BMP-2) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals.,AIMed.d46.s403
744,AIMed.d46,False,"BMP-2 is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.",AIMed.d46.s404
745,AIMed.d46,False,"BMP-2 is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.",AIMed.d46.s404
746,AIMed.d46,False,"BMP-2 is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.",AIMed.d46.s404
747,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
748,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
749,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
750,AIMed.d46,True,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
751,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
752,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
753,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
754,AIMed.d46,False,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
755,AIMed.d46,True,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
756,AIMed.d46,True,The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.,AIMed.d46.s405
757,AIMed.d46,True,A large epitope 1 for high-affinity BMPR-IA binding was detected spanning the interface of the BMP-2 dimer.,AIMed.d46.s406
758,AIMed.d47,True,Crystal structure of the BMP-2-BRIA ectodomain complex.,AIMed.d47.s411
759,AIMed.d47,False,Bone morphogenetic proteins (BMPs) belong to the large transforming growth factor-beta (TGF-beta) superfamily of multifunctional cytokines.,AIMed.d47.s412
760,AIMed.d47,False,Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).,AIMed.d47.s415
761,AIMed.d47,False,Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).,AIMed.d47.s415
762,AIMed.d47,False,Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).,AIMed.d47.s415
763,AIMed.d47,False,Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).,AIMed.d47.s415
764,AIMed.d47,True,Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).,AIMed.d47.s415
765,AIMed.d47,True,Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).,AIMed.d47.s415
766,AIMed.d47,False,The receptor chains bind to the 'wrist' epitopes of the BMP-2 dimer and contact both BMP-2 monomers.,AIMed.d47.s416
767,AIMed.d48,False,LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.,AIMed.d48.s419
768,AIMed.d48,True,LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.,AIMed.d48.s419
769,AIMed.d48,True,LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.,AIMed.d48.s419
770,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
771,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
772,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
773,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
774,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
775,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
776,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
777,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
778,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
779,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
780,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
781,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
782,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
783,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
784,AIMed.d48,False,"Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.",AIMed.d48.s420
785,AIMed.d48,False,We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK-293 cells.,AIMed.d48.s422
786,AIMed.d48,True,We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK-293 cells.,AIMed.d48.s422
787,AIMed.d48,True,We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK-293 cells.,AIMed.d48.s422
788,AIMed.d48,False,LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.,AIMed.d48.s423
789,AIMed.d48,False,LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.,AIMed.d48.s423
790,AIMed.d48,False,LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.,AIMed.d48.s423
791,AIMed.d48,False,"The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or I309, respectively.",AIMed.d48.s424
792,AIMed.d48,False,"The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or I309, respectively.",AIMed.d48.s424
793,AIMed.d48,False,"The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or I309, respectively.",AIMed.d48.s424
794,AIMed.d48,False,A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.,AIMed.d48.s426
795,AIMed.d48,False,A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.,AIMed.d48.s426
796,AIMed.d48,False,A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.,AIMed.d48.s426
797,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
798,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
799,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
800,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
801,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
802,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
803,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
804,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
805,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
806,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
807,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
808,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
809,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
810,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
811,AIMed.d49,True,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
812,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
813,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
814,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
815,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
816,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
817,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
818,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
819,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
820,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
821,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
822,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
823,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
824,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
825,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
826,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
827,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
828,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
829,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
830,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
831,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
832,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
833,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
834,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
835,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
836,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
837,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
838,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
839,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
840,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
841,AIMed.d49,False,"FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.",AIMed.d49.s431
842,AIMed.d49,True,FGF-7 contains this primary site as well as a region that restricts interaction with FGFR1.,AIMed.d49.s433
843,AIMed.d49,True,The sequences that confer on FGF-7 its specific binding to KGFR have not been identified.,AIMed.d49.s434
844,AIMed.d49,True,By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of FGF-7 contributes to high affinity receptor binding and is critical for KGFR recognition.,AIMed.d49.s435
845,AIMed.d49,False,Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.,AIMed.d49.s436
846,AIMed.d49,False,Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.,AIMed.d49.s436
847,AIMed.d49,False,Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.,AIMed.d49.s436
848,AIMed.d49,False,Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.,AIMed.d49.s436
849,AIMed.d49,False,Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.,AIMed.d49.s436
850,AIMed.d49,True,Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.,AIMed.d49.s436
851,AIMed.d49,False,The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.,AIMed.d49.s438
852,AIMed.d49,True,The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.,AIMed.d49.s438
853,AIMed.d49,False,The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.,AIMed.d49.s438
854,AIMed.d49,False,The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.,AIMed.d49.s438
855,AIMed.d49,False,The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.,AIMed.d49.s438
856,AIMed.d49,True,The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.,AIMed.d49.s438
857,AIMed.d50,False,"Type I interferons bind to two cell surface receptors, ifnar1 and ifnar2, as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response.",AIMed.d50.s441
858,AIMed.d50,True,"Here, we quantitatively mapped the complete binding region of ifnar2 on interferon (IFN)alpha2 by 35 individual mutations to alanine and isosteric residues.",AIMed.d50.s442
859,AIMed.d50,True,"Interestingly, the ifnar2 binding site overlaps the largest continuous hydrophobic patch on IFNalpha2.",AIMed.d50.s445
860,AIMed.d50,False,"Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward ifnar2 results in linear function over the whole range of affinities investigated, suggesting that ifnar2 binding is the rate-determining step in cellular activation.",AIMed.d50.s447
861,AIMed.d51,True,Here we report the crystal structure of the FGFR2 ectodomain in a dimeric form that is induced by simultaneous binding to FGF1 and a heparin decasaccharide.,AIMed.d51.s455
862,AIMed.d51,True,The structure of the FGF1-FGFR2-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.,AIMed.d51.s458
863,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
864,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
865,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
866,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
867,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
868,AIMed.d52,True,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
869,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
870,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
871,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
872,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
873,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
874,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
875,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
876,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
877,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
878,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
879,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
880,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
881,AIMed.d52,True,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
882,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
883,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
884,AIMed.d52,True,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
885,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
886,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
887,AIMed.d52,True,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
888,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
889,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
890,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
891,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
892,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
893,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
894,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
895,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
896,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
897,AIMed.d52,True,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
898,AIMed.d52,False,"We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.",AIMed.d52.s464
899,AIMed.d53,False,Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130.,AIMed.d53.s469
900,AIMed.d53,True,Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130.,AIMed.d53.s469
901,AIMed.d53,True,Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130.,AIMed.d53.s469
902,AIMed.d53,False,"In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.",AIMed.d53.s470
903,AIMed.d53,True,"In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.",AIMed.d53.s470
904,AIMed.d53,False,"In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.",AIMed.d53.s470
905,AIMed.d53,False,"In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.",AIMed.d53.s470
906,AIMed.d53,True,"In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.",AIMed.d53.s470
907,AIMed.d53,False,"In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.",AIMed.d53.s470
908,AIMed.d53,False,"Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.",AIMed.d53.s471
909,AIMed.d53,True,"Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.",AIMed.d53.s471
910,AIMed.d53,False,"Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.",AIMed.d53.s471
911,AIMed.d53,False,"Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.",AIMed.d53.s471
912,AIMed.d53,True,"Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.",AIMed.d53.s471
913,AIMed.d53,False,"Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.",AIMed.d53.s471
914,AIMed.d53,False,The cross-reactivity of gp130 is apparently due to a chemical plasticity evident in the amphipathic gp130 cytokine-binding sites.,AIMed.d53.s472
915,AIMed.d54,False,"Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.",AIMed.d54.s473
916,AIMed.d54,True,"Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.",AIMed.d54.s473
917,AIMed.d54,True,"Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.",AIMed.d54.s473
918,AIMed.d54,False,"PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).",AIMed.d54.s475
919,AIMed.d54,False,"PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).",AIMed.d54.s475
920,AIMed.d54,False,"PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).",AIMed.d54.s475
921,AIMed.d54,False,"PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).",AIMed.d54.s475
922,AIMed.d54,False,"PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).",AIMed.d54.s475
923,AIMed.d54,False,"PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).",AIMed.d54.s475
924,AIMed.d54,True,Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.,AIMed.d54.s477
925,AIMed.d54,False,Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.,AIMed.d54.s477
926,AIMed.d54,False,Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.,AIMed.d54.s477
927,AIMed.d54,False,Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.,AIMed.d54.s477
928,AIMed.d54,True,Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.,AIMed.d54.s477
929,AIMed.d54,False,Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.,AIMed.d54.s477
930,AIMed.d54,False,PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.,AIMed.d54.s478
931,AIMed.d54,False,PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.,AIMed.d54.s478
932,AIMed.d54,False,PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.,AIMed.d54.s478
933,AIMed.d54,False,PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.,AIMed.d54.s478
934,AIMed.d54,False,PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.,AIMed.d54.s478
935,AIMed.d54,False,PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.,AIMed.d54.s478
936,AIMed.d54,False,Analysis of PDGF-CC in vivo in a diabetic mouse model of delayed wound healing showed that PDGF-CC significantly enhanced repair of a full-thickness skin excision.,AIMed.d54.s479
937,AIMed.d54,False,"Together, these studies describe a third member of the PDGF family (PDGF-C) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to PDGF-AB.",AIMed.d54.s480
938,AIMed.d56,True,"Cloning of TRAP, a ligand for CD40 on human T cells.",AIMed.d56.s494
939,AIMed.d56,False,"A cDNA clone, designated TRAP (TNF-related activation protein) was isolated from a collection of T cell activation genes.",AIMed.d56.s495
940,AIMed.d56,False,"TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.",AIMed.d56.s499
941,AIMed.d56,False,"TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.",AIMed.d56.s499
942,AIMed.d56,False,"TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.",AIMed.d56.s499
943,AIMed.d56,True,"Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct.",AIMed.d56.s500
944,AIMed.d56,False,"Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct.",AIMed.d56.s500
945,AIMed.d56,True,"Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct.",AIMed.d56.s500
946,AIMed.d57,True,"Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system.",AIMed.d57.s503
947,AIMed.d57,False,"Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system.",AIMed.d57.s503
948,AIMed.d57,False,"Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system.",AIMed.d57.s503
949,AIMed.d57,False,A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90.,AIMed.d57.s504
950,AIMed.d57,True,A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90.,AIMed.d57.s504
951,AIMed.d57,False,A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90.,AIMed.d57.s504
952,AIMed.d57,True,"Reticulocyte lysate forms complexes between hsp90 and a temperature-sensitive mutant of Rous sarcoma virus pp60v-src, which is normally present in cytosol virtually entirely in the multiprotein complex form.",AIMed.d57.s505
953,AIMed.d57,False,"In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.",AIMed.d57.s506
954,AIMed.d57,False,"In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.",AIMed.d57.s506
955,AIMed.d57,True,"In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.",AIMed.d57.s506
956,AIMed.d57,False,"In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.",AIMed.d57.s506
957,AIMed.d57,False,"In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.",AIMed.d57.s506
958,AIMed.d57,True,"In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.",AIMed.d57.s506
959,AIMed.d57,True,"The native and reconstituted pp60src-hsp90 complexes have similar thermal stability and, like steroid receptor heterocomplexes, they are stabilized by molybdate.",AIMed.d57.s508
960,AIMed.d57,True,"As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.",AIMed.d57.s509
961,AIMed.d57,False,"As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.",AIMed.d57.s509
962,AIMed.d57,False,"As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.",AIMed.d57.s509
963,AIMed.d58,False,"A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) containing one src homology 2 (SH2) domain and two SH3 domains was isolated.",AIMed.d58.s511
964,AIMed.d58,False,"While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.",AIMed.d58.s516
965,AIMed.d58,False,"While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.",AIMed.d58.s516
966,AIMed.d58,False,"While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.",AIMed.d58.s516
967,AIMed.d58,False,"While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.",AIMed.d58.s516
968,AIMed.d58,False,"While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.",AIMed.d58.s516
969,AIMed.d58,False,"While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.",AIMed.d58.s516
970,AIMed.d58,False,These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.,AIMed.d58.s517
971,AIMed.d59,False,Analysis of the oligomerization of myogenin and E2A products in vivo using a two-hybrid assay system.,AIMed.d59.s518
972,AIMed.d59,False,"Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.",AIMed.d59.s520
973,AIMed.d59,False,"Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.",AIMed.d59.s520
974,AIMed.d59,False,"Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.",AIMed.d59.s520
975,AIMed.d59,True,"Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.",AIMed.d59.s520
976,AIMed.d59,True,"Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.",AIMed.d59.s520
977,AIMed.d59,False,"Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.",AIMed.d59.s520
978,AIMed.d59,False,"The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent.",AIMed.d59.s523
979,AIMed.d59,True,"The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent.",AIMed.d59.s523
980,AIMed.d59,True,"The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent.",AIMed.d59.s523
981,AIMed.d59,False,"Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.",AIMed.d59.s524
982,AIMed.d59,False,"Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.",AIMed.d59.s524
983,AIMed.d59,False,"Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.",AIMed.d59.s524
984,AIMed.d59,False,"Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.",AIMed.d59.s524
985,AIMed.d59,False,"Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.",AIMed.d59.s524
986,AIMed.d59,False,"Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.",AIMed.d59.s524
987,AIMed.d60,True,Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.,AIMed.d60.s525
988,AIMed.d60,False,Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.,AIMed.d60.s525
989,AIMed.d60,False,Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.,AIMed.d60.s525
990,AIMed.d60,True,"MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.",AIMed.d60.s527
991,AIMed.d60,True,"MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.",AIMed.d60.s527
992,AIMed.d60,True,"MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.",AIMed.d60.s527
993,AIMed.d60,True,The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.,AIMed.d60.s528
994,AIMed.d60,False,The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.,AIMed.d60.s528
995,AIMed.d60,False,The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.,AIMed.d60.s528
996,AIMed.d60,False,"Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.",AIMed.d60.s529
997,AIMed.d60,False,"Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.",AIMed.d60.s529
998,AIMed.d60,False,"Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.",AIMed.d60.s529
999,AIMed.d60,True,These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.,AIMed.d60.s530
1000,AIMed.d60,False,These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.,AIMed.d60.s530
1001,AIMed.d60,False,These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.,AIMed.d60.s530
1002,AIMed.d61,False,An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.,AIMed.d61.s532
1003,AIMed.d61,False,An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.,AIMed.d61.s532
1004,AIMed.d61,False,An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.,AIMed.d61.s532
1005,AIMed.d61,False,An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.,AIMed.d61.s532
1006,AIMed.d61,False,An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.,AIMed.d61.s532
1007,AIMed.d61,False,An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.,AIMed.d61.s532
1008,AIMed.d61,False,"Ligand binding analysis revealed high affinity binding (Kd = 0.2 nM) with approximately 94,000 +/- 7,500 sites/cell for 125I-TNF-alpha and approximately 5-fold lower affinity for TNF-beta (Kd = 1.1 nM) with 264,000 +/- 2,000 sites/cell.",AIMed.d61.s533
1009,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1010,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1011,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1012,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1013,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1014,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1015,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1016,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1017,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1018,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1019,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1020,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1021,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1022,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1023,AIMed.d61,False,"Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.",AIMed.d61.s534
1024,AIMed.d61,False,Immunoprecipitation of TNF-R2 from 32P-labeled 293/TNF-R2 cells demonstrated that the receptor is phosphorylated.,AIMed.d61.s535
1025,AIMed.d61,False,TNF-alpha treatment of 293/TNF-R2 cells did not significantly affect the degree or pattern of phosphorylation.,AIMed.d61.s537
1026,AIMed.d61,False,Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.,AIMed.d61.s539
1027,AIMed.d61,False,Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.,AIMed.d61.s539
1028,AIMed.d61,False,Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.,AIMed.d61.s539
1029,AIMed.d63,True,Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes.,AIMed.d63.s544
1030,AIMed.d63,True,Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes.,AIMed.d63.s544
1031,AIMed.d63,False,Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes.,AIMed.d63.s544
1032,AIMed.d63,False,"In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.",AIMed.d63.s545
1033,AIMed.d63,False,"In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.",AIMed.d63.s545
1034,AIMed.d63,False,"In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.",AIMed.d63.s545
1035,AIMed.d63,False,"In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.",AIMed.d63.s545
1036,AIMed.d63,False,"In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.",AIMed.d63.s545
1037,AIMed.d63,False,"In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.",AIMed.d63.s545
1038,AIMed.d63,False,"We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.",AIMed.d63.s546
1039,AIMed.d63,False,"We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.",AIMed.d63.s546
1040,AIMed.d63,False,"We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.",AIMed.d63.s546
1041,AIMed.d63,False,"We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.",AIMed.d63.s546
1042,AIMed.d63,False,"We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.",AIMed.d63.s546
1043,AIMed.d63,False,"We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.",AIMed.d63.s546
1044,AIMed.d63,False,"These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.",AIMed.d63.s547
1045,AIMed.d63,True,"These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.",AIMed.d63.s547
1046,AIMed.d63,False,"These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.",AIMed.d63.s547
1047,AIMed.d63,False,"These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.",AIMed.d63.s547
1048,AIMed.d63,False,"These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.",AIMed.d63.s547
1049,AIMed.d63,False,"These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.",AIMed.d63.s547
1050,AIMed.d64,False,"We have isolated and characterized a cDNA clone, phFGFR, encoding a human fibroblast growth factor (FGF) receptor. phFGFR contains an open reading frame which encodes an 820 amino acid polypeptide with three immunoglobulin-like domains in the extracellular part and an intracellular split tyrosine kinase domain.",AIMed.d64.s549
1051,AIMed.d64,False,"Transient expression in COS-1 cells and immunoprecipitation using an antiserum raised against a C-terminal peptide, gave rise to two components, representing mature (130 kDa) and precursor (115 kDa) forms of the phFGFR encoded polypeptide, which was denoted hFGFR-1.",AIMed.d64.s550
1052,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1053,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1054,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1055,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1056,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1057,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1058,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1059,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1060,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1061,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1062,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1063,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1064,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1065,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1066,AIMed.d64,False,"Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.",AIMed.d64.s551
1067,AIMed.d64,True,"From Scatchard analyses, the Kd:s for binding of aFGF and bFGF to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.",AIMed.d64.s552
1068,AIMed.d64,True,"From Scatchard analyses, the Kd:s for binding of aFGF and bFGF to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.",AIMed.d64.s552
1069,AIMed.d64,False,"From Scatchard analyses, the Kd:s for binding of aFGF and bFGF to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.",AIMed.d64.s552
1070,AIMed.d64,True,"Thus, phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF.",AIMed.d64.s553
1071,AIMed.d64,True,"Thus, phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF.",AIMed.d64.s553
1072,AIMed.d64,False,"Thus, phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF.",AIMed.d64.s553
1073,AIMed.d65,True,Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.,AIMed.d65.s554
1074,AIMed.d65,False,Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.,AIMed.d65.s554
1075,AIMed.d65,False,Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.,AIMed.d65.s554
1076,AIMed.d65,False,Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.,AIMed.d65.s554
1077,AIMed.d65,False,Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.,AIMed.d65.s554
1078,AIMed.d65,True,Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.,AIMed.d65.s554
1079,AIMed.d65,False,The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.,AIMed.d65.s555
1080,AIMed.d65,False,The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.,AIMed.d65.s555
1081,AIMed.d65,False,The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.,AIMed.d65.s555
1082,AIMed.d65,False,The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.,AIMed.d65.s555
1083,AIMed.d65,False,The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.,AIMed.d65.s555
1084,AIMed.d65,False,The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.,AIMed.d65.s555
1085,AIMed.d65,False,"Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.",AIMed.d65.s558
1086,AIMed.d65,False,"Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.",AIMed.d65.s558
1087,AIMed.d65,False,"Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.",AIMed.d65.s558
1088,AIMed.d65,False,"Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.",AIMed.d65.s558
1089,AIMed.d65,False,"Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.",AIMed.d65.s558
1090,AIMed.d65,False,"Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.",AIMed.d65.s558
1091,AIMed.d65,False,These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.,AIMed.d65.s560
1092,AIMed.d65,False,These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.,AIMed.d65.s560
1093,AIMed.d65,False,These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.,AIMed.d65.s560
1094,AIMed.d65,False,These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.,AIMed.d65.s560
1095,AIMed.d65,False,These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.,AIMed.d65.s560
1096,AIMed.d65,False,These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.,AIMed.d65.s560
1097,AIMed.d68,False,"Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.",AIMed.d68.s578
1098,AIMed.d68,False,"Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.",AIMed.d68.s578
1099,AIMed.d68,False,"Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.",AIMed.d68.s578
1100,AIMed.d68,False,"Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.",AIMed.d68.s580
1101,AIMed.d68,False,"Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.",AIMed.d68.s580
1102,AIMed.d68,False,"Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.",AIMed.d68.s580
1103,AIMed.d68,False,"Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.",AIMed.d68.s580
1104,AIMed.d68,False,"Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.",AIMed.d68.s580
1105,AIMed.d68,False,"Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.",AIMed.d68.s580
1106,AIMed.d68,True,Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells.,AIMed.d68.s581
1107,AIMed.d68,False,Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells.,AIMed.d68.s581
1108,AIMed.d68,True,Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells.,AIMed.d68.s581
1109,AIMed.d68,False,"These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.",AIMed.d68.s582
1110,AIMed.d68,False,"These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.",AIMed.d68.s582
1111,AIMed.d68,False,"These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.",AIMed.d68.s582
1112,AIMed.d68,False,The motif may represent an activating domain that has to be provided to cdc25 by intermolecular interaction with cyclin B.,AIMed.d68.s585
1113,AIMed.d69,True,Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.,AIMed.d69.s586
1114,AIMed.d69,True,"In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3).",AIMed.d69.s587
1115,AIMed.d69,False,"In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3).",AIMed.d69.s587
1116,AIMed.d69,True,"In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3).",AIMed.d69.s587
1117,AIMed.d69,True,"Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity.",AIMed.d69.s589
1118,AIMed.d69,False,"Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity.",AIMed.d69.s589
1119,AIMed.d69,False,"Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity.",AIMed.d69.s589
1120,AIMed.d69,True,Phosphorylation of recombinant human c-Jun proteins in vitro by GSK-3 decreases their DNA-binding activity.,AIMed.d69.s590
1121,AIMed.d69,True,"We propose that c-Jun is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to protein kinase C activation.",AIMed.d69.s592
1122,AIMed.d70,False,Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif.,AIMed.d70.s593
1123,AIMed.d70,False,Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif.,AIMed.d70.s593
1124,AIMed.d70,False,Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif.,AIMed.d70.s593
1125,AIMed.d70,False,The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins.,AIMed.d70.s594
1126,AIMed.d70,False,The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins.,AIMed.d70.s594
1127,AIMed.d70,False,The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins.,AIMed.d70.s594
1128,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1129,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1130,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1131,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1132,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1133,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1134,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1135,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1136,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1137,AIMed.d70,False,"Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.",AIMed.d70.s595
1138,AIMed.d70,False,"A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII alpha.",AIMed.d70.s597
1139,AIMed.d70,True,"A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII alpha.",AIMed.d70.s597
1140,AIMed.d70,False,"A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII alpha.",AIMed.d70.s597
1141,AIMed.d70,False,"Specifically, substitution of proline for Ala-498 significantly diminished RII alpha binding, and similar mutation of Ile-502 or Ile-507 abolished interaction.",AIMed.d70.s599
1142,AIMed.d70,False,"Mutation of Ala-522 to proline, which is located outside the predicted amphipathic helix region, had no effect on RII alpha binding.",AIMed.d70.s600
1143,AIMed.d70,False,These data suggest that anchoring proteins interact with RII alpha via an amphipathic helix binding motif.,AIMed.d70.s601
1144,AIMed.d71,False,The proto-oncogene c-jun is a component of the AP-1 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli.,AIMed.d71.s603
1145,AIMed.d71,False,We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.,AIMed.d71.s606
1146,AIMed.d71,False,We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.,AIMed.d71.s606
1147,AIMed.d71,True,We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.,AIMed.d71.s606
1148,AIMed.d71,False,We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.,AIMed.d71.s606
1149,AIMed.d71,True,We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.,AIMed.d71.s606
1150,AIMed.d71,False,We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.,AIMed.d71.s606
1151,AIMed.d71,False,The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.,AIMed.d71.s607
1152,AIMed.d71,False,The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.,AIMed.d71.s607
1153,AIMed.d71,False,The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.,AIMed.d71.s607
1154,AIMed.d71,False,"MAP kinase activation of c-jun may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.",AIMed.d71.s608
1155,AIMed.d73,False,The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the B cell activation protein Bp50.,AIMed.d73.s621
1156,AIMed.d73,False,Unlabeled TNF-alpha and TNF-beta were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.,AIMed.d73.s623
1157,AIMed.d73,False,Unlabeled TNF-alpha and TNF-beta were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.,AIMed.d73.s623
1158,AIMed.d73,False,Unlabeled TNF-alpha and TNF-beta were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.,AIMed.d73.s623
1159,AIMed.d74,True,Two cDNA clones encoding a receptor for human granulocyte-macrophage colony-stimulating factor (hGM-CSF-R) were isolated by expression screening of a library made from human placental mRNA.,AIMed.d74.s627
1160,AIMed.d74,False,"It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, erythropoietin and interleukin-2 (beta-chain) and also to the prolactin receptor.",AIMed.d74.s630
1161,AIMed.d74,False,"It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, erythropoietin and interleukin-2 (beta-chain) and also to the prolactin receptor.",AIMed.d74.s630
1162,AIMed.d74,False,"It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, erythropoietin and interleukin-2 (beta-chain) and also to the prolactin receptor.",AIMed.d74.s630
1163,AIMed.d74,False,When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not interleukin-3.,AIMed.d74.s631
1164,AIMed.d74,True,When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not interleukin-3.,AIMed.d74.s631
1165,AIMed.d74,False,When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not interleukin-3.,AIMed.d74.s631
1166,AIMed.d76,True,The T-cell antigen CD5 acts as a receptor and substrate for the protein-tyrosine kinase p56lck.,AIMed.d76.s637
1167,AIMed.d76,True,CD5 is a T-cell-specific antigen which binds to the B-cell antigen CD72 and acts as a coreceptor in the stimulation of T-cell growth.,AIMed.d76.s638
1168,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1169,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1170,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1171,AIMed.d76,True,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1172,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1173,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1174,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1175,AIMed.d76,True,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1176,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1177,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1178,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1179,AIMed.d76,True,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1180,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1181,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1182,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1183,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1184,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1185,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1186,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1187,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1188,AIMed.d76,False,CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.,AIMed.d76.s639
1189,AIMed.d76,False,"In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.",AIMed.d76.s641
1190,AIMed.d76,True,"In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.",AIMed.d76.s641
1191,AIMed.d76,True,"In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.",AIMed.d76.s641
1192,AIMed.d76,False,Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.,AIMed.d76.s642
1193,AIMed.d76,False,Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.,AIMed.d76.s642
1194,AIMed.d76,False,Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.,AIMed.d76.s642
1195,AIMed.d76,False,"Further, anti-CD5 and anti-p56lck coprecipitated each other in a variety of detergents, including Nonidet P-40 and Triton X-100.",AIMed.d76.s643
1196,AIMed.d76,False,Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.,AIMed.d76.s644
1197,AIMed.d76,False,Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.,AIMed.d76.s644
1198,AIMed.d76,False,Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.,AIMed.d76.s644
1199,AIMed.d76,False,Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.,AIMed.d76.s644
1200,AIMed.d76,False,Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.,AIMed.d76.s644
1201,AIMed.d76,False,Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.,AIMed.d76.s644
1202,AIMed.d76,False,No binding between p59fyn(T) and CD5 was detected in T cells.,AIMed.d76.s645
1203,AIMed.d76,False,"The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.",AIMed.d76.s646
1204,AIMed.d76,True,"The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.",AIMed.d76.s646
1205,AIMed.d76,False,"The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.",AIMed.d76.s646
1206,AIMed.d76,True,In vivo labelling with 32P(i) also showed a four- to fivefold increase in Y-394 occupancy in p56lck when associated with CD5.,AIMed.d76.s647
1207,AIMed.d76,True,The use of glutathione S-transferase-Lck fusion proteins in precipitation analysis showed that the SH2 domain of p56lck could recognize CD5 as expressed in the baculovirus expression system.,AIMed.d76.s648
1208,AIMed.d76,False,CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS ),AIMed.d76.s649
1209,AIMed.d76,False,CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS ),AIMed.d76.s649
1210,AIMed.d76,False,CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS ),AIMed.d76.s649
1211,AIMed.d76,False,CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS ),AIMed.d76.s649
1212,AIMed.d76,True,CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS ),AIMed.d76.s649
1213,AIMed.d76,False,CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS ),AIMed.d76.s649
1214,AIMed.d77,False,"Desmoplakin (DPI), a desmosomal component lacking a transmembrane domain, has been implicated in this interaction, although most studies have been conducted with cells that contain few or no desmosomes, and efforts to demonstrate direct interactions between desmoplakin and intermediate filaments have not been successful.",AIMed.d77.s652
1215,AIMed.d77,True,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1216,AIMed.d77,True,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1217,AIMed.d77,True,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1218,AIMed.d77,True,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1219,AIMed.d77,False,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1220,AIMed.d77,False,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1221,AIMed.d77,False,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1222,AIMed.d77,False,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1223,AIMed.d77,False,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1224,AIMed.d77,False,"We show that the carboxy terminal ""tail"" of DPI associates directly with the amino terminal ""head"" of type II epidermal keratins, including K1, K2, K5, and K6.",AIMed.d77.s654
1225,AIMed.d77,True,"We have engineered and purified recombinant K5 head and DPI tail, and we demonstrate direct interaction in vitro by solution-binding assays and by ligand blot assays.",AIMed.d77.s655
1226,AIMed.d77,True,We have identified an 18-amino acid residue stretch in the K5 head that is conserved only among type II epidermal keratins and that appears to play some role in DPI tail binding.,AIMed.d77.s657
1227,AIMed.d79,True,"The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein.",AIMed.d79.s671
1228,AIMed.d79,False,"The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein.",AIMed.d79.s671
1229,AIMed.d79,False,"The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein.",AIMed.d79.s671
1230,AIMed.d79,False,The retinoblastoma protein (Rb) is a target of viral oncoproteins.,AIMed.d79.s672
1231,AIMed.d79,False,It contains an Rb-binding motif that shares an antigenic epitope with the C terminus of E1A.,AIMed.d79.s676
1232,AIMed.d79,False,A domain is conserved between RIZ and the PRDI-BF1/Blimp-1 differentiation factor.,AIMed.d79.s677
1233,AIMed.d79,False,A domain is conserved between RIZ and the PRDI-BF1/Blimp-1 differentiation factor.,AIMed.d79.s677
1234,AIMed.d79,False,A domain is conserved between RIZ and the PRDI-BF1/Blimp-1 differentiation factor.,AIMed.d79.s677
1235,AIMed.d79,False,"While the function of RIZ is not yet clear, its structure and pattern of expression suggest a role for RIZ in transcriptional regulation during neuronal differentiation and pathogenesis of retinoblastoma.",AIMed.d79.s681
1236,AIMed.d80,True,"FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.",AIMed.d80.s682
1237,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1238,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1239,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1240,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1241,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1242,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1243,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1244,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1245,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1246,AIMed.d80,True,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1247,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1248,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1249,AIMed.d80,True,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1250,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1251,AIMed.d80,True,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1252,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1253,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1254,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1255,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1256,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1257,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1258,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1259,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1260,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1261,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1262,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1263,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1264,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1265,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1266,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1267,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1268,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1269,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1270,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1271,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1272,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1273,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1274,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1275,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1276,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1277,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1278,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1279,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1280,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1281,AIMed.d80,False,"Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.",AIMed.d80.s683
1282,AIMed.d80,False,FADD contains a death domain homologous to the death domains of Fas and TNFR-1.,AIMed.d80.s684
1283,AIMed.d80,False,FADD contains a death domain homologous to the death domains of Fas and TNFR-1.,AIMed.d80.s684
1284,AIMed.d80,False,FADD contains a death domain homologous to the death domains of Fas and TNFR-1.,AIMed.d80.s684
1285,AIMed.d80,True,"A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.",AIMed.d80.s685
1286,AIMed.d80,False,"A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.",AIMed.d80.s685
1287,AIMed.d80,False,"A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.",AIMed.d80.s685
1288,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1289,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1290,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1291,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1292,AIMed.d80,True,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1293,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1294,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1295,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1296,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1297,AIMed.d80,False,"Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.",AIMed.d80.s686
1298,AIMed.d80,False,These findings suggest that FADD may play an important role in the proximal signal transduction of Fas.,AIMed.d80.s687
1299,AIMed.d81,True,RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.,AIMed.d81.s688
1300,AIMed.d81,True,RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.,AIMed.d81.s688
1301,AIMed.d81,True,RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.,AIMed.d81.s688
1302,AIMed.d81,False,RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.,AIMed.d81.s688
1303,AIMed.d81,False,RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.,AIMed.d81.s688
1304,AIMed.d81,False,RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.,AIMed.d81.s688
1305,AIMed.d81,False,Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells.,AIMed.d81.s689
1306,AIMed.d81,False,Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells.,AIMed.d81.s689
1307,AIMed.d81,False,Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells.,AIMed.d81.s689
1308,AIMed.d81,False,"Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.",AIMed.d81.s690
1309,AIMed.d81,True,"Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.",AIMed.d81.s690
1310,AIMed.d81,False,"Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.",AIMed.d81.s690
1311,AIMed.d81,True,"Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.",AIMed.d81.s690
1312,AIMed.d81,False,"Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.",AIMed.d81.s690
1313,AIMed.d81,True,"Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.",AIMed.d81.s690
1314,AIMed.d81,False,"RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.",AIMed.d81.s691
1315,AIMed.d81,False,"RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.",AIMed.d81.s691
1316,AIMed.d81,False,"RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.",AIMed.d81.s691
1317,AIMed.d81,False,"RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.",AIMed.d81.s691
1318,AIMed.d81,True,"RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.",AIMed.d81.s691
1319,AIMed.d81,False,"RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.",AIMed.d81.s691
1320,AIMed.d81,False,RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and TNFR1 intracellular domains.,AIMed.d81.s692
1321,AIMed.d81,False,RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and TNFR1 intracellular domains.,AIMed.d81.s692
1322,AIMed.d81,False,RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and TNFR1 intracellular domains.,AIMed.d81.s692
1323,AIMed.d82,False,Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.,AIMed.d82.s695
1324,AIMed.d82,False,"Previously, a mammalian protein that directly associates with FKBP12-rapamycin has been identified and its encoding gene has been cloned from both human (designated FRAP) [Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. & Schreiber, S.L. (1994) Nature (London) 369, 756-758] and rat (designated RAFT) [Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S.H. (1994) Cell 78, 35-43].",AIMed.d82.s697
1325,AIMed.d82,False,"Previously, a mammalian protein that directly associates with FKBP12-rapamycin has been identified and its encoding gene has been cloned from both human (designated FRAP) [Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. & Schreiber, S.L. (1994) Nature (London) 369, 756-758] and rat (designated RAFT) [Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S.H. (1994) Cell 78, 35-43].",AIMed.d82.s697
1326,AIMed.d82,True,"Previously, a mammalian protein that directly associates with FKBP12-rapamycin has been identified and its encoding gene has been cloned from both human (designated FRAP) [Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. & Schreiber, S.L. (1994) Nature (London) 369, 756-758] and rat (designated RAFT) [Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S.H. (1994) Cell 78, 35-43].",AIMed.d82.s697
1327,AIMed.d82,True,"Using an in vitro transcription/translation assay method coupled with proteolysis studies, we have identified an 11-kDa FKBP12-rapamycin-binding domain within FRAP.",AIMed.d82.s699
1328,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1329,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1330,AIMed.d83,True,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1331,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1332,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1333,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1334,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1335,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1336,AIMed.d83,False,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1337,AIMed.d83,True,"By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.",AIMed.d83.s704
1338,AIMed.d83,False,Superposition of the CNTF and growth hormone structures showed that the location of these epitopes on CNTF is analogous to the location of the first and second receptor epitopes on the surface of growth hormone.,AIMed.d83.s707
1339,AIMed.d85,True,Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains.,AIMed.d85.s717
1340,AIMed.d85,False,"In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.",AIMed.d85.s718
1341,AIMed.d85,False,"In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.",AIMed.d85.s718
1342,AIMed.d85,False,"In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.",AIMed.d85.s718
1343,AIMed.d85,True,Studies in vivo and in vitro demonstrated a highly specific interaction between the SH3 domains of p47nck and Wiskott-Aldrich syndrome protein.,AIMed.d85.s720
1344,AIMed.d85,False,"In vitro translation studies identified the 66-kDa protein as the protein product of WASP, and subcellular fractionation experiments showed that p66WASP is mainly present in the cytosol fraction, although significant amounts are also present in membrane and nuclear fractions.",AIMed.d85.s722
1345,AIMed.d85,True,The main p47nck region implicated in the association with p66WASP was found to be the carboxy-terminal SH3 domain.,AIMed.d85.s723
1346,AIMed.d87,False,Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.,AIMed.d87.s733
1347,AIMed.d87,False,Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.,AIMed.d87.s733
1348,AIMed.d87,False,Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.,AIMed.d87.s733
1349,AIMed.d87,False,Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.,AIMed.d87.s733
1350,AIMed.d87,False,Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.,AIMed.d87.s733
1351,AIMed.d87,False,Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.,AIMed.d87.s733
1352,AIMed.d87,True,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1353,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1354,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1355,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1356,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1357,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1358,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1359,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1360,AIMed.d87,True,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1361,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1362,AIMed.d87,True,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1363,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1364,AIMed.d87,True,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1365,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1366,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1367,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1368,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1369,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1370,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1371,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1372,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1373,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1374,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1375,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1376,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1377,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1378,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1379,AIMed.d87,False,Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.,AIMed.d87.s734
1380,AIMed.d87,False,"The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and IGF-1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).",AIMed.d87.s735
1381,AIMed.d87,False,"The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and IGF-1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).",AIMed.d87.s735
1382,AIMed.d87,False,"The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and IGF-1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).",AIMed.d87.s735
1383,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1384,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1385,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1386,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1387,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1388,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1389,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1390,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1391,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1392,AIMed.d87,True,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1393,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1394,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1395,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1396,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1397,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1398,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1399,AIMed.d87,True,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1400,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1401,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1402,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1403,AIMed.d87,False,"The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.",AIMed.d87.s736
1404,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1405,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1406,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1407,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1408,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1409,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1410,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1411,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1412,AIMed.d87,True,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1413,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1414,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1415,AIMed.d87,True,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1416,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1417,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1418,AIMed.d87,False,"Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.",AIMed.d87.s737
1419,AIMed.d87,False,The internal binding site thus revealed was not altered by further mutating Y960/F for IR or Y950/F for IGF-1R.,AIMed.d87.s738
1420,AIMed.d87,False,Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.,AIMed.d87.s739
1421,AIMed.d87,True,Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.,AIMed.d87.s739
1422,AIMed.d87,False,Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.,AIMed.d87.s739
1423,AIMed.d87,True,Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.,AIMed.d87.s739
1424,AIMed.d87,False,Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.,AIMed.d87.s739
1425,AIMed.d87,False,Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.,AIMed.d87.s739
1426,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1427,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1428,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1429,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1430,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1431,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1432,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1433,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1434,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1435,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1436,AIMed.d87,True,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1437,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1438,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1439,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1440,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1441,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1442,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1443,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1444,AIMed.d87,False,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1445,AIMed.d87,True,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1446,AIMed.d87,True,This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).,AIMed.d87.s740
1447,AIMed.d87,False,"Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.",AIMed.d87.s741
1448,AIMed.d87,False,"Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.",AIMed.d87.s741
1449,AIMed.d87,True,"Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.",AIMed.d87.s741
1450,AIMed.d89,True,The mitogenic effects of the B beta chain of fibrinogen are mediated through cell surface calreticulin.,AIMed.d89.s753
1451,AIMed.d89,False,Immunoprecipitation experiments employing a polyclonal anti-calreticulin antibody provided further evidence that the 60-kDa protein isolated in this study was calreticulin.,AIMed.d89.s761
1452,AIMed.d89,False,"Further, polyclonal antibodies to human calreticulin significantly inhibited the mitogenic activity of fibrinogen B beta chain on human fibroblasts.",AIMed.d89.s762
1453,AIMed.d89,True,The present study has shown that cell surface calreticulin binds to the B beta chain of fibrinogen mediating its mitogenic activity.,AIMed.d89.s763
1454,AIMed.d90,False,"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).",AIMed.d90.s764
1455,AIMed.d90,False,"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).",AIMed.d90.s764
1456,AIMed.d90,False,"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).",AIMed.d90.s764
1457,AIMed.d90,False,"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).",AIMed.d90.s764
1458,AIMed.d90,False,"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).",AIMed.d90.s764
1459,AIMed.d90,False,"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).",AIMed.d90.s764
1460,AIMed.d90,False,"Using radiolabeled PU.1 protein as a probe, we screened a B cell cDNA expression library and isolated a number of clones encoding PU.1 interacting proteins.",AIMed.d90.s767
1461,AIMed.d90,False,"Three of these clones encode DNA binding proteins (NF-IL6 beta, HMG I/Y, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.",AIMed.d90.s768
1462,AIMed.d90,False,"Three of these clones encode DNA binding proteins (NF-IL6 beta, HMG I/Y, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.",AIMed.d90.s768
1463,AIMed.d90,False,"Three of these clones encode DNA binding proteins (NF-IL6 beta, HMG I/Y, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.",AIMed.d90.s768
1464,AIMed.d90,True,"We have characterized the physical and functional interactions between PU.1 and NF-IL6 beta, a leucine zipper transcription factor implicated in inflammatory responses.",AIMed.d90.s769
1465,AIMed.d90,False,We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted PU.1-NF-IL6 beta physical interaction.,AIMed.d90.s770
1466,AIMed.d90,False,We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted PU.1-NF-IL6 beta physical interaction.,AIMed.d90.s770
1467,AIMed.d90,True,We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted PU.1-NF-IL6 beta physical interaction.,AIMed.d90.s770
1468,AIMed.d90,False,"In transient expression assays, we found that PU.1 and NF-IL6 beta can functionally cooperate to synergistically activate transcription.",AIMed.d90.s773
1469,AIMed.d90,False,"Electrophoretic mobility shift assays showed that PU.1 and NF-IL6 beta can simultaneously bind to adjacent DNA binding sites, but apparently do not influence the kinetics or affinity of each other's DNA binding.",AIMed.d90.s774
1470,AIMed.d91,False,Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.,AIMed.d91.s776
1471,AIMed.d91,False,Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.,AIMed.d91.s776
1472,AIMed.d91,False,Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.,AIMed.d91.s776
1473,AIMed.d91,False,Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).,AIMed.d91.s777
1474,AIMed.d91,False,Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).,AIMed.d91.s777
1475,AIMed.d91,False,Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).,AIMed.d91.s777
1476,AIMed.d91,False,Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).,AIMed.d91.s777
1477,AIMed.d91,False,Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).,AIMed.d91.s777
1478,AIMed.d91,False,Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).,AIMed.d91.s777
1479,AIMed.d91,False,"Here we report the cloning, expression, and biochemical characterization of the 32-kDa subunit of human (h) TFIID, termed hTAFII32.",AIMed.d91.s779
1480,AIMed.d91,False,We find that hTAFII32 is the human homologue of Drosophila TAFII40.,AIMed.d91.s780
1481,AIMed.d91,True,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1482,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1483,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1484,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1485,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1486,AIMed.d91,True,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1487,AIMed.d91,True,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1488,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1489,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1490,AIMed.d91,False,"In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.",AIMed.d91.s781
1491,AIMed.d91,False,"Moreover, a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain.",AIMed.d91.s782
1492,AIMed.d91,False,"Moreover, a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain.",AIMed.d91.s782
1493,AIMed.d91,False,"Moreover, a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain.",AIMed.d91.s782
1494,AIMed.d92,False,A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation.,AIMed.d92.s784
1495,AIMed.d92,False,A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation.,AIMed.d92.s784
1496,AIMed.d92,False,A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation.,AIMed.d92.s784
1497,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1498,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1499,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1500,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1501,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1502,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1503,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1504,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1505,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1506,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1507,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1508,AIMed.d92,True,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1509,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1510,AIMed.d92,True,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1511,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1512,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1513,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1514,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1515,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1516,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1517,AIMed.d92,False,"Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.",AIMed.d92.s785
1518,AIMed.d92,False,Here we have utilized affinity crosslinking agents with 125I-NGF to detect an association of trkA and p75 receptors in embryonic spinal cord and brain tissues enriched in the two receptors.,AIMed.d92.s787
1519,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1520,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1521,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1522,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1523,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1524,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1525,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1526,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1527,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1528,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1529,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1530,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1531,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1532,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1533,AIMed.d92,False,"Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.",AIMed.d92.s788
1534,AIMed.d92,False,"Our results indicate that the trkA and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.",AIMed.d92.s789
1535,AIMed.d92,False,"Our results indicate that the trkA and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.",AIMed.d92.s789
1536,AIMed.d92,False,"Our results indicate that the trkA and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.",AIMed.d92.s789
1537,AIMed.d94,False,"Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.",AIMed.d94.s796
1538,AIMed.d94,False,"Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.",AIMed.d94.s796
1539,AIMed.d94,False,"Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.",AIMed.d94.s796
1540,AIMed.d94,False,"Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.",AIMed.d94.s796
1541,AIMed.d94,False,"Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.",AIMed.d94.s796
1542,AIMed.d94,False,"Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.",AIMed.d94.s796
1543,AIMed.d94,False,"We have isolated a human cDNA encoding the first eosinophil-selective chemokine receptor, designated CC chemokine receptor 3 (CC CKR3).",AIMed.d94.s797
1544,AIMed.d94,False,CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).,AIMed.d94.s798
1545,AIMed.d94,False,CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).,AIMed.d94.s798
1546,AIMed.d94,False,CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).,AIMed.d94.s798
1547,AIMed.d94,False,CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).,AIMed.d94.s798
1548,AIMed.d94,False,CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).,AIMed.d94.s798
1549,AIMed.d94,False,CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).,AIMed.d94.s798
1550,AIMed.d94,False,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1551,AIMed.d94,False,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1552,AIMed.d94,True,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1553,AIMed.d94,True,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1554,AIMed.d94,False,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1555,AIMed.d94,True,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1556,AIMed.d94,True,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1557,AIMed.d94,False,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1558,AIMed.d94,False,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1559,AIMed.d94,False,"When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.",AIMed.d94.s799
1560,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1561,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1562,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1563,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1564,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1565,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1566,AIMed.d94,True,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1567,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1568,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1569,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1570,AIMed.d94,True,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1571,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1572,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1573,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1574,AIMed.d94,False,"However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.",AIMed.d94.s800
1575,AIMed.d95,True,Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.,AIMed.d95.s802
1576,AIMed.d95,True,The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.,AIMed.d95.s803
1577,AIMed.d95,False,The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.,AIMed.d95.s803
1578,AIMed.d95,True,The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.,AIMed.d95.s803
1579,AIMed.d96,True,"It binds homophilically, i.e., PTPmu on the surface of one cell binds to PTPmu on an apposing cell, and the binding site lies within the immunoglobulin domain.",AIMed.d96.s808
1580,AIMed.d96,False,"In this article, we demonstrate that PTPmu associates with a complex containing cadherins, alpha- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.",AIMed.d96.s811
1581,AIMed.d96,False,"In this article, we demonstrate that PTPmu associates with a complex containing cadherins, alpha- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.",AIMed.d96.s811
1582,AIMed.d96,True,"In this article, we demonstrate that PTPmu associates with a complex containing cadherins, alpha- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.",AIMed.d96.s811
1583,AIMed.d96,True,"In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E-cadherin, but not to alpha- or beta-catenin.",AIMed.d96.s813
1584,AIMed.d96,False,"In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E-cadherin, but not to alpha- or beta-catenin.",AIMed.d96.s813
1585,AIMed.d96,False,"In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E-cadherin, but not to alpha- or beta-catenin.",AIMed.d96.s813
1586,AIMed.d96,False,"After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.",AIMed.d96.s815
1587,AIMed.d96,False,"After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.",AIMed.d96.s815
1588,AIMed.d96,False,"After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.",AIMed.d96.s815
1589,AIMed.d97,False,"Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to DAF-4, a BMP type II receptor from Caenorhabditis elegans.",AIMed.d97.s820
1590,AIMed.d97,False,"Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to DAF-4, a BMP type II receptor from Caenorhabditis elegans.",AIMed.d97.s820
1591,AIMed.d97,False,"Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to DAF-4, a BMP type II receptor from Caenorhabditis elegans.",AIMed.d97.s820
1592,AIMed.d97,False,"In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.",AIMed.d97.s821
1593,AIMed.d97,True,"In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.",AIMed.d97.s821
1594,AIMed.d97,False,"In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.",AIMed.d97.s821
1595,AIMed.d97,True,"In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.",AIMed.d97.s821
1596,AIMed.d97,False,"In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.",AIMed.d97.s821
1597,AIMed.d97,True,"In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.",AIMed.d97.s821
1598,AIMed.d97,False,Binding of OP-1/BMP-7 to BMPR-II was also observed in nontransfected cell lines.,AIMed.d97.s823
1599,AIMed.d97,True,Binding of OP-1/BMP-7 to BMPR-II was also observed in nontransfected cell lines.,AIMed.d97.s823
1600,AIMed.d97,True,Binding of OP-1/BMP-7 to BMPR-II was also observed in nontransfected cell lines.,AIMed.d97.s823
1601,AIMed.d97,True,"Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by OP-1/BMP-7.",AIMed.d97.s824
1602,AIMed.d97,False,"Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by OP-1/BMP-7.",AIMed.d97.s824
1603,AIMed.d97,True,"Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by OP-1/BMP-7.",AIMed.d97.s824
1604,AIMed.d98,True,"Raf-1, which is known to bind 14-3-3 proteins, has recently been shown to associate with cdc25A and to stimulate its phosphatase activity.",AIMed.d98.s832
1605,AIMed.d98,False,"14-3-3 protein, however, has no effect on the cdc25A-kinase activity of Raf-1.",AIMed.d98.s833
1606,AIMed.d98,True,"Instead, 14-3-3 may facilitate the association of cdc25 with Raf-1 in vivo, participating in the linkage between mitogenic signaling and the cell cycle machinery.",AIMed.d98.s834
1607,AIMed.d99,False,"The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf.",AIMed.d99.s838
1608,AIMed.d99,False,"The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf.",AIMed.d99.s838
1609,AIMed.d99,False,"The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf.",AIMed.d99.s838
1610,AIMed.d99,False,"The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf.",AIMed.d99.s838
1611,AIMed.d99,False,"The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf.",AIMed.d99.s838
1612,AIMed.d99,False,"The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf.",AIMed.d99.s838
1613,AIMed.d99,False,"CSA protein interacts with CSB protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH.",AIMed.d99.s841
1614,AIMed.d99,True,"CSA protein interacts with CSB protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH.",AIMed.d99.s841
1615,AIMed.d99,True,"CSA protein interacts with CSB protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH.",AIMed.d99.s841
1616,AIMed.d99,False,These observations suggest that the products of the CSA and CSB genes are involved in transcription.,AIMed.d99.s842
1617,AIMed.d100,False,Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex.,AIMed.d100.s846
1618,AIMed.d100,False,Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex.,AIMed.d100.s846
1619,AIMed.d100,False,Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex.,AIMed.d100.s846
1620,AIMed.d100,False,"The hTAFII250 gene is identical to a gene, CCG1, (ref 7,8), implicated in cell-cycle progression.",AIMed.d100.s849
1621,AIMed.d100,False,"Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex.",AIMed.d100.s850
1622,AIMed.d100,True,"Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex.",AIMed.d100.s850
1623,AIMed.d100,False,"Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex.",AIMed.d100.s850
1624,AIMed.d100,False,"This largest TAF may therefore play a central role in TFIID assembly by interacting with both TBP and other TAFs, as well as serving to link the control of transcription to the cell cycle.",AIMed.d100.s851
1625,AIMed.d101,True,The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.,AIMed.d101.s852
1626,AIMed.d101,True,The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.,AIMed.d101.s852
1627,AIMed.d101,False,The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.,AIMed.d101.s852
1628,AIMed.d101,True,Fos and Jun oncoproteins form a complex that regulates transcription from promoters containing AP-1 binding sites.,AIMed.d101.s853
1629,AIMed.d101,False,"The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.",AIMed.d101.s855
1630,AIMed.d101,True,"The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.",AIMed.d101.s855
1631,AIMed.d101,True,"The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.",AIMed.d101.s855
1632,AIMed.d101,True,"The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.",AIMed.d101.s855
1633,AIMed.d101,True,"The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.",AIMed.d101.s855
1634,AIMed.d101,False,"The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.",AIMed.d101.s855
1635,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1636,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1637,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1638,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1639,AIMed.d101,True,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1640,AIMed.d101,True,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1641,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1642,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1643,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1644,AIMed.d101,True,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1645,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1646,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1647,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1648,AIMed.d101,False,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1649,AIMed.d101,True,"Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.",AIMed.d101.s856
1650,AIMed.d101,True,"A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.",AIMed.d101.s857
1651,AIMed.d101,False,"A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.",AIMed.d101.s857
1652,AIMed.d101,False,"A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.",AIMed.d101.s857
1653,AIMed.d101,True,"A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.",AIMed.d101.s857
1654,AIMed.d101,True,"A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.",AIMed.d101.s857
1655,AIMed.d101,False,"A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.",AIMed.d101.s857
1656,AIMed.d101,False,"We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.",AIMed.d101.s858
1657,AIMed.d101,True,"We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.",AIMed.d101.s858
1658,AIMed.d101,True,"We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.",AIMed.d101.s858
1659,AIMed.d102,True,The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.,AIMed.d102.s859
1660,AIMed.d102,False,The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.,AIMed.d102.s859
1661,AIMed.d102,False,The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.,AIMed.d102.s859
1662,AIMed.d102,False,The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.,AIMed.d102.s859
1663,AIMed.d102,False,The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.,AIMed.d102.s859
1664,AIMed.d102,False,The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.,AIMed.d102.s859
1665,AIMed.d102,False,"RB, the protein product of the retinoblastoma tumor-suppressor gene, regulates the activity of specific transcription factors.",AIMed.d102.s860
1666,AIMed.d102,False,Here we report that stimulation of Sp1-mediated transcription by RB is partially abrogated at the nonpermissive temperature in ts13 cells.,AIMed.d102.s862
1667,AIMed.d102,False,"These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.",AIMed.d102.s863
1668,AIMed.d102,False,"These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.",AIMed.d102.s863
1669,AIMed.d102,False,"These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.",AIMed.d102.s863
1670,AIMed.d102,False,"These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.",AIMed.d102.s863
1671,AIMed.d102,False,"These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.",AIMed.d102.s863
1672,AIMed.d102,False,"These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.",AIMed.d102.s863
1673,AIMed.d102,False,The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.,AIMed.d102.s864
1674,AIMed.d102,False,The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.,AIMed.d102.s864
1675,AIMed.d102,False,The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.,AIMed.d102.s864
1676,AIMed.d102,True,"Furthermore, we demonstrate that RB binds directly to hTAFII250 in vitro and in vivo.",AIMed.d102.s865
1677,AIMed.d102,True,"These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with TAFII250.",AIMed.d102.s866
1678,AIMed.d102,False,"These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with TAFII250.",AIMed.d102.s866
1679,AIMed.d102,False,"These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with TAFII250.",AIMed.d102.s866
1680,AIMed.d103,True,"Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID.",AIMed.d103.s867
1681,AIMed.d103,False,"Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID.",AIMed.d103.s867
1682,AIMed.d103,True,"Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID.",AIMed.d103.s867
1683,AIMed.d103,False,"Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID.",AIMed.d103.s867
1684,AIMed.d103,True,"Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID.",AIMed.d103.s867
1685,AIMed.d103,False,"Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID.",AIMed.d103.s867
1686,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1687,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1688,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1689,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1690,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1691,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1692,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1693,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1694,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1695,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1696,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1697,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1698,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1699,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1700,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1701,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1702,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1703,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1704,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1705,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1706,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1707,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1708,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1709,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1710,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1711,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1712,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1713,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1714,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1715,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1716,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1717,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1718,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1719,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1720,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1721,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1722,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1723,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1724,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1725,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1726,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1727,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1728,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1729,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1730,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1731,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1732,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1733,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1734,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1735,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1736,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1737,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1738,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1739,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1740,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1741,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1742,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1743,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1744,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1745,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1746,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1747,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1748,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1749,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1750,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1751,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1752,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1753,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1754,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1755,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1756,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1757,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1758,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1759,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1760,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1761,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1762,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1763,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1764,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1765,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1766,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1767,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1768,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1769,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1770,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1771,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1772,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1773,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1774,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1775,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1776,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1777,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1778,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1779,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1780,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1781,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1782,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1783,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1784,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1785,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1786,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1787,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1788,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1789,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1790,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1791,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1792,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1793,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1794,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1795,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1796,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1797,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1798,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1799,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1800,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1801,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1802,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1803,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1804,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1805,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1806,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1807,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1808,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1809,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1810,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1811,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1812,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1813,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1814,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1815,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1816,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1817,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1818,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1819,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1820,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1821,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1822,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1823,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1824,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1825,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1826,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1827,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1828,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1829,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1830,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1831,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1832,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1833,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1834,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1835,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1836,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1837,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1838,AIMed.d103,False,"We have cloned cDNAs encoding three novel TAFIIs [TATA-binding protein (TBP)-associated factors] from the human (h) HeLa cell TFIID complexes hTAFII28, hTAFII20 and hTAFII18. hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 (hTFIID alpha and hTFIID beta respectively), and is the homologue of Drosophila (d)TAFII30 beta. hTAFII18 is a novel hTAFII which shows homology to the N-terminal region of the yeast TAFIISPT3, but has no known Drosophila counterpart.",AIMed.d103.s868
1839,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1840,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1841,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1842,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1843,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1844,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1845,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1846,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1847,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1848,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1849,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1850,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1851,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1852,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1853,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1854,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1855,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1856,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1857,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1858,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1859,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1860,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1861,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1862,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1863,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1864,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1865,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1866,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1867,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1868,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1869,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1870,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1871,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1872,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1873,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1874,AIMed.d103,False,"In contrast to hTAFII28, hTAFII18 is a TFIID beta-specific hTAFII. hTAFII20 is the homologue of p22, an alternatively spliced form of dTAFII30 alpha (p32).",AIMed.d103.s869
1875,AIMed.d103,False,"We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly; in contrast to its Drosophila homologue, hTAFII28 also interacts directly with TBP.",AIMed.d103.s871
1876,AIMed.d103,True,"We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly; in contrast to its Drosophila homologue, hTAFII28 also interacts directly with TBP.",AIMed.d103.s871
1877,AIMed.d103,False,"We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly; in contrast to its Drosophila homologue, hTAFII28 also interacts directly with TBP.",AIMed.d103.s871
1878,AIMed.d103,False,"We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly; in contrast to its Drosophila homologue, hTAFII28 also interacts directly with TBP.",AIMed.d103.s871
1879,AIMed.d103,True,"We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly; in contrast to its Drosophila homologue, hTAFII28 also interacts directly with TBP.",AIMed.d103.s871
1880,AIMed.d103,False,"We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly; in contrast to its Drosophila homologue, hTAFII28 also interacts directly with TBP.",AIMed.d103.s871
1881,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1882,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1883,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1884,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1885,AIMed.d103,True,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1886,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1887,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1888,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1889,AIMed.d103,True,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1890,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1891,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1892,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1893,AIMed.d103,True,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1894,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1895,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1896,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1897,AIMed.d103,True,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1898,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1899,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1900,AIMed.d103,False,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1901,AIMed.d103,True,"Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28. hTAFII18 also interacts with TBP, but it interacts more strongly with hTAFII28 and hTAFII30.",AIMed.d103.s872
1902,AIMed.d103,False,The binding of hTAFII28 and hTAFII30 requires distinct domains of hTAFII18.,AIMed.d103.s873
1903,AIMed.d103,True,The binding of hTAFII28 and hTAFII30 requires distinct domains of hTAFII18.,AIMed.d103.s873
1904,AIMed.d103,True,The binding of hTAFII28 and hTAFII30 requires distinct domains of hTAFII18.,AIMed.d103.s873
1905,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1906,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1907,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1908,AIMed.d103,True,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1909,AIMed.d103,True,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1910,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1911,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1912,AIMed.d103,True,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1913,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1914,AIMed.d103,False,"As observed with the homologous Drosophila proteins, hTAFII20 interacts directly with TBP; however, additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected.",AIMed.d103.s874
1915,AIMed.d103,False,"These results reveal differences not only in subunit composition, but also in the organization of dTFIID and hTFIID complexes.",AIMed.d103.s875
1916,AIMed.d104,False,This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.,AIMed.d104.s878
1917,AIMed.d104,False,This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.,AIMed.d104.s878
1918,AIMed.d104,False,This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.,AIMed.d104.s878
1919,AIMed.d104,False,This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.,AIMed.d104.s878
1920,AIMed.d104,False,This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.,AIMed.d104.s878
1921,AIMed.d104,False,This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.,AIMed.d104.s878
1922,AIMed.d104,False,"The first cDNA from the E2F family to be cloned was designated E2F-1, and multiple E2F family members have now been identified.",AIMed.d104.s879
1923,AIMed.d104,False,"The first cDNA from the E2F family to be cloned was designated E2F-1, and multiple E2F family members have now been identified.",AIMed.d104.s879
1924,AIMed.d104,False,"The first cDNA from the E2F family to be cloned was designated E2F-1, and multiple E2F family members have now been identified.",AIMed.d104.s879
1925,AIMed.d104,False,Here we demonstrate that DP is also a family of polypeptides with at least two members (hDP-1 and hDP-2).,AIMed.d104.s881
1926,AIMed.d104,False,"Both hDP-1 and hDP-2 bind to all E2F family members in vivo, and each complex is capable of activating transcription.",AIMed.d104.s882
1927,AIMed.d104,False,"Both hDP-1 and hDP-2 bind to all E2F family members in vivo, and each complex is capable of activating transcription.",AIMed.d104.s882
1928,AIMed.d104,False,"Both hDP-1 and hDP-2 bind to all E2F family members in vivo, and each complex is capable of activating transcription.",AIMed.d104.s882
1929,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1930,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1931,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1932,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1933,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1934,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1935,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1936,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1937,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1938,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1939,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1940,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1941,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1942,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1943,AIMed.d104,False,"However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.",AIMed.d104.s883
1944,AIMed.d105,True,Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.,AIMed.d105.s884
1945,AIMed.d105,False,"The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.",AIMed.d105.s885
1946,AIMed.d105,False,"The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.",AIMed.d105.s885
1947,AIMed.d105,True,"The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.",AIMed.d105.s885
1948,AIMed.d105,False,We expressed differently tagged forms of gp130 and used them in solution-phase binding assays to show that the soluble extracellular domains of gp130 undergo dimerization in the absence of membranes.,AIMed.d105.s886
1949,AIMed.d105,False,"We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.",AIMed.d105.s889
1950,AIMed.d105,False,"We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.",AIMed.d105.s889
1951,AIMed.d105,False,"We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.",AIMed.d105.s889
1952,AIMed.d105,True,"We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.",AIMed.d105.s889
1953,AIMed.d105,True,"We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.",AIMed.d105.s889
1954,AIMed.d105,True,"We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.",AIMed.d105.s889
1955,AIMed.d105,False,"The binding properties of these variants in vitro, and the result of using a neutralizing monoclonal antibody directed against site 3, lead to the conclusion that gp130 dimer is formed through direct binding at two independent and differently oriented sites on IL-6.",AIMed.d105.s890
1956,AIMed.d105,True,"Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules.",AIMed.d105.s891
1957,AIMed.d105,True,"Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules.",AIMed.d105.s891
1958,AIMed.d105,True,"Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules.",AIMed.d105.s891
1959,AIMed.d108,False,p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.,AIMed.d108.s909
1960,AIMed.d108,True,p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.,AIMed.d108.s909
1961,AIMed.d108,True,p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.,AIMed.d108.s909
1962,AIMed.d108,False,The multisubunit transcription factor IID (TFIID) is thought to be a primary target for site-specific activators of transcription.,AIMed.d108.s911
1963,AIMed.d108,False,"Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.",AIMed.d108.s912
1964,AIMed.d108,False,"Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.",AIMed.d108.s912
1965,AIMed.d108,False,"Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.",AIMed.d108.s912
1966,AIMed.d108,True,"Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.",AIMed.d108.s912
1967,AIMed.d108,False,"Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.",AIMed.d108.s912
1968,AIMed.d108,True,"Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.",AIMed.d108.s912
1969,AIMed.d108,True,"A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and TAFII60.",AIMed.d108.s913
1970,AIMed.d108,False,"A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and TAFII60.",AIMed.d108.s913
1971,AIMed.d108,True,"A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and TAFII60.",AIMed.d108.s913
1972,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1973,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1974,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1975,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1976,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1977,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1978,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1979,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1980,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1981,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1982,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1983,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1984,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1985,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1986,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1987,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1988,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1989,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1990,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1991,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1992,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1993,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1994,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1995,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1996,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1997,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1998,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
1999,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2000,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2001,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2002,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2003,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2004,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2005,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2006,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2007,AIMed.d108,False,"Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.",AIMed.d108.s914
2008,AIMed.d108,True,"Together, these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex.",AIMed.d108.s915
2009,AIMed.d108,True,"Together, these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex.",AIMed.d108.s915
2010,AIMed.d108,False,"Together, these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex.",AIMed.d108.s915
2011,AIMed.d109,True,Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA.,AIMed.d109.s916
2012,AIMed.d109,True,The Fos and Jun families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements.,AIMed.d109.s917
2013,AIMed.d109,True,We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of c-Fos and c-Jun bound to DNA.,AIMed.d109.s918
2014,AIMed.d109,True,Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the Fos-Jun heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation.,AIMed.d109.s921
2015,AIMed.d110,False,TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).,AIMed.d110.s924
2016,AIMed.d110,False,TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).,AIMed.d110.s924
2017,AIMed.d110,False,TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).,AIMed.d110.s924
2018,AIMed.d110,False,"The cloning of a complementary DNA encoding a human TFIID TAF, TAFII55, that has no known homolog in Drosophila TFIID is now described.",AIMed.d110.s926
2019,AIMed.d110,False,"The cloning of a complementary DNA encoding a human TFIID TAF, TAFII55, that has no known homolog in Drosophila TFIID is now described.",AIMed.d110.s926
2020,AIMed.d110,False,"The cloning of a complementary DNA encoding a human TFIID TAF, TAFII55, that has no known homolog in Drosophila TFIID is now described.",AIMed.d110.s926
2021,AIMed.d110,True,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2022,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2023,AIMed.d110,True,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2024,AIMed.d110,True,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2025,AIMed.d110,True,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2026,AIMed.d110,True,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2027,AIMed.d110,True,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2028,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2029,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2030,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2031,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2032,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2033,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2034,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2035,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2036,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2037,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2038,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2039,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2040,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2041,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2042,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2043,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2044,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2045,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2046,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2047,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2048,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2049,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2050,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2051,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2052,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2053,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2054,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2055,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2056,AIMed.d110,False,"TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.",AIMed.d110.s927
2057,AIMed.d110,False,"The TAFII55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.",AIMed.d110.s928
2058,AIMed.d110,True,"The TAFII55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.",AIMed.d110.s928
2059,AIMed.d110,True,"The TAFII55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.",AIMed.d110.s928
2060,AIMed.d112,True,Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.,AIMed.d112.s944
2061,AIMed.d112,True,Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.,AIMed.d112.s944
2062,AIMed.d112,True,Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.,AIMed.d112.s944
2063,AIMed.d112,False,Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.,AIMed.d112.s944
2064,AIMed.d112,False,Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.,AIMed.d112.s944
2065,AIMed.d112,False,Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.,AIMed.d112.s944
2066,AIMed.d112,False,The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.,AIMed.d112.s945
2067,AIMed.d112,False,The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.,AIMed.d112.s945
2068,AIMed.d112,False,The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.,AIMed.d112.s945
2069,AIMed.d112,False,The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.,AIMed.d112.s945
2070,AIMed.d112,False,The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.,AIMed.d112.s945
2071,AIMed.d112,False,The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.,AIMed.d112.s945
2072,AIMed.d112,True,Here we show that Syk and Lyn from human B lymphocytes can interact directly.,AIMed.d112.s946
2073,AIMed.d112,True,"Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.",AIMed.d112.s947
2074,AIMed.d112,False,"Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.",AIMed.d112.s947
2075,AIMed.d112,False,"Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.",AIMed.d112.s947
2076,AIMed.d112,False,"Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.",AIMed.d112.s947
2077,AIMed.d112,False,"Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.",AIMed.d112.s947
2078,AIMed.d112,True,"Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.",AIMed.d112.s947
2079,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2080,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2081,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2082,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2083,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2084,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2085,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2086,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2087,AIMed.d112,True,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2088,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2089,AIMed.d112,True,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2090,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2091,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2092,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2093,AIMed.d112,False,"This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.",AIMed.d112.s948
2094,AIMed.d112,False,"Crosslinking of cell surface IgM led to rapid activation of both tyrosine and serine/threonine protein kinase activities that resulted in phosphorylation in vitro of proteins coprecipitating with Syk--in particular, a serine/threonine phosphorylated protein 120 kDa in size (pp120).",AIMed.d112.s950
2095,AIMed.d112,False,"Several phosphoproteins, including one of 72 kDa and one of 120 kDa, coprecipitated with phospholipase C-gamma 1 (PLC gamma 1).",AIMed.d112.s951
2096,AIMed.d112,True,Sequential immunoprecipitation identified the 72-kDa protein associated with PLC gamma 1 as Syk.,AIMed.d112.s952
2097,AIMed.d112,False,The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk-associated pp120 by several criteria.,AIMed.d112.s953
2098,AIMed.d112,True,The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk-associated pp120 by several criteria.,AIMed.d112.s953
2099,AIMed.d112,False,The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk-associated pp120 by several criteria.,AIMed.d112.s953
2100,AIMed.d112,True,"Thus, pp120 may serve as a link between Syk and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.",AIMed.d112.s954
2101,AIMed.d112,True,"Thus, pp120 may serve as a link between Syk and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.",AIMed.d112.s954
2102,AIMed.d112,True,"Thus, pp120 may serve as a link between Syk and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.",AIMed.d112.s954
2103,AIMed.d113,False,Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity.,AIMed.d113.s955
2104,AIMed.d113,True,Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity.,AIMed.d113.s955
2105,AIMed.d113,False,Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity.,AIMed.d113.s955
2106,AIMed.d113,True,"Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1.",AIMed.d113.s956
2107,AIMed.d113,False,"Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1.",AIMed.d113.s956
2108,AIMed.d113,False,"Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1.",AIMed.d113.s956
2109,AIMed.d113,False,"The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers.",AIMed.d113.s957
2110,AIMed.d113,False,"The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers.",AIMed.d113.s957
2111,AIMed.d113,False,"The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers.",AIMed.d113.s957
2112,AIMed.d113,False,"In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.",AIMed.d113.s958
2113,AIMed.d113,False,"In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.",AIMed.d113.s958
2114,AIMed.d113,False,"In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.",AIMed.d113.s958
2115,AIMed.d113,False,"In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.",AIMed.d113.s958
2116,AIMed.d113,False,"In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.",AIMed.d113.s958
2117,AIMed.d113,False,"In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.",AIMed.d113.s958
2118,AIMed.d113,False,The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.,AIMed.d113.s960
2119,AIMed.d113,False,The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.,AIMed.d113.s960
2120,AIMed.d113,False,The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.,AIMed.d113.s960
2121,AIMed.d114,False,Syntrophin binds to an alternatively spliced exon of dystrophin.,AIMed.d114.s961
2122,AIMed.d114,False,We expressed the cDNA of human beta 1-syntrophin and the COOH terminus of human dystrophin in reticulocyte lysates using an in vitro transcription/translation system.,AIMed.d114.s964
2123,AIMed.d114,True,"We demonstrate that the 53 amino acids encoded on exon 74 of dystrophin, an alternatively spliced exon, are necessary and sufficient for interaction with translated beta 1-syntrophin in our assay.",AIMed.d114.s966
2124,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2125,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2126,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2127,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2128,AIMed.d114,True,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2129,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2130,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2131,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2132,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2133,AIMed.d114,True,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2134,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2135,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2136,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2137,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2138,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2139,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2140,AIMed.d114,True,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2141,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2142,AIMed.d114,True,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2143,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2144,AIMed.d114,False,"In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.",AIMed.d114.s968
2145,AIMed.d114,False,"We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.",AIMed.d114.s969
2146,AIMed.d114,True,"We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.",AIMed.d114.s969
2147,AIMed.d114,False,"We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.",AIMed.d114.s969
2148,AIMed.d114,False,"We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.",AIMed.d114.s969
2149,AIMed.d114,True,"We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.",AIMed.d114.s969
2150,AIMed.d114,False,"We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.",AIMed.d114.s969
2151,AIMed.d115,False,Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor.,AIMed.d115.s970
2152,AIMed.d115,False,Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor.,AIMed.d115.s970
2153,AIMed.d115,True,Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor.,AIMed.d115.s970
2154,AIMed.d115,False,"A few general transcription factors, in particular TFIID and TFIIB, have been found to bind transcriptional activators.",AIMed.d115.s971
2155,AIMed.d115,False,"Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.",AIMed.d115.s972
2156,AIMed.d115,False,"Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.",AIMed.d115.s972
2157,AIMed.d115,False,"Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.",AIMed.d115.s972
2158,AIMed.d115,False,"Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.",AIMed.d115.s972
2159,AIMed.d115,False,"Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.",AIMed.d115.s972
2160,AIMed.d115,False,"Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.",AIMed.d115.s972
2161,AIMed.d115,False,"Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.",AIMed.d115.s973
2162,AIMed.d115,False,"Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.",AIMed.d115.s973
2163,AIMed.d115,False,"Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.",AIMed.d115.s973
2164,AIMed.d115,False,"Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.",AIMed.d115.s973
2165,AIMed.d115,True,"Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.",AIMed.d115.s973
2166,AIMed.d115,False,"Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.",AIMed.d115.s973
2167,AIMed.d115,False,"Further, RAP74's central charged cluster domain is required for binding to SRF's activation domain.",AIMed.d115.s974
2168,AIMed.d115,False,Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.,AIMed.d115.s975
2169,AIMed.d115,False,Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.,AIMed.d115.s975
2170,AIMed.d115,False,Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.,AIMed.d115.s975
2171,AIMed.d115,False,The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.,AIMed.d115.s976
2172,AIMed.d115,True,The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.,AIMed.d115.s976
2173,AIMed.d115,False,The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.,AIMed.d115.s976
2174,AIMed.d115,False,The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.,AIMed.d115.s976
2175,AIMed.d115,True,The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.,AIMed.d115.s976
2176,AIMed.d115,False,The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.,AIMed.d115.s976
2177,AIMed.d116,True,Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product.,AIMed.d116.s977
2178,AIMed.d116,False,The protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a tumour suppressor and negative growth regulator.,AIMed.d116.s978
2179,AIMed.d116,True,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2180,AIMed.d116,True,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2181,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2182,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2183,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2184,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2185,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2186,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2187,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2188,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2189,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2190,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2191,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2192,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2193,AIMed.d116,False,Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.,AIMed.d116.s980
2194,AIMed.d116,True,"This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between Rb and UBF.",AIMed.d116.s981
2195,AIMed.d116,False,"These results indicate that there is an additional mechanism by which Rb suppresses cell growth, namely that Rb directly represses transcription of the rRNA genes.",AIMed.d116.s982
2196,AIMed.d117,False,The beta:beta activin homodimer and alpha:beta inhibin heterodimer are mutual antagonists which share a common beta subunit.,AIMed.d117.s984
2197,AIMed.d117,False,"Activin type I receptors, SKR1 and SKR2, were first cloned from well differentiated human hepatoma cells (HepG2).",AIMed.d117.s987
2198,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2199,AIMed.d117,True,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2200,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2201,AIMed.d117,True,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2202,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2203,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2204,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2205,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2206,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2207,AIMed.d117,False,Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.,AIMed.d117.s989
2208,AIMed.d117,False,SKR2 complexes in which an activin beta chain occupies each receptor subunit.,AIMed.d117.s990
2209,AIMed.d117,False,"Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII.",AIMed.d117.s991
2210,AIMed.d117,True,"Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII.",AIMed.d117.s991
2211,AIMed.d117,False,"Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII.",AIMed.d117.s991
2212,AIMed.d117,False,"Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII.",AIMed.d117.s991
2213,AIMed.d117,False,"Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII.",AIMed.d117.s991
2214,AIMed.d117,False,"Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII.",AIMed.d117.s991
2215,AIMed.d118,True,The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.,AIMed.d118.s996
2216,AIMed.d118,False,The p53 tumour-suppressor protein controls the expression of a gene encoding the p21 cyclin-dependent protein kinase (CDK) regulator.,AIMed.d118.s997
2217,AIMed.d118,False,Levels of p21 protein are increased in senescent cells and p21 overexpression blocks the growth of tumour cells.,AIMed.d118.s998
2218,AIMed.d118,True,"In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA).",AIMed.d118.s999
2219,AIMed.d118,True,"In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA).",AIMed.d118.s999
2220,AIMed.d118,False,"In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA).",AIMed.d118.s999
2221,AIMed.d118,False,"p21 controls CDK activity, thereby affecting cell-cycle control, whereas PCNA functions in both DNA replication and repair.",AIMed.d118.s1000
2222,AIMed.d118,True,Here we use simian virus 40 DNA replication in vitro to show than p21 directly inhibits PCNA-dependent DNA replication in the absence of a cyclin/CDK.,AIMed.d118.s1001
2223,AIMed.d118,False,"Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase.",AIMed.d118.s1002
2224,AIMed.d118,True,"Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase.",AIMed.d118.s1002
2225,AIMed.d118,True,"Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase.",AIMed.d118.s1002
2226,AIMed.d118,True,This regulation results from a direct interaction between p21 and PCNA.,AIMed.d118.s1003
2227,AIMed.d118,False,"Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.",AIMed.d118.s1004
2228,AIMed.d118,False,"Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.",AIMed.d118.s1004
2229,AIMed.d118,False,"Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.",AIMed.d118.s1004
2230,AIMed.d119,True,Nuclear protein CBP is a coactivator for the transcription factor CREB.,AIMed.d119.s1005
2231,AIMed.d119,True,"CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.",AIMed.d119.s1007
2232,AIMed.d119,False,"CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.",AIMed.d119.s1007
2233,AIMed.d119,True,"CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.",AIMed.d119.s1007
2234,AIMed.d119,False,"CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.",AIMed.d119.s1007
2235,AIMed.d119,False,"CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.",AIMed.d119.s1007
2236,AIMed.d119,False,"CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.",AIMed.d119.s1007
2237,AIMed.d119,True,"We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB.",AIMed.d119.s1009
2238,AIMed.d119,False,"We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB.",AIMed.d119.s1009
2239,AIMed.d119,True,"We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB.",AIMed.d119.s1009
2240,AIMed.d119,False,We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus.,AIMed.d119.s1010
2241,AIMed.d119,True,We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus.,AIMed.d119.s1010
2242,AIMed.d119,False,We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus.,AIMed.d119.s1010
2243,AIMed.d119,False,The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).,AIMed.d119.s1011
2244,AIMed.d119,False,The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).,AIMed.d119.s1011
2245,AIMed.d119,True,The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).,AIMed.d119.s1011
2246,AIMed.d119,True,"Consistent with its role as a coactivator, CBP augments the activity of phosphorylated CREB to activate transcription of cAMP-responsive genes.",AIMed.d119.s1012
2247,AIMed.d120,True,"Specific binding of the transglutaminase, platelet factor XIII, to HSP27.",AIMed.d120.s1013
2248,AIMed.d120,False,"However, the function of HSP27 and the identity of proteins that interact with HSP27 remain unknown.",AIMed.d120.s1016
2249,AIMed.d120,False,"To identify specific HSP27-protein interactions, a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with HSP27 from human platelet lysates and erythroleukemia cells.",AIMed.d120.s1017
2250,AIMed.d120,True,Immunoblotting studies were used to confirm the binding of FXIII from fresh platelet lysates to the HSP27 fusion protein.,AIMed.d120.s1020
2251,AIMed.d120,True,FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.,AIMed.d120.s1021
2252,AIMed.d120,False,FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.,AIMed.d120.s1021
2253,AIMed.d120,False,FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.,AIMed.d120.s1021
2254,AIMed.d120,False,The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.,AIMed.d120.s1022
2255,AIMed.d120,True,The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.,AIMed.d120.s1022
2256,AIMed.d120,False,The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.,AIMed.d120.s1022
2257,AIMed.d120,False,The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.,AIMed.d120.s1022
2258,AIMed.d120,True,The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.,AIMed.d120.s1022
2259,AIMed.d120,False,The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.,AIMed.d120.s1022
2260,AIMed.d121,True,"Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.",AIMed.d121.s1023
2261,AIMed.d121,False,"Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.",AIMed.d121.s1023
2262,AIMed.d121,False,"Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.",AIMed.d121.s1023
2263,AIMed.d121,False,"Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.",AIMed.d121.s1023
2264,AIMed.d121,True,"Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.",AIMed.d121.s1023
2265,AIMed.d121,False,"Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.",AIMed.d121.s1023
2266,AIMed.d121,False,The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.,AIMed.d121.s1025
2267,AIMed.d121,True,The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.,AIMed.d121.s1025
2268,AIMed.d121,False,The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.,AIMed.d121.s1025
2269,AIMed.d121,False,The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.,AIMed.d121.s1025
2270,AIMed.d121,False,The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.,AIMed.d121.s1025
2271,AIMed.d121,True,The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.,AIMed.d121.s1025
2272,AIMed.d121,True,"Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.",AIMed.d121.s1028
2273,AIMed.d121,False,"Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.",AIMed.d121.s1028
2274,AIMed.d121,False,"Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.",AIMed.d121.s1028
2275,AIMed.d121,False,"Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.",AIMed.d121.s1028
2276,AIMed.d121,False,"Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.",AIMed.d121.s1028
2277,AIMed.d121,True,"Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.",AIMed.d121.s1028
2278,AIMed.d121,True,"In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).",AIMed.d121.s1029
2279,AIMed.d121,True,"In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).",AIMed.d121.s1029
2280,AIMed.d121,False,"In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).",AIMed.d121.s1029
2281,AIMed.d121,False,These mutations have no impact on the ability of the p53 protein to bind to a p53-specific DNA element.,AIMed.d121.s1031
2282,AIMed.d121,False,These very same hydrophobic residues contact the hdm-2 and Ad5 E1B 55-kD oncogene products.,AIMed.d121.s1033
2283,AIMed.d122,True,"In previous studies (Scott, J. D., Stofko, R. E., McDonald, J. R., Comer, J. D., Vitalis, E. A., and Mangili J. (1990) J. Biol. Chem. 265, 21561-21566) we have shown that dimerization of RII alpha was required for interaction with the cytoskeletal component microtubule-associated protein 2.",AIMed.d122.s1036
2284,AIMed.d122,True,"Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.",AIMed.d122.s1041
2285,AIMed.d122,False,"Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.",AIMed.d122.s1041
2286,AIMed.d122,True,"Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.",AIMed.d122.s1041
2287,AIMed.d123,True,Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system.,AIMed.d123.s1043
2288,AIMed.d123,False,Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.,AIMed.d123.s1044
2289,AIMed.d123,False,Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.,AIMed.d123.s1044
2290,AIMed.d123,False,Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.,AIMed.d123.s1044
2291,AIMed.d123,True,Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.,AIMed.d123.s1044
2292,AIMed.d123,False,Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.,AIMed.d123.s1044
2293,AIMed.d123,True,Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.,AIMed.d123.s1044
2294,AIMed.d123,True,"Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.",AIMed.d123.s1045
2295,AIMed.d123,False,"Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.",AIMed.d123.s1045
2296,AIMed.d123,False,"Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.",AIMed.d123.s1045
2297,AIMed.d123,False,"In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.",AIMed.d123.s1046
2298,AIMed.d123,True,"In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.",AIMed.d123.s1046
2299,AIMed.d123,False,"In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.",AIMed.d123.s1046
2300,AIMed.d123,True,We demonstrate that IRS-1 forms a specific complex with the cytoplasmic domain of the insulin receptor when both are expressed as hybrid proteins in yeast cells.,AIMed.d123.s1047
2301,AIMed.d123,False,"Lastly, in agreement with our findings for yeast cells, we show that the insulin receptor is unable to phosphorylate an IRS-1 protein containing a deletion of amino acids 45 to 516 when expressed in COS cells.",AIMed.d123.s1052
2302,AIMed.d124,True,"The protein Raf-1, a key mediator of mitogenesis and differentiation, associates with p21ras (refs 1-3).",AIMed.d124.s1055
2303,AIMed.d124,False,"These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.",AIMed.d124.s1058
2304,AIMed.d124,False,"These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.",AIMed.d124.s1058
2305,AIMed.d124,False,"These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.",AIMed.d124.s1058
2306,AIMed.d124,False,"These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.",AIMed.d124.s1058
2307,AIMed.d124,False,"These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.",AIMed.d124.s1058
2308,AIMed.d124,False,"These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.",AIMed.d124.s1058
2309,AIMed.d124,False,Expression of 14-3-3 proteins in Xenopus oocytes enhanced Raf-1 activity and promoted Raf-1-dependent oocyte maturation.,AIMed.d124.s1059
2310,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2311,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2312,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2313,AIMed.d125,True,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2314,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2315,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2316,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2317,AIMed.d125,True,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2318,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2319,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2320,AIMed.d125,True,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2321,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2322,AIMed.d125,True,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2323,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2324,AIMed.d125,False,"Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.",AIMed.d125.s1062
2325,AIMed.d125,True,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2326,AIMed.d125,False,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2327,AIMed.d125,False,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2328,AIMed.d125,False,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2329,AIMed.d125,True,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2330,AIMed.d125,True,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2331,AIMed.d125,True,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2332,AIMed.d125,False,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2333,AIMed.d125,False,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2334,AIMed.d125,False,Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.,AIMed.d125.s1066
2335,AIMed.d125,False,Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.,AIMed.d125.s1067
2336,AIMed.d125,False,Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.,AIMed.d125.s1067
2337,AIMed.d125,False,Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.,AIMed.d125.s1067
2338,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2339,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2340,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2341,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2342,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2343,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2344,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2345,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2346,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2347,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2348,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2349,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2350,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2351,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2352,AIMed.d125,False,"Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.",AIMed.d125.s1068
2353,AIMed.d125,False,"In contrast to LexA/Bcl-2 fusion proteins, expression of a LexA/Bax protein was lethal to yeast.",AIMed.d125.s1069
2354,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2355,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2356,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2357,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2358,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2359,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2360,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2361,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2362,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2363,AIMed.d125,False,"This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).",AIMed.d125.s1070
2364,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2365,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2366,AIMed.d125,True,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2367,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2368,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2369,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2370,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2371,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2372,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2373,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2374,AIMed.d125,True,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2375,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2376,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2377,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2378,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2379,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2380,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2381,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2382,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2383,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2384,AIMed.d125,False,"The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.",AIMed.d125.s1071
2385,AIMed.d126,False,The rates of commitment to renaturation of rhodanese and glutamine synthetase in the presence of the groE chaperonins.,AIMed.d126.s1072
2386,AIMed.d126,False,"Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.",AIMed.d126.s1074
2387,AIMed.d126,False,"Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.",AIMed.d126.s1074
2388,AIMed.d126,True,"Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.",AIMed.d126.s1074
2389,AIMed.d126,False,"Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.",AIMed.d126.s1074
2390,AIMed.d126,True,"Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.",AIMed.d126.s1074
2391,AIMed.d126,True,"Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.",AIMed.d126.s1074
2392,AIMed.d126,True,"Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable ""folding arrested"" complexes with groEL.",AIMed.d126.s1075
2393,AIMed.d126,False,"Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable ""folding arrested"" complexes with groEL.",AIMed.d126.s1075
2394,AIMed.d126,True,"Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable ""folding arrested"" complexes with groEL.",AIMed.d126.s1075
2395,AIMed.d126,False,"At 25 degrees C, the rate profiles indicate the release and commitment to folding of GS to its native state occurs far earlier (t1/2 < 1 min) than for rhodanese (t1/2 = 5 min).",AIMed.d126.s1078
2396,AIMed.d126,False,"In contrast, the renaturation rate for rhodanese with the groE chaperonins mirrored the committed renaturation rates following groEL depletion.",AIMed.d126.s1080
2397,AIMed.d126,True,This suggests that rhodanese must interact with groEL throughout most of its folding reaction before it acquires a folding competent (groE independent) state.,AIMed.d126.s1081
2398,AIMed.d126,False,"If current models of chaperonin mechanism are correct, rhodanese undergoes more rebinding and release cycles than does GS.",AIMed.d126.s1082
2399,AIMed.d127,True,Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.,AIMed.d127.s1084
2400,AIMed.d127,True,Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.,AIMed.d127.s1084
2401,AIMed.d127,False,Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.,AIMed.d127.s1084
2402,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2403,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2404,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2405,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2406,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2407,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2408,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2409,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2410,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2411,AIMed.d127,False,Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.,AIMed.d127.s1085
2412,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2413,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2414,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2415,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2416,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2417,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2418,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2419,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2420,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2421,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2422,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2423,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2424,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2425,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2426,AIMed.d127,False,"IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.",AIMed.d127.s1087
2427,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2428,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2429,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2430,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2431,AIMed.d127,True,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2432,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2433,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2434,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2435,AIMed.d127,True,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2436,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2437,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2438,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2439,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2440,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2441,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2442,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2443,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2444,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2445,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2446,AIMed.d127,False,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2447,AIMed.d127,True,"Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.",AIMed.d127.s1088
2448,AIMed.d127,False,"Thus, gamma c mutations in at least some XSCID and XCID patients prevent normal Jak3 activation, suggesting that mutations of Jak3 may result in an XSCID-like phenotype.",AIMed.d127.s1090
2449,AIMed.d128,False,The X-ray structure of a growth hormone-prolactin receptor complex.,AIMed.d128.s1091
2450,AIMed.d128,False,"The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.",AIMed.d128.s1092
2451,AIMed.d128,False,"The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.",AIMed.d128.s1092
2452,AIMed.d128,False,"The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.",AIMed.d128.s1092
2453,AIMed.d128,False,"The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.",AIMed.d128.s1092
2454,AIMed.d128,False,"The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.",AIMed.d128.s1092
2455,AIMed.d128,False,"The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.",AIMed.d128.s1092
2456,AIMed.d128,True,"The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.",AIMed.d128.s1094
2457,AIMed.d128,False,"The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.",AIMed.d128.s1094
2458,AIMed.d128,False,"The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.",AIMed.d128.s1094
2459,AIMed.d128,False,"The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.",AIMed.d128.s1094
2460,AIMed.d128,False,"The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.",AIMed.d128.s1094
2461,AIMed.d128,True,"The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.",AIMed.d128.s1094
2462,AIMed.d128,True,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2463,AIMed.d128,True,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2464,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2465,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2466,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2467,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2468,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2469,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2470,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2471,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2472,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2473,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2474,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2475,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2476,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2477,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2478,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2479,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2480,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2481,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2482,AIMed.d128,False,"In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.",AIMed.d128.s1097
2483,AIMed.d128,True,We present here the crystal structure of the 1:1 complex of hGH bound to the extracellular domain of the hPRLR.,AIMed.d128.s1098
2484,AIMed.d128,False,Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.,AIMed.d128.s1099
2485,AIMed.d128,True,Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.,AIMed.d128.s1099
2486,AIMed.d128,False,Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.,AIMed.d128.s1099
2487,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2488,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2489,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2490,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2491,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2492,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2493,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2494,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2495,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2496,AIMed.d129,False,"Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.",AIMed.d129.s1101
2497,AIMed.d129,False,"p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.",AIMed.d129.s1102
2498,AIMed.d129,False,"p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.",AIMed.d129.s1102
2499,AIMed.d129,False,"p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.",AIMed.d129.s1102
2500,AIMed.d129,False,"p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.",AIMed.d129.s1102
2501,AIMed.d129,False,"p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.",AIMed.d129.s1102
2502,AIMed.d129,False,"p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.",AIMed.d129.s1102
2503,AIMed.d129,False,"Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.",AIMed.d129.s1104
2504,AIMed.d129,False,"Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.",AIMed.d129.s1104
2505,AIMed.d129,False,"Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.",AIMed.d129.s1104
2506,AIMed.d129,False,Bacterially overexpressed human p23 was used to raise several monoclonal antibodies to p23.,AIMed.d129.s1110
2507,AIMed.d129,True,These antibodies specifically immunoprecipitate p23 in complex with hsp90 in all tissues tested and can be used to immunoaffinity isolate progesterone receptor complexes from chicken oviduct cytosol.,AIMed.d129.s1111
2508,AIMed.d130,False,Cloning of the complete coding region for human protein phosphatase inhibitor 2 using the two hybrid system and expression of inhibitor 2 in E. coli.,AIMed.d130.s1112
2509,AIMed.d131,False,Expression cloning and characterization of a human IL-10 receptor.,AIMed.d131.s1119
2510,AIMed.d131,False,"cDNA clones encoding a human IL-10R (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.",AIMed.d131.s1120
2511,AIMed.d131,True,"cDNA clones encoding a human IL-10R (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.",AIMed.d131.s1120
2512,AIMed.d131,True,"cDNA clones encoding a human IL-10R (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.",AIMed.d131.s1120
2513,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2514,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2515,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2516,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2517,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2518,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2519,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2520,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2521,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2522,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2523,AIMed.d131,True,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2524,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2525,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2526,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2527,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2528,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2529,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2530,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2531,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2532,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2533,AIMed.d131,False,"The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.",AIMed.d131.s1121
2534,AIMed.d131,False,"Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.",AIMed.d131.s1122
2535,AIMed.d131,False,"Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.",AIMed.d131.s1122
2536,AIMed.d131,False,"Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.",AIMed.d131.s1122
2537,AIMed.d131,False,"Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.",AIMed.d131.s1122
2538,AIMed.d131,False,"Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.",AIMed.d131.s1122
2539,AIMed.d131,False,"Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.",AIMed.d131.s1122
2540,AIMed.d131,False,"In a number of human T cell clones, expression of hIL-10R mRNA is down-regulated after activation of the cells with anti-CD3 Ab and phorbol ester.",AIMed.d131.s1124
2541,AIMed.d131,False,"Like mIL-10R, hIL-10R is structurally related to IFNR.",AIMed.d131.s1126
2542,AIMed.d131,False,"Like mIL-10R, hIL-10R is structurally related to IFNR.",AIMed.d131.s1126
2543,AIMed.d131,False,"Like mIL-10R, hIL-10R is structurally related to IFNR.",AIMed.d131.s1126
2544,AIMed.d131,False,"Because IL-10 inhibits macrophage activation by IFN-gamma, this relationship suggests possible shared receptor or signal transduction pathway components.",AIMed.d131.s1127
2545,AIMed.d132,False,Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.,AIMed.d132.s1128
2546,AIMed.d132,False,Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.,AIMed.d132.s1128
2547,AIMed.d132,False,Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.,AIMed.d132.s1128
2548,AIMed.d132,False,Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.,AIMed.d132.s1128
2549,AIMed.d132,False,Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.,AIMed.d132.s1128
2550,AIMed.d132,False,Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.,AIMed.d132.s1128
2551,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2552,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2553,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2554,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2555,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2556,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2557,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2558,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2559,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2560,AIMed.d132,False,"The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.",AIMed.d132.s1129
2561,AIMed.d132,False,Studies with monoclonal antibodies specific for the IL-2 receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for IL-7 that are involved in the differentiation of T and B cells.,AIMed.d132.s1130
2562,AIMed.d135,False,Tumor necrosis factor (TNF) and lymphotoxin-alpha (LT-alpha) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses.,AIMed.d135.s1147
2563,AIMed.d135,False,"The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.",AIMed.d135.s1148
2564,AIMed.d135,True,"The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.",AIMed.d135.s1148
2565,AIMed.d135,True,"The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.",AIMed.d135.s1148
2566,AIMed.d135,False,"Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex.",AIMed.d135.s1149
2567,AIMed.d135,True,"Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex.",AIMed.d135.s1149
2568,AIMed.d135,False,"Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex.",AIMed.d135.s1149
2569,AIMed.d135,False,"A receptor specific for human LT-beta was identified, which suggests that cell surface LT may have functions that are distinct from those of secreted LT-alpha.",AIMed.d135.s1150
2570,AIMed.d136,False,"The cytokine, designated interleukin-15 (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.",AIMed.d136.s1153
2571,AIMed.d136,False,"The cytokine, designated interleukin-15 (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.",AIMed.d136.s1153
2572,AIMed.d136,False,"The cytokine, designated interleukin-15 (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.",AIMed.d136.s1153
2573,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2574,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2575,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2576,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2577,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2578,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2579,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2580,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2581,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2582,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2583,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2584,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2585,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2586,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2587,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2588,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2589,AIMed.d136,True,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2590,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2591,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2592,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2593,AIMed.d136,False,"Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.",AIMed.d136.s1154
2594,AIMed.d137,True,The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP.,AIMed.d137.s1155
2595,AIMed.d137,True,The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP.,AIMed.d137.s1155
2596,AIMed.d137,False,The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP.,AIMed.d137.s1155
2597,AIMed.d137,False,We had previously shown that the ubiquitous Oct1 and the lymphoid-specific Oct2 transcription factors stimulate transcription at the level of stable preinitiation complex formation.,AIMed.d137.s1156
2598,AIMed.d137,False,"We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the TATA box binding protein component of the TFIID factor.",AIMed.d137.s1157
2599,AIMed.d137,False,"We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the TATA box binding protein component of the TFIID factor.",AIMed.d137.s1157
2600,AIMed.d137,False,"We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the TATA box binding protein component of the TFIID factor.",AIMed.d137.s1157
2601,AIMed.d137,False,By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2.,AIMed.d137.s1158
2602,AIMed.d137,True,By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2.,AIMed.d137.s1158
2603,AIMed.d137,True,By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2.,AIMed.d137.s1158
2604,AIMed.d137,True,We show that the POU homeodomain of Oct2 and the evolutionarily conserved C-terminal core domain of TBP are both required and sufficient for the interaction.,AIMed.d137.s1161
2605,AIMed.d137,False,"The Oct1 POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with TBP.",AIMed.d137.s1162
2606,AIMed.d137,True,"The Oct1 POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with TBP.",AIMed.d137.s1162
2607,AIMed.d137,False,"The Oct1 POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with TBP.",AIMed.d137.s1162
2608,AIMed.d137,False,"The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.",AIMed.d137.s1163
2609,AIMed.d137,False,"The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.",AIMed.d137.s1163
2610,AIMed.d137,True,"The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.",AIMed.d137.s1163
2611,AIMed.d137,True,"The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.",AIMed.d137.s1163
2612,AIMed.d137,False,"The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.",AIMed.d137.s1163
2613,AIMed.d137,False,"The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.",AIMed.d137.s1163
2614,AIMed.d137,False,Co-transfection of human TBP and Oct2 expression vectors into B cells resulted in a synergistic activation of an octamer motif containing promoter.,AIMed.d137.s1164
2615,AIMed.d138,False,Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast PRP9.,AIMed.d138.s1165
2616,AIMed.d138,False,Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast PRP9.,AIMed.d138.s1165
2617,AIMed.d138,True,Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast PRP9.,AIMed.d138.s1165
2618,AIMed.d138,False,"In the assembly of a prespliceosome, U2 small nuclear ribonucleoprotein (snRNP) functions in pre-messenger RNA (mRNA) splicing together with splicing factors (SFs) 3a, SF3b, and several other proteins.",AIMed.d138.s1166
2619,AIMed.d138,False,Here it is shown that the SF3a subunits correspond to three of the 17S U2 snRNP-specific polypeptides.,AIMed.d138.s1168
2620,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2621,AIMed.d138,True,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2622,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2623,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2624,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2625,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2626,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2627,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2628,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2629,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2630,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2631,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2632,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2633,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2634,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2635,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2636,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2637,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2638,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2639,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2640,AIMed.d138,False,"SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome.",AIMed.d138.s1169
2641,AIMed.d138,False,"Furthermore, the 60-kilodalton subunit of SF3a is related to the yeast splicing protein PRP9.",AIMed.d138.s1170
2642,AIMed.d139,False,Spectrin cagliari. an Ala-->Gly substitution in helix 1 of beta spectrin repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer.,AIMed.d139.s1171
2643,AIMed.d139,True,The self-association site appears to be formed by interactions between helices 1 and 2 of beta spectrin repeat 17 of one dimer with helix 3 of alpha spectrin repeat 1 of the other dimer to form two combined alpha-beta triple-helical segments.,AIMed.d139.s1173
2644,AIMed.d139,False,"Following linkage studies which were most consistent with a beta spectrin gene mutation, a nucleotide change was identified in codon 2018, resulting in an Ala-->Gly substitution in the first helical domain of beta spectrin repeat 17.",AIMed.d139.s1177
2645,AIMed.d141,False,The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.,AIMed.d141.s1188
2646,AIMed.d141,False,"The cyclin-dependent kinase Cdk2 associates with cyclins A, D, and E and has been implicated in the control of the G1 to S phase transition in mammals.",AIMed.d141.s1189
2647,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2648,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2649,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2650,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2651,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2652,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2653,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2654,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2655,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2656,AIMed.d141,False,"CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.",AIMed.d141.s1191
2657,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2658,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2659,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2660,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2661,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2662,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2663,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2664,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2665,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2666,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2667,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2668,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2669,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2670,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2671,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2672,AIMed.d141,True,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2673,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2674,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2675,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2676,AIMed.d141,True,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2677,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2678,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2679,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2680,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2681,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2682,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2683,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2684,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2685,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2686,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2687,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2688,AIMed.d141,True,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2689,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2690,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2691,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2692,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2693,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2694,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2695,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2696,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2697,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2698,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2699,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2700,AIMed.d141,True,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2701,AIMed.d141,False,"p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.",AIMed.d141.s1192
2702,AIMed.d141,False,Cotransfection experiments indicate that CIP1 and SV40 T antigen function in a mutually antagonistic manner to control cell cycle progression.,AIMed.d141.s1193
2703,AIMed.d142,True,Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1.,AIMed.d142.s1194
2704,AIMed.d142,False,The recently cloned YY1 is such an Inr-binding protein.,AIMed.d142.s1197
2705,AIMed.d142,False,The ability of YY1 to initiate transcription is augmented by the presence of a TATA motif or binding sites for transcription factor Sp1.,AIMed.d142.s1199
2706,AIMed.d142,False,"To study the mechanism underlying the apparent functional cooperation between YY1 and Sp1, we explored the possibility of protein-protein interactions between these two transcription factors.",AIMed.d142.s1200
2707,AIMed.d142,True,We found that YY1 and Sp1 can form a physical complex.,AIMed.d142.s1201
2708,AIMed.d142,True,"In addition, we identified domains within YY1 and Sp1 that mediate their interactions with each other.",AIMed.d142.s1202
2709,AIMed.d142,True,The physical interaction between YY1 and Sp1 may thus form the basis for the functional interplay observed previously.,AIMed.d142.s1203
2710,AIMed.d143,False,Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.,AIMed.d143.s1204
2711,AIMed.d143,False,Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.,AIMed.d143.s1204
2712,AIMed.d143,False,Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.,AIMed.d143.s1204
2713,AIMed.d143,False,IL-11 is a novel cytokine with a variety of biofunctions which overlap with those of IL-6.,AIMed.d143.s1205
2714,AIMed.d143,False,We have previously identified IL-11 specific binding protein which is distinct from that of IL-6 in a number of cell lines.,AIMed.d143.s1206
2715,AIMed.d143,False,The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.,AIMed.d143.s1207
2716,AIMed.d143,False,The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.,AIMed.d143.s1207
2717,AIMed.d143,False,The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.,AIMed.d143.s1207
2718,AIMed.d143,False,The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.,AIMed.d143.s1207
2719,AIMed.d143,False,The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.,AIMed.d143.s1207
2720,AIMed.d143,False,The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.,AIMed.d143.s1207
2721,AIMed.d143,False,"We have examined early signals triggered by IL-11 or IL-6 in a multifactor-dependent human erythroleukemic cell line, TF-1.",AIMed.d143.s1208
2722,AIMed.d143,False,"The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.",AIMed.d143.s1209
2723,AIMed.d143,True,"The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.",AIMed.d143.s1209
2724,AIMed.d143,True,"The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.",AIMed.d143.s1209
2725,AIMed.d143,False,"These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130.",AIMed.d143.s1210
2726,AIMed.d143,False,"These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130.",AIMed.d143.s1210
2727,AIMed.d143,False,"These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130.",AIMed.d143.s1210
2728,AIMed.d143,False,We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions.,AIMed.d143.s1211
2729,AIMed.d143,False,We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions.,AIMed.d143.s1211
2730,AIMed.d143,False,We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions.,AIMed.d143.s1211
2731,AIMed.d143,False,"It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.",AIMed.d143.s1212
2732,AIMed.d143,False,"It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.",AIMed.d143.s1212
2733,AIMed.d143,False,"It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.",AIMed.d143.s1212
2734,AIMed.d143,False,"It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.",AIMed.d143.s1212
2735,AIMed.d143,False,"It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.",AIMed.d143.s1212
2736,AIMed.d143,False,"It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.",AIMed.d143.s1212
2737,AIMed.d143,False,"Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells.",AIMed.d143.s1214
2738,AIMed.d143,False,"Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells.",AIMed.d143.s1214
2739,AIMed.d143,False,"Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells.",AIMed.d143.s1214
2740,AIMed.d143,False,"These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.",AIMed.d143.s1215
2741,AIMed.d143,False,"These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.",AIMed.d143.s1215
2742,AIMed.d143,False,"These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.",AIMed.d143.s1215
2743,AIMed.d144,True,The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.,AIMed.d144.s1216
2744,AIMed.d144,False,The retinoblastoma protein (p110RB) interacts with many cellular proteins in complexes potentially important for its growth-suppressing function.,AIMed.d144.s1217
2745,AIMed.d144,False,"One clone encodes a novel type 1 protein phosphatase catalytic subunit (PP-1 alpha 2), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.",AIMed.d144.s1219
2746,AIMed.d144,False,"One clone encodes a novel type 1 protein phosphatase catalytic subunit (PP-1 alpha 2), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.",AIMed.d144.s1219
2747,AIMed.d144,False,"One clone encodes a novel type 1 protein phosphatase catalytic subunit (PP-1 alpha 2), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.",AIMed.d144.s1219
2748,AIMed.d144,True,In vitro-binding assays demonstrated that PP-1 alpha isoforms preferentially bind the hypophosphorylated form of p110RB.,AIMed.d144.s1220
2749,AIMed.d144,True,"Moreover, similar p110RB sequences are required for binding PP-1 alpha 2 and SV40 large T antigen.",AIMed.d144.s1221
2750,AIMed.d144,False,"Moreover, similar p110RB sequences are required for binding PP-1 alpha 2 and SV40 large T antigen.",AIMed.d144.s1221
2751,AIMed.d144,True,"Moreover, similar p110RB sequences are required for binding PP-1 alpha 2 and SV40 large T antigen.",AIMed.d144.s1221
2752,AIMed.d145,False,The novel fold of the TNF receptor structure is likely to be representative of the nerve growth factor (NGF)/TNF receptor family as a whole.,AIMed.d145.s1229
2753,AIMed.d146,False,Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.,AIMed.d146.s1230
2754,AIMed.d146,False,Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.,AIMed.d146.s1230
2755,AIMed.d146,False,Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.,AIMed.d146.s1230
2756,AIMed.d146,False,"We have previously demonstrated such changes by affinity cross-linking studies, and have shown that unstimulated human T cells express a single IL-7R of 90 kDa, whereas activated T cells express an additional 76-kDa IL-7 binding protein.",AIMed.d146.s1233
2757,AIMed.d146,False,In this study the origin and function of the p90 and p76 molecules have been investigated.,AIMed.d146.s1234
2758,AIMed.d146,False,"To determine the role of each of these receptors in IL-7 driven proliferation, IL-7R expression and proliferative capacity were monitored during mitogenic stimulation.",AIMed.d146.s1235
2759,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2760,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2761,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2762,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2763,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2764,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2765,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2766,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2767,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2768,AIMed.d146,False,"These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.",AIMed.d146.s1236
2769,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2770,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2771,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2772,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2773,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2774,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2775,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2776,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2777,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2778,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2779,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2780,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2781,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2782,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2783,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2784,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2785,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2786,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2787,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2788,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2789,AIMed.d146,False,"IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.",AIMed.d146.s1237
2790,AIMed.d146,False,Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.,AIMed.d146.s1238
2791,AIMed.d146,False,Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.,AIMed.d146.s1238
2792,AIMed.d146,False,Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.,AIMed.d146.s1238
2793,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2794,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2795,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2796,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2797,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2798,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2799,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2800,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2801,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2802,AIMed.d146,False,"In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.",AIMed.d146.s1239
2803,AIMed.d146,False,"These antibodies also immunoprecipitated the cloned IL-7R as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa IL-7R.",AIMed.d146.s1240
2804,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2805,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2806,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2807,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2808,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2809,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2810,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2811,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2812,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2813,AIMed.d146,False,"In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.",AIMed.d146.s1241
2814,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2815,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2816,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2817,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2818,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2819,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2820,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2821,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2822,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2823,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2824,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2825,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2826,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2827,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2828,AIMed.d146,False,"These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.",AIMed.d146.s1242
2829,AIMed.d146,False,Taken together these data suggest that the 76-kDa receptor is a novel high affinity IL-7R that may be necessary for IL-7 driven proliferation in human T cells.,AIMed.d146.s1243
2830,AIMed.d147,True,Characterization of the retinoblastoma binding proteins RBP1 and RBP2.,AIMed.d147.s1244
2831,AIMed.d147,False,Characterization of the retinoblastoma binding proteins RBP1 and RBP2.,AIMed.d147.s1244
2832,AIMed.d147,True,Characterization of the retinoblastoma binding proteins RBP1 and RBP2.,AIMed.d147.s1244
2833,AIMed.d147,False,"The retinoblastoma gene product, pRB, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.",AIMed.d147.s1245
2834,AIMed.d147,True,"We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB.",AIMed.d147.s1248
2835,AIMed.d147,False,"We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB.",AIMed.d147.s1248
2836,AIMed.d147,True,"We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB.",AIMed.d147.s1248
2837,AIMed.d147,False,"The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.",AIMed.d147.s1249
2838,AIMed.d147,False,"The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.",AIMed.d147.s1249
2839,AIMed.d147,False,"The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.",AIMed.d147.s1249
2840,AIMed.d147,False,"The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.",AIMed.d147.s1249
2841,AIMed.d147,False,"The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.",AIMed.d147.s1249
2842,AIMed.d147,False,"The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.",AIMed.d147.s1249
2843,AIMed.d147,True,In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.,AIMed.d147.s1250
2844,AIMed.d147,False,In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.,AIMed.d147.s1250
2845,AIMed.d147,False,In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.,AIMed.d147.s1250
2846,AIMed.d148,False,"Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein",AIMed.d148.s1251
2847,AIMed.d148,True,"Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein",AIMed.d148.s1251
2848,AIMed.d148,True,"Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein",AIMed.d148.s1251
2849,AIMed.d148,False,".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.",AIMed.d148.s1252
2850,AIMed.d148,False,".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.",AIMed.d148.s1252
2851,AIMed.d148,False,".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.",AIMed.d148.s1252
2852,AIMed.d148,False,Other recent studies have identified human cyclin D1 (PRAD1) as a putative G1 cyclin and candidate proto-oncogene.,AIMed.d148.s1253
2853,AIMed.d148,False,"Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro.",AIMed.d148.s1257
2854,AIMed.d148,True,"Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro.",AIMed.d148.s1257
2855,AIMed.d148,True,"Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro.",AIMed.d148.s1257
2856,AIMed.d148,True,"In synchronized human osteosarcoma cells, cyclin D1 is induced in early G1 and becomes associated with p9Ckshs1, a Cdk-binding subunit.",AIMed.d148.s1258
2857,AIMed.d148,True,"Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.",AIMed.d148.s1259
2858,AIMed.d148,False,"Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.",AIMed.d148.s1259
2859,AIMed.d148,False,"Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.",AIMed.d148.s1259
2860,AIMed.d148,True,"Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.",AIMed.d148.s1259
2861,AIMed.d148,False,"Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.",AIMed.d148.s1259
2862,AIMed.d148,False,"Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.",AIMed.d148.s1259
2863,AIMed.d150,True,Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein.,AIMed.d150.s1273
2864,AIMed.d150,False,Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein.,AIMed.d150.s1273
2865,AIMed.d150,False,Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein.,AIMed.d150.s1273
2866,AIMed.d150,False,The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression.,AIMed.d150.s1274
2867,AIMed.d150,False,Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation.,AIMed.d150.s1275
2868,AIMed.d150,True,"In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo.",AIMed.d150.s1276
2869,AIMed.d150,False,"In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo.",AIMed.d150.s1276
2870,AIMed.d150,False,"In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo.",AIMed.d150.s1276
2871,AIMed.d150,False,Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma.,AIMed.d150.s1277
2872,AIMed.d150,False,Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma.,AIMed.d150.s1277
2873,AIMed.d150,False,Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma.,AIMed.d150.s1277
2874,AIMed.d150,True,Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells.,AIMed.d150.s1278
2875,AIMed.d150,False,"After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription.",AIMed.d150.s1279
2876,AIMed.d150,False,"After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription.",AIMed.d150.s1279
2877,AIMed.d150,False,"After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription.",AIMed.d150.s1279
2878,AIMed.d150,False,Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation.,AIMed.d150.s1280
2879,AIMed.d150,False,These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor.,AIMed.d150.s1281
2880,AIMed.d151,False,The proximal sequence element (PSE)-binding transcription factor (PTF) specifically recognizes the PSEs of both RNA polymerase II- and RNA polymerase III-transcribed small nuclear RNA (snRNA) genes.,AIMed.d151.s1284
2881,AIMed.d151,False,"We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha, -beta, -gamma, and -delta.",AIMed.d151.s1285
2882,AIMed.d151,False,"We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha, -beta, -gamma, and -delta.",AIMed.d151.s1285
2883,AIMed.d151,False,"We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha, -beta, -gamma, and -delta.",AIMed.d151.s1285
2884,AIMed.d151,False,"We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.",AIMed.d151.s1286
2885,AIMed.d151,False,"We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.",AIMed.d151.s1286
2886,AIMed.d151,False,"We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.",AIMed.d151.s1286
2887,AIMed.d151,False,"Immunoprecipitation studies confirm that the four PTF subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex; they further show that the PTF so defined, including the gamma and delta subunits specifically, is essential for transcription of both class II and class III snRNA genes.",AIMed.d151.s1287
2888,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2889,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2890,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2891,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2892,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2893,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2894,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2895,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2896,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2897,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2898,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2899,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2900,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2901,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2902,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2903,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2904,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2905,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2906,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2907,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2908,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2909,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2910,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2911,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2912,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2913,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2914,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2915,AIMed.d151,False,"Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.",AIMed.d151.s1288
2916,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2917,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2918,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2919,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2920,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2921,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2922,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2923,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2924,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2925,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2926,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2927,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2928,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2929,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2930,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2931,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2932,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2933,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2934,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2935,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2936,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2937,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2938,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2939,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2940,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2941,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2942,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2943,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2944,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2945,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2946,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2947,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2948,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2949,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2950,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2951,AIMed.d151,False,"Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.",AIMed.d151.s1289
2952,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2953,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2954,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2955,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2956,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2957,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2958,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2959,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2960,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2961,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2962,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2963,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2964,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2965,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2966,AIMed.d151,False,"In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.",AIMed.d151.s1290
2967,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2968,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2969,AIMed.d152,True,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2970,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2971,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2972,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2973,AIMed.d152,True,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2974,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2975,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2976,AIMed.d152,False,TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.,AIMed.d152.s1291
2977,AIMed.d152,False,Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1).,AIMed.d152.s1292
2978,AIMed.d152,False,Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1).,AIMed.d152.s1292
2979,AIMed.d152,False,Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1).,AIMed.d152.s1292
2980,AIMed.d152,False,TRADD is a TNFR1-associated signal transducer that is involved in activating both pathways.,AIMed.d152.s1293
2981,AIMed.d152,False,"Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.",AIMed.d152.s1294
2982,AIMed.d152,True,"Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.",AIMed.d152.s1294
2983,AIMed.d152,True,"Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.",AIMed.d152.s1294
2984,AIMed.d152,True,"Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.",AIMed.d152.s1294
2985,AIMed.d152,True,"Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.",AIMed.d152.s1294
2986,AIMed.d152,False,"Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.",AIMed.d152.s1294
2987,AIMed.d152,False,"A TRAF2 mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated NF-kappa B activation, but does not affect TNF-induced apoptosis.",AIMed.d152.s1295
2988,AIMed.d152,False,"Conversely, a FADD mutant lacking its N-terminal 79 amino acids is a dominant-negative inhibitor of TNF-induced apoptosis, but does not inhibit NF-kappa B activation.",AIMed.d152.s1296
2989,AIMed.d152,False,"Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.",AIMed.d152.s1297
2990,AIMed.d152,False,"Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.",AIMed.d152.s1297
2991,AIMed.d152,False,"Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.",AIMed.d152.s1297
2992,AIMed.d153,True,Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response.,AIMed.d153.s1298
2993,AIMed.d153,False,"CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.",AIMed.d153.s1299
2994,AIMed.d153,True,"CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.",AIMed.d153.s1299
2995,AIMed.d153,True,"CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.",AIMed.d153.s1299
2996,AIMed.d153,True,"CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.",AIMed.d153.s1299
2997,AIMed.d153,True,"CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.",AIMed.d153.s1299
2998,AIMed.d153,False,"CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.",AIMed.d153.s1299
2999,AIMed.d153,True,"In the present study, we examined both the binding of ADA and CD26 and the functional consequences of this interaction.",AIMed.d153.s1300
3000,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3001,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3002,AIMed.d153,True,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3003,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3004,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3005,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3006,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3007,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3008,AIMed.d153,True,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3009,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3010,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3011,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3012,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3013,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3014,AIMed.d153,False,"We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.",AIMed.d153.s1301
3015,AIMed.d153,False,"Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.",AIMed.d153.s1302
3016,AIMed.d153,False,"Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.",AIMed.d153.s1302
3017,AIMed.d153,False,"Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.",AIMed.d153.s1302
3018,AIMed.d153,False,"Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.",AIMed.d153.s1302
3019,AIMed.d153,False,"Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.",AIMed.d153.s1302
3020,AIMed.d153,False,"Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.",AIMed.d153.s1302
3021,AIMed.d153,False,"In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human ADA acquired ADA from an extracellular source.",AIMed.d153.s1303
3022,AIMed.d153,False,"In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human ADA acquired ADA from an extracellular source.",AIMed.d153.s1303
3023,AIMed.d153,False,"In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human ADA acquired ADA from an extracellular source.",AIMed.d153.s1303
3024,AIMed.d153,False,"More importantly, adenosine in the absence of cell surface ADA inhibited T cell proliferation and IL-2 production induced by various stimuli.",AIMed.d153.s1304
3025,AIMed.d153,False,"On the other hand, cells expressing ADA and CD26 on the surface were much more resistant to the inhibitory effect of adenosine.",AIMed.d153.s1305
3026,AIMed.d153,False,"These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.",AIMed.d153.s1306
3027,AIMed.d153,True,"These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.",AIMed.d153.s1306
3028,AIMed.d153,False,"These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.",AIMed.d153.s1306
3029,AIMed.d154,False,We have cloned and characterized human acidic (alpha 1-) syntrophin and a second isoform of human basic (beta 2-) syntrophin.,AIMed.d154.s1309
3030,AIMed.d154,False,"The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.",AIMed.d154.s1311
3031,AIMed.d154,False,"The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.",AIMed.d154.s1311
3032,AIMed.d154,False,"The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.",AIMed.d154.s1311
3033,AIMed.d154,False,Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations: beta 2-syntrophin to chromosome 16q22-23 and alpha 1-syntrophin to chromosome 20q11.2.,AIMed.d154.s1313
3034,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3035,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3036,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3037,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3038,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3039,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3040,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3041,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3042,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3043,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3044,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3045,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3046,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3047,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3048,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3049,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3050,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3051,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3052,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3053,AIMed.d154,False,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3054,AIMed.d154,True,"Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.",AIMed.d154.s1314
3055,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3056,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3057,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3058,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3059,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3060,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3061,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3062,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3063,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3064,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3065,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3066,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3067,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3068,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3069,AIMed.d157,False,"Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.",AIMed.d157.s1328
3070,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3071,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3072,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3073,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3074,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3075,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3076,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3077,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3078,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3079,AIMed.d157,False,"Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.",AIMed.d157.s1329
3080,AIMed.d157,False,The subcellular distributions of PKC and AKAP79 were similar in neurons.,AIMed.d157.s1330
3081,AIMed.d158,False,TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex.,AIMed.d158.s1332
3082,AIMed.d158,True,The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.,AIMed.d158.s1333
3083,AIMed.d158,False,The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.,AIMed.d158.s1333
3084,AIMed.d158,False,The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.,AIMed.d158.s1333
3085,AIMed.d158,True,The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.,AIMed.d158.s1333
3086,AIMed.d158,False,The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.,AIMed.d158.s1333
3087,AIMed.d158,False,The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.,AIMed.d158.s1333
3088,AIMed.d158,False,"Here, we show that TRADD interacts strongly with RIP, another death domain protein that was shown previously to associate with Fas antigen.",AIMed.d158.s1334
3089,AIMed.d158,True,"Here, we show that TRADD interacts strongly with RIP, another death domain protein that was shown previously to associate with Fas antigen.",AIMed.d158.s1334
3090,AIMed.d158,True,"Here, we show that TRADD interacts strongly with RIP, another death domain protein that was shown previously to associate with Fas antigen.",AIMed.d158.s1334
3091,AIMed.d158,False,We also show that RIP is a serine-threonine kinase that is recruited by TRADD to TNFR1 in a TNF-dependent process.,AIMed.d158.s1335
3092,AIMed.d158,False,We also show that RIP is a serine-threonine kinase that is recruited by TRADD to TNFR1 in a TNF-dependent process.,AIMed.d158.s1335
3093,AIMed.d158,False,We also show that RIP is a serine-threonine kinase that is recruited by TRADD to TNFR1 in a TNF-dependent process.,AIMed.d158.s1335
3094,AIMed.d158,False,Overexpression of the intact RIP protein induces both NF-kappa B activation and apoptosis.,AIMed.d158.s1336
3095,AIMed.d158,False,"However, expression of the death domain of RIP Induces apoptosis, but potently inhibits NF-kappa B activation by TNF.",AIMed.d158.s1337
3096,AIMed.d158,False,These results suggest that distinct domains of RIP participate in the TNF signaling cascades leading to apoptosis and NF-kappa B activation.,AIMed.d158.s1338
3097,AIMed.d159,True,"The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.",AIMed.d159.s1340
3098,AIMed.d159,False,"The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.",AIMed.d159.s1340
3099,AIMed.d159,False,"The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.",AIMed.d159.s1340
3100,AIMed.d160,False,Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.,AIMed.d160.s1343
3101,AIMed.d160,False,Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.,AIMed.d160.s1343
3102,AIMed.d160,False,Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.,AIMed.d160.s1343
3103,AIMed.d160,False,Vascular endothelial growth factor (VEGF) expression in various cell types is induced by hypoxia and other stimuli.,AIMed.d160.s1344
3104,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3105,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3106,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3107,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3108,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3109,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3110,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3111,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3112,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3113,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3114,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3115,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3116,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3117,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3118,AIMed.d160,False,"VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.",AIMed.d160.s1345
3119,AIMed.d160,False,Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR/Flk-1.,AIMed.d160.s1346
3120,AIMed.d160,False,Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR/Flk-1.,AIMed.d160.s1346
3121,AIMed.d160,False,Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR/Flk-1.,AIMed.d160.s1346
3122,AIMed.d160,False,"Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.",AIMed.d160.s1347
3123,AIMed.d160,False,"Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.",AIMed.d160.s1347
3124,AIMed.d160,False,"Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.",AIMed.d160.s1347
3125,AIMed.d160,False,A VEGF model based on PDGFb indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer.,AIMed.d160.s1348
3126,AIMed.d160,False,"Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.",AIMed.d160.s1349
3127,AIMed.d160,False,"Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.",AIMed.d160.s1349
3128,AIMed.d160,False,"Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.",AIMed.d160.s1349
3129,AIMed.d160,False,"Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.",AIMed.d160.s1349
3130,AIMed.d160,False,"Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.",AIMed.d160.s1349
3131,AIMed.d160,False,"Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.",AIMed.d160.s1349
3132,AIMed.d160,False,"Endothelial cell mitogenesis was abolished in mutants lacking KDR affinity; however, FLT-1 deficient mutants induced normal proliferation.",AIMed.d160.s1350
3133,AIMed.d160,False,"Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.",AIMed.d160.s1352
3134,AIMed.d160,False,"Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.",AIMed.d160.s1352
3135,AIMed.d160,False,"Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.",AIMed.d160.s1352
3136,AIMed.d161,True,"Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7.",AIMed.d161.s1353
3137,AIMed.d161,True,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3138,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3139,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3140,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3141,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3142,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3143,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3144,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3145,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3146,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3147,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3148,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3149,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3150,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3151,AIMed.d161,False,"SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.",AIMed.d161.s1355
3152,AIMed.d161,False,"Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, Grb7.",AIMed.d161.s1357
3153,AIMed.d161,False,"Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, Grb7.",AIMed.d161.s1357
3154,AIMed.d161,True,"Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, Grb7.",AIMed.d161.s1357
3155,AIMed.d161,False,We have localized the region of interaction to tyrosine 580 in the carboxyl end of SHPTP2 and to the SH2 domain in the carboxy-terminus of Grb7.,AIMed.d161.s1358
3156,AIMed.d161,True,We demonstrate that Grb7 binds to SHPTP2 in vitro under conditions where the latter is tyrosine-phosphorylated.,AIMed.d161.s1359
3157,AIMed.d162,False,We found that the human TR subtype beta 1 (h-TR beta 1) physically interacted with p53 via its DNA binding domain.,AIMed.d162.s1367
3158,AIMed.d162,True,We found that the human TR subtype beta 1 (h-TR beta 1) physically interacted with p53 via its DNA binding domain.,AIMed.d162.s1367
3159,AIMed.d162,True,We found that the human TR subtype beta 1 (h-TR beta 1) physically interacted with p53 via its DNA binding domain.,AIMed.d162.s1367
3160,AIMed.d162,True,"As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration-dependent manner.",AIMed.d162.s1368
3161,AIMed.d162,False,"As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration-dependent manner.",AIMed.d162.s1368
3162,AIMed.d162,False,"As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration-dependent manner.",AIMed.d162.s1368
3163,AIMed.d162,True,"In transfected cells, wild-type p53 repressed the hormone-dependent transcriptional activation of h-TR beta 1.",AIMed.d162.s1369
3164,AIMed.d162,False,"In contrast, mutant p53 either had no effect or activated the transcriptional activity of h-TR beta 1 depending on the type of hormone response elements.",AIMed.d162.s1370
3165,AIMed.d163,False,"Enhanced degradation of EGF receptors by a sorting nexin, SNX1.",AIMed.d163.s1372
3166,AIMed.d163,False,"Enhanced degradation of EGF receptors by a sorting nexin, SNX1.",AIMed.d163.s1372
3167,AIMed.d163,False,"Enhanced degradation of EGF receptors by a sorting nexin, SNX1.",AIMed.d163.s1372
3168,AIMed.d163,True,"A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.",AIMed.d163.s1374
3169,AIMed.d163,False,"A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.",AIMed.d163.s1374
3170,AIMed.d163,True,"A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.",AIMed.d163.s1374
3171,AIMed.d163,True,"A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.",AIMed.d163.s1374
3172,AIMed.d163,False,"A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.",AIMed.d163.s1374
3173,AIMed.d163,True,"A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.",AIMed.d163.s1374
3174,AIMed.d163,False,"SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.",AIMed.d163.s1375
3175,AIMed.d163,False,"SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.",AIMed.d163.s1375
3176,AIMed.d163,False,"SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.",AIMed.d163.s1375
3177,AIMed.d163,False,"Thus, SNX1 is likely to play a role in sorting EGFR to lysosomes.",AIMed.d163.s1376
3178,AIMed.d164,True,The splicing factor U2AF (U2 snRNP auxiliary factor) is a heterodimer with subunits of 65 and 35 kD (U2AF65 and U2AF35).,AIMed.d164.s1378
3179,AIMed.d164,False,"U2AF65 binds specifically to 3' splice sites, but previous studies failed to demonstrate a function for U2AF35.",AIMed.d164.s1379
3180,AIMed.d164,False,"Nuclear extracts deficient in U2AF35 were inactive; however, both constitutive and enhancer-dependent splicing could be restored by the addition of purified recombinant U2AF35.",AIMed.d164.s1381
3181,AIMed.d164,False,In vitro protein-RNA interaction studies with pre-mRNAs containing either a constitutive or regulated splicing enhancer revealed that U2AF35 directly mediates interactions between U2AF65 and proteins bound to the enhancers.,AIMed.d164.s1382
3182,AIMed.d164,False,"Thus, U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron.",AIMed.d164.s1383
3183,AIMed.d164,False,"Thus, U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron.",AIMed.d164.s1383
3184,AIMed.d164,False,"Thus, U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron.",AIMed.d164.s1383
3185,AIMed.d165,False,"Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.",AIMed.d165.s1384
3186,AIMed.d165,False,"Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.",AIMed.d165.s1384
3187,AIMed.d165,False,"Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.",AIMed.d165.s1384
3188,AIMed.d165,False,"Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.",AIMed.d165.s1384
3189,AIMed.d165,True,"Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.",AIMed.d165.s1384
3190,AIMed.d165,False,"Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.",AIMed.d165.s1384
3191,AIMed.d165,False,At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).,AIMed.d165.s1388
3192,AIMed.d165,False,At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).,AIMed.d165.s1388
3193,AIMed.d165,False,At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).,AIMed.d165.s1388
3194,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3195,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3196,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3197,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3198,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3199,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3200,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3201,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3202,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3203,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3204,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3205,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3206,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3207,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3208,AIMed.d165,False,"We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.",AIMed.d165.s1389
3209,AIMed.d165,False,"Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).",AIMed.d165.s1390
3210,AIMed.d165,False,"Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).",AIMed.d165.s1390
3211,AIMed.d165,False,"Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).",AIMed.d165.s1390
3212,AIMed.d165,False,"Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.",AIMed.d165.s1391
3213,AIMed.d165,False,"Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.",AIMed.d165.s1391
3214,AIMed.d165,False,"Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.",AIMed.d165.s1391
3215,AIMed.d165,False,"Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.",AIMed.d165.s1391
3216,AIMed.d165,False,"Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.",AIMed.d165.s1391
3217,AIMed.d165,True,"Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.",AIMed.d165.s1391
3218,AIMed.d165,False,XPG protein interacts with multiple subunits of TFIIH and with CSB protein.,AIMed.d165.s1392
3219,AIMed.d165,True,XPG protein interacts with multiple subunits of TFIIH and with CSB protein.,AIMed.d165.s1392
3220,AIMed.d165,False,XPG protein interacts with multiple subunits of TFIIH and with CSB protein.,AIMed.d165.s1392
3221,AIMed.d166,False,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3222,AIMed.d166,True,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3223,AIMed.d166,False,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3224,AIMed.d166,True,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3225,AIMed.d166,True,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3226,AIMed.d166,False,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3227,AIMed.d166,True,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3228,AIMed.d166,False,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3229,AIMed.d166,False,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3230,AIMed.d166,False,Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.,AIMed.d166.s1394
3231,AIMed.d166,True,"The region of hLIF most important for binding to the hLIF-R is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop.",AIMed.d166.s1395
3232,AIMed.d166,True,"The two residues of hLIF that contribute the majority of free energy for hLIF-R binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact.",AIMed.d166.s1397
3233,AIMed.d166,True,A second region of hLIF that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on hLIF-R binding.,AIMed.d166.s1399
3234,AIMed.d166,True,Residues in hLIF from both the A- and C-helices are involved in binding the gp130 co-receptor.,AIMed.d166.s1400
3235,AIMed.d166,False,Abolition of the gp130 binding site in hLIF created antagonists of LIF action.,AIMed.d166.s1401
3236,AIMed.d166,True,Abolition of the gp130 binding site in hLIF created antagonists of LIF action.,AIMed.d166.s1401
3237,AIMed.d166,False,Abolition of the gp130 binding site in hLIF created antagonists of LIF action.,AIMed.d166.s1401
3238,AIMed.d167,True,The glut 1 glucose transporter interacts with calnexin and calreticulin.,AIMed.d167.s1402
3239,AIMed.d167,True,The glut 1 glucose transporter interacts with calnexin and calreticulin.,AIMed.d167.s1402
3240,AIMed.d167,False,The glut 1 glucose transporter interacts with calnexin and calreticulin.,AIMed.d167.s1402
3241,AIMed.d167,False,A truncated version of the integral membrane glycoprotein Glut 1 (GT155) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes.,AIMed.d167.s1405
3242,AIMed.d167,True,"Following immunoprecipitation with an anticalnexin antiserum, a cross-linker-independent association was observed between GT155 and calnexin.",AIMed.d167.s1406
3243,AIMed.d167,True,"In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa).",AIMed.d167.s1407
3244,AIMed.d167,True,"In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa).",AIMed.d167.s1407
3245,AIMed.d167,False,"In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa).",AIMed.d167.s1407
3246,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3247,AIMed.d167,True,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3248,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3249,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3250,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3251,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3252,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3253,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3254,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3255,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3256,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3257,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3258,AIMed.d167,True,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3259,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3260,AIMed.d167,False,"Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.",AIMed.d167.s1408
3261,AIMed.d167,False,A GT155 mutant that was not glycosylated (AGGT155) did not associate with calnexin or CAP-60.,AIMed.d167.s1409
3262,AIMed.d167,False,A GT155 mutant that was not glycosylated (AGGT155) did not associate with calnexin or CAP-60.,AIMed.d167.s1409
3263,AIMed.d167,False,A GT155 mutant that was not glycosylated (AGGT155) did not associate with calnexin or CAP-60.,AIMed.d167.s1409
3264,AIMed.d167,False,"Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.",AIMed.d167.s1410
3265,AIMed.d167,False,"Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.",AIMed.d167.s1410
3266,AIMed.d167,True,"Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.",AIMed.d167.s1410
3267,AIMed.d167,True,"Thus, our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation-dependent manner.",AIMed.d167.s1411
3268,AIMed.d167,True,"Thus, our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation-dependent manner.",AIMed.d167.s1411
3269,AIMed.d167,False,"Thus, our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation-dependent manner.",AIMed.d167.s1411
3270,AIMed.d168,False,Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family.,AIMed.d168.s1412
3271,AIMed.d168,False,The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.,AIMed.d168.s1413
3272,AIMed.d168,False,The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.,AIMed.d168.s1413
3273,AIMed.d168,True,The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.,AIMed.d168.s1413
3274,AIMed.d168,True,We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding.,AIMed.d168.s1414
3275,AIMed.d168,False,We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding.,AIMed.d168.s1414
3276,AIMed.d168,True,We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding.,AIMed.d168.s1414
3277,AIMed.d168,True,Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays.,AIMed.d168.s1415
3278,AIMed.d168,False,Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays.,AIMed.d168.s1415
3279,AIMed.d168,False,Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays.,AIMed.d168.s1415
3280,AIMed.d168,True,Substitution of phenylalanine at position 93 (Phe93) with alanine (F93A mutation) resulted in a drastic reduction in EPO binding in the EBP.,AIMed.d168.s1416
3281,AIMed.d168,True,"Furthermore, the F93A mutation in full-length EPOR expressed in COS cells abolished detectable EPO binding.",AIMed.d168.s1419
3282,AIMed.d168,True,These data indicate that Phe93 is a critical EPO binding determinant of the EPOR.,AIMed.d168.s1422
3283,AIMed.d169,False,Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.,AIMed.d169.s1424
3284,AIMed.d169,False,Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.,AIMed.d169.s1424
3285,AIMed.d169,False,Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.,AIMed.d169.s1424
3286,AIMed.d169,False,"Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.",AIMed.d169.s1425
3287,AIMed.d169,False,"Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.",AIMed.d169.s1425
3288,AIMed.d169,False,"Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.",AIMed.d169.s1425
3289,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3290,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3291,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3292,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3293,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3294,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3295,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3296,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3297,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3298,AIMed.d169,False,"Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.",AIMed.d169.s1427
3299,AIMed.d169,True,We have cloned a cDNA encoding an IL-13 binding protein (IL-13R) from the Caki-1 human renal carcinoma cell line.,AIMed.d169.s1428
3300,AIMed.d169,False,"The IL-13R shows homology with the IL-5 receptor, and to a lesser extent, with the prolactin receptor.",AIMed.d169.s1430
3301,AIMed.d169,False,COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.,AIMed.d169.s1431
3302,AIMed.d169,False,COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.,AIMed.d169.s1431
3303,AIMed.d169,True,COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.,AIMed.d169.s1431
3304,AIMed.d169,False,COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.,AIMed.d169.s1432
3305,AIMed.d169,False,COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.,AIMed.d169.s1432
3306,AIMed.d169,False,COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.,AIMed.d169.s1432
3307,AIMed.d169,False,COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.,AIMed.d169.s1432
3308,AIMed.d169,False,COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.,AIMed.d169.s1432
3309,AIMed.d169,False,COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.,AIMed.d169.s1432
3310,AIMed.d171,True,Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.,AIMed.d171.s1441
3311,AIMed.d171,True,Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.,AIMed.d171.s1441
3312,AIMed.d171,True,Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.,AIMed.d171.s1441
3313,AIMed.d171,False,The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.,AIMed.d171.s1442
3314,AIMed.d171,False,The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.,AIMed.d171.s1442
3315,AIMed.d171,False,The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.,AIMed.d171.s1442
3316,AIMed.d171,True,The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.,AIMed.d171.s1442
3317,AIMed.d171,True,The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.,AIMed.d171.s1442
3318,AIMed.d171,True,The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.,AIMed.d171.s1442
3319,AIMed.d171,True,p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.,AIMed.d171.s1443
3320,AIMed.d171,False,p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.,AIMed.d171.s1443
3321,AIMed.d171,True,p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.,AIMed.d171.s1443
3322,AIMed.d172,False,Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.,AIMed.d172.s1446
3323,AIMed.d172,True,Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.,AIMed.d172.s1446
3324,AIMed.d172,False,Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.,AIMed.d172.s1446
3325,AIMed.d172,False,"The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.",AIMed.d172.s1447
3326,AIMed.d172,False,"The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.",AIMed.d172.s1447
3327,AIMed.d172,False,"The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.",AIMed.d172.s1447
3328,AIMed.d172,False,"The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.",AIMed.d172.s1447
3329,AIMed.d172,False,"The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.",AIMed.d172.s1447
3330,AIMed.d172,False,"The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.",AIMed.d172.s1447
3331,AIMed.d172,True,Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).,AIMed.d172.s1448
3332,AIMed.d172,False,Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).,AIMed.d172.s1448
3333,AIMed.d172,True,Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).,AIMed.d172.s1448
3334,AIMed.d172,True,Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).,AIMed.d172.s1448
3335,AIMed.d172,False,Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).,AIMed.d172.s1448
3336,AIMed.d172,True,Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).,AIMed.d172.s1448
3337,AIMed.d172,True,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3338,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3339,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3340,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3341,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3342,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3343,AIMed.d172,True,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3344,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3345,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3346,AIMed.d172,False,"This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.",AIMed.d172.s1451
3347,AIMed.d172,False,VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1.,AIMed.d172.s1452
3348,AIMed.d172,False,VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1.,AIMed.d172.s1452
3349,AIMed.d172,False,VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1.,AIMed.d172.s1452
3350,AIMed.d173,False,The kinetics of amyloid fibril formation by beta-amyloid peptide (Abeta) are typical of a nucleation-dependent polymerization mechanism.,AIMed.d173.s1456
3351,AIMed.d173,False,Fusion proteins were created by linking the Abeta fragment to a LexA DNA-binding domain (bait) and also to a B42 transactivation domain (prey).,AIMed.d173.s1459
3352,AIMed.d173,False,Fusion proteins were created by linking the Abeta fragment to a LexA DNA-binding domain (bait) and also to a B42 transactivation domain (prey).,AIMed.d173.s1459
3353,AIMed.d173,False,Fusion proteins were created by linking the Abeta fragment to a LexA DNA-binding domain (bait) and also to a B42 transactivation domain (prey).,AIMed.d173.s1459
3354,AIMed.d173,False,Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.,AIMed.d173.s1460
3355,AIMed.d173,False,Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.,AIMed.d173.s1460
3356,AIMed.d173,False,Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.,AIMed.d173.s1460
3357,AIMed.d173,False,Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.,AIMed.d173.s1460
3358,AIMed.d173,False,Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.,AIMed.d173.s1460
3359,AIMed.d173,False,Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.,AIMed.d173.s1460
3360,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3361,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3362,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3363,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3364,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3365,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3366,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3367,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3368,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3369,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3370,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3371,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3372,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3373,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3374,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3375,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3376,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3377,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3378,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3379,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3380,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3381,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3382,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3383,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3384,AIMed.d173,True,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3385,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3386,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3387,AIMed.d173,False,"LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.",AIMed.d173.s1462
3388,AIMed.d173,False,"Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.",AIMed.d173.s1463
3389,AIMed.d173,False,"Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.",AIMed.d173.s1463
3390,AIMed.d173,False,"Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.",AIMed.d173.s1463
3391,AIMed.d173,False,"Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.",AIMed.d173.s1463
3392,AIMed.d173,False,"Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.",AIMed.d173.s1463
3393,AIMed.d173,False,"Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.",AIMed.d173.s1463
3394,AIMed.d174,False,Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.,AIMed.d174.s1466
3395,AIMed.d174,False,Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.,AIMed.d174.s1466
3396,AIMed.d174,False,Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.,AIMed.d174.s1466
3397,AIMed.d174,False,Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.,AIMed.d174.s1466
3398,AIMed.d174,False,Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.,AIMed.d174.s1466
3399,AIMed.d174,False,Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.,AIMed.d174.s1466
3400,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3401,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3402,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3403,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3404,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3405,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3406,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3407,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3408,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3409,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3410,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3411,AIMed.d174,True,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3412,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3413,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3414,AIMed.d174,False,The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.,AIMed.d174.s1467
3415,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3416,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3417,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3418,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3419,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3420,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3421,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3422,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3423,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3424,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3425,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3426,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3427,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3428,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3429,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3430,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3431,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3432,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3433,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3434,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3435,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3436,AIMed.d174,True,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3437,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3438,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3439,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3440,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3441,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3442,AIMed.d174,False,"Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (""soluble"") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.",AIMed.d174.s1468
3443,AIMed.d174,True,"Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.",AIMed.d174.s1469
3444,AIMed.d174,False,"Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.",AIMed.d174.s1469
3445,AIMed.d174,False,"Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.",AIMed.d174.s1469
3446,AIMed.d174,False,"Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.",AIMed.d174.s1469
3447,AIMed.d174,False,"Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.",AIMed.d174.s1469
3448,AIMed.d174,False,"Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.",AIMed.d174.s1469
3449,AIMed.d174,True,The increased binding affinity of IL-6D appears to be due to its ability to cross-link two sIL-6R molecules on the biosensor surface.,AIMed.d174.s1471
3450,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3451,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3452,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3453,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3454,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3455,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3456,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3457,AIMed.d174,True,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3458,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3459,AIMed.d174,False,Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.,AIMed.d174.s1472
3460,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3461,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3462,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3463,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3464,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3465,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3466,AIMed.d174,True,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3467,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3468,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3469,AIMed.d174,False,These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.,AIMed.d174.s1473
3470,AIMed.d174,True,"A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.",AIMed.d174.s1474
3471,AIMed.d174,False,"A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.",AIMed.d174.s1474
3472,AIMed.d174,False,"A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.",AIMed.d174.s1474
3473,AIMed.d174,False,"Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.",AIMed.d174.s1475
3474,AIMed.d174,False,"Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.",AIMed.d174.s1475
3475,AIMed.d174,True,"Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.",AIMed.d174.s1475
3476,AIMed.d174,False,"Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.",AIMed.d174.s1475
3477,AIMed.d174,True,"Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.",AIMed.d174.s1475
3478,AIMed.d174,False,"Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.",AIMed.d174.s1475
3479,AIMed.d175,True,Physical interaction of mammalian CDC37 with CDK4,AIMed.d175.s1476
3480,AIMed.d175,False,.CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins.,AIMed.d175.s1477
3481,AIMed.d175,False,CDK4 is a cyclin D-dependent kinase that controls progression through G1 of the mammalian cell cycle.,AIMed.d175.s1479
3482,AIMed.d175,False,We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37.,AIMed.d175.s1480
3483,AIMed.d175,True,We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37.,AIMed.d175.s1480
3484,AIMed.d175,True,We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37.,AIMed.d175.s1480
3485,AIMed.d175,True,A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.,AIMed.d175.s1481
3486,AIMed.d175,False,A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.,AIMed.d175.s1481
3487,AIMed.d175,False,A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.,AIMed.d175.s1481
3488,AIMed.d175,False,A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.,AIMed.d175.s1481
3489,AIMed.d175,False,A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.,AIMed.d175.s1481
3490,AIMed.d175,True,A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.,AIMed.d175.s1481
3491,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3492,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3493,AIMed.d175,True,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3494,AIMed.d175,True,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3495,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3496,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3497,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3498,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3499,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3500,AIMed.d175,False,Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.,AIMed.d175.s1482
3501,AIMed.d176,True,"Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70.",AIMed.d176.s1483
3502,AIMed.d176,True,"Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70.",AIMed.d176.s1483
3503,AIMed.d176,False,"Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70.",AIMed.d176.s1483
3504,AIMed.d176,False,"Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70.",AIMed.d176.s1483
3505,AIMed.d176,False,"Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70.",AIMed.d176.s1483
3506,AIMed.d176,False,"Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70.",AIMed.d176.s1483
3507,AIMed.d176,False,"Previous studies on the assembly of progesterone receptor (PR) complexes in vitro have suggested that PR assembly is a dynamic, ordered process involving at least eight nonreceptor proteins.",AIMed.d176.s1484
3508,AIMed.d176,False,"Previous studies on the assembly of progesterone receptor (PR) complexes in vitro have suggested that PR assembly is a dynamic, ordered process involving at least eight nonreceptor proteins.",AIMed.d176.s1484
3509,AIMed.d176,False,"Previous studies on the assembly of progesterone receptor (PR) complexes in vitro have suggested that PR assembly is a dynamic, ordered process involving at least eight nonreceptor proteins.",AIMed.d176.s1484
3510,AIMed.d176,False,"One of these proteins, p60, appears transiently during assembly and is not a component of functionally mature PR complexes.",AIMed.d176.s1485
3511,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3512,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3513,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3514,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3515,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3516,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3517,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3518,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3519,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3520,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3521,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3522,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3523,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3524,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3525,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3526,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3527,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3528,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3529,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3530,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3531,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3532,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3533,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3534,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3535,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3536,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3537,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3538,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3539,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3540,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3541,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3542,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3543,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3544,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3545,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3546,AIMed.d176,False,"In the present study we observe that a monoclonal antibody specific for p60 can, on the one hand, inhibit formation of mature PR complexes containing heat shock protein 90 (hsp90), p23, and immunophilins and, on the other, enhance recovery of early PR complexes containing hsp70 and Hip (p48).",AIMed.d176.s1486
3547,AIMed.d176,False,This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60.,AIMed.d176.s1487
3548,AIMed.d176,False,This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60.,AIMed.d176.s1487
3549,AIMed.d176,False,This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60.,AIMed.d176.s1487
3550,AIMed.d176,False,This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60.,AIMed.d176.s1487
3551,AIMed.d176,False,This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60.,AIMed.d176.s1487
3552,AIMed.d176,False,This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60.,AIMed.d176.s1487
3553,AIMed.d176,False,"Since p60 is typically found in a complex with hsp90 and hsp70, we have further characterized its interactions with these proteins.",AIMed.d176.s1488
3554,AIMed.d176,True,"Since p60 is typically found in a complex with hsp90 and hsp70, we have further characterized its interactions with these proteins.",AIMed.d176.s1488
3555,AIMed.d176,True,"Since p60 is typically found in a complex with hsp90 and hsp70, we have further characterized its interactions with these proteins.",AIMed.d176.s1488
3556,AIMed.d176,False,P60 can bind either hsp70 or hsp90 independently and in an ATP-independent manner.,AIMed.d176.s1489
3557,AIMed.d176,True,P60 can bind either hsp70 or hsp90 independently and in an ATP-independent manner.,AIMed.d176.s1489
3558,AIMed.d176,True,P60 can bind either hsp70 or hsp90 independently and in an ATP-independent manner.,AIMed.d176.s1489
3559,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3560,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3561,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3562,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3563,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3564,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3565,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3566,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3567,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3568,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3569,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3570,AIMed.d176,True,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3571,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3572,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3573,AIMed.d176,False,"Since hsp90 and hsp70 do not readily associate on their own, it appears that p60 is the central organizing component of an hsp90-p60-hsp70 complex.",AIMed.d176.s1490
3574,AIMed.d176,False,"Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70.",AIMed.d176.s1491
3575,AIMed.d176,False,"Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70.",AIMed.d176.s1491
3576,AIMed.d176,True,"Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70.",AIMed.d176.s1491
3577,AIMed.d176,False,"Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70.",AIMed.d176.s1491
3578,AIMed.d176,True,"Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70.",AIMed.d176.s1491
3579,AIMed.d176,True,"Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70.",AIMed.d176.s1491
3580,AIMed.d176,True,The hsp90-p60-hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90-binding drug geldanamycin.,AIMed.d176.s1492
3581,AIMed.d176,False,The hsp90-p60-hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90-binding drug geldanamycin.,AIMed.d176.s1492
3582,AIMed.d176,False,The hsp90-p60-hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90-binding drug geldanamycin.,AIMed.d176.s1492
3583,AIMed.d176,False,The hsp90-p60-hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90-binding drug geldanamycin.,AIMed.d176.s1492
3584,AIMed.d176,False,The hsp90-p60-hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90-binding drug geldanamycin.,AIMed.d176.s1492
3585,AIMed.d176,False,The hsp90-p60-hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90-binding drug geldanamycin.,AIMed.d176.s1492
3586,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3587,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3588,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3589,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3590,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3591,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3592,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3593,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3594,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3595,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3596,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3597,AIMed.d176,True,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3598,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3599,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3600,AIMed.d176,False,The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes (hsp70) or in mature PR complexes (hsp90).,AIMed.d176.s1493
3601,AIMed.d176,False,"From these results, it appears that p60 is a key mediator in the chaperoned assembly and functional maturation of PR complexes.",AIMed.d176.s1494
3602,AIMed.d177,True,We have selected such mutations in the transcription factor E2F1 that affect its ability to heterodimerize with DP1.,AIMed.d177.s1503
3603,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3604,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3605,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3606,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3607,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3608,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3609,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3610,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3611,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3612,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3613,AIMed.d179,True,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3614,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3615,AIMed.d179,True,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3616,AIMed.d179,False,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3617,AIMed.d179,True,Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase.,AIMed.d179.s1519
3618,AIMed.d179,False,"The growth-promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin/CCKB receptor, which belongs to the family of G protein-coupled receptors.",AIMed.d179.s1520
3619,AIMed.d179,False,"The growth-promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin/CCKB receptor, which belongs to the family of G protein-coupled receptors.",AIMed.d179.s1520
3620,AIMed.d179,False,"The growth-promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin/CCKB receptor, which belongs to the family of G protein-coupled receptors.",AIMed.d179.s1520
3621,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3622,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3623,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3624,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3625,AIMed.d179,True,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3626,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3627,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3628,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3629,AIMed.d179,True,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3630,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3631,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3632,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3633,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3634,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3635,AIMed.d179,False,"In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor.",AIMed.d179.s1522
3636,AIMed.d179,True,"The gastrin-induced phosphorylation of IRS-1 was rapid and transient, occurring within 30 s of treatment and diminishing thereafter.",AIMed.d179.s1523
3637,AIMed.d179,True,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3638,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3639,AIMed.d179,True,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3640,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3641,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3642,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3643,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3644,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3645,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3646,AIMed.d179,False,"Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase).",AIMed.d179.s1525
3647,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3648,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3649,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3650,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3651,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3652,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3653,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3654,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3655,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3656,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3657,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3658,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3659,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3660,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3661,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3662,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3663,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3664,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3665,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3666,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3667,AIMed.d179,False,"In addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase.",AIMed.d179.s1526
3668,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3669,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3670,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3671,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3672,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3673,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3674,AIMed.d179,False,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3675,AIMed.d179,True,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3676,AIMed.d179,True,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3677,AIMed.d179,True,We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin.,AIMed.d179.s1527
3678,AIMed.d179,True,We report here that Grb2 also interacts with tyrosine-phosphorylated IRS-1 in response to gastrin.,AIMed.d179.s1528
3679,AIMed.d179,False,We report here that Grb2 also interacts with tyrosine-phosphorylated IRS-1 in response to gastrin.,AIMed.d179.s1528
3680,AIMed.d179,False,We report here that Grb2 also interacts with tyrosine-phosphorylated IRS-1 in response to gastrin.,AIMed.d179.s1528
3681,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3682,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3683,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3684,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3685,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3686,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3687,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3688,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3689,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3690,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3691,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3692,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3693,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3694,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3695,AIMed.d179,False,"Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein-coupled receptor and the insulin receptor.",AIMed.d179.s1529
3696,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3697,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3698,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3699,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3700,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3701,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3702,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3703,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3704,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3705,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3706,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3707,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3708,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3709,AIMed.d180,True,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3710,AIMed.d180,False,"GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.",AIMed.d180.s1532
3711,AIMed.d180,False,"In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).",AIMed.d180.s1533
3712,AIMed.d180,True,"In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).",AIMed.d180.s1533
3713,AIMed.d180,True,"In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).",AIMed.d180.s1533
3714,AIMed.d180,False,"In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).",AIMed.d180.s1533
3715,AIMed.d180,False,"In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).",AIMed.d180.s1533
3716,AIMed.d180,False,"In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).",AIMed.d180.s1533
3717,AIMed.d180,True,PKC phosphorylates GAP-43 on serine 41.,AIMed.d180.s1534
3718,AIMed.d180,False,"Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.",AIMed.d180.s1536
3719,AIMed.d180,False,"Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.",AIMed.d180.s1536
3720,AIMed.d180,True,"Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.",AIMed.d180.s1536
3721,AIMed.d180,False,"Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.",AIMed.d180.s1536
3722,AIMed.d180,True,"Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.",AIMed.d180.s1536
3723,AIMed.d180,False,"Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.",AIMed.d180.s1536
3724,AIMed.d180,True,"These results, along with other recent findings, suggest a novel role for the interaction between GAP-43 and CaM.",AIMed.d180.s1537
3725,AIMed.d182,True,Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.,AIMed.d182.s1545
3726,AIMed.d182,True,The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.,AIMed.d182.s1546
3727,AIMed.d182,True,The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.,AIMed.d182.s1546
3728,AIMed.d182,False,The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.,AIMed.d182.s1546
3729,AIMed.d182,False,"In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53.",AIMed.d182.s1547
3730,AIMed.d182,True,The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.,AIMed.d182.s1548
3731,AIMed.d182,False,The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.,AIMed.d182.s1548
3732,AIMed.d182,False,The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.,AIMed.d182.s1548
3733,AIMed.d182,False,The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.,AIMed.d182.s1548
3734,AIMed.d182,False,The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.,AIMed.d182.s1548
3735,AIMed.d182,True,The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.,AIMed.d182.s1548
3736,AIMed.d182,False,"The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.",AIMed.d182.s1549
3737,AIMed.d182,False,"The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.",AIMed.d182.s1549
3738,AIMed.d182,False,"The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.",AIMed.d182.s1549
3739,AIMed.d182,False,"The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.",AIMed.d182.s1549
3740,AIMed.d182,True,"The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.",AIMed.d182.s1549
3741,AIMed.d182,False,"The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.",AIMed.d182.s1549
3742,AIMed.d182,False,"These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain.",AIMed.d182.s1550
3743,AIMed.d182,True,"These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain.",AIMed.d182.s1550
3744,AIMed.d182,False,"These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain.",AIMed.d182.s1550
3745,AIMed.d183,False,The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.,AIMed.d183.s1552
3746,AIMed.d183,False,The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.,AIMed.d183.s1552
3747,AIMed.d183,True,The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.,AIMed.d183.s1552
3748,AIMed.d183,False,"JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.",AIMed.d183.s1553
3749,AIMed.d183,True,"JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.",AIMed.d183.s1553
3750,AIMed.d183,False,"JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.",AIMed.d183.s1553
3751,AIMed.d183,False,"JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.",AIMed.d183.s1553
3752,AIMed.d183,False,"JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.",AIMed.d183.s1553
3753,AIMed.d183,False,"JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.",AIMed.d183.s1553
3754,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3755,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3756,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3757,AIMed.d183,True,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3758,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3759,AIMed.d183,True,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3760,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3761,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3762,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3763,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3764,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3765,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3766,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3767,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3768,AIMed.d183,False,Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.,AIMed.d183.s1554
3769,AIMed.d183,True,"In the baculovirus coexpression system, Raf-1 was activated by JAK2 in the presence of p21ras.",AIMed.d183.s1555
3770,AIMed.d183,False,"In the baculovirus coexpression system, Raf-1 was activated by JAK2 in the presence of p21ras.",AIMed.d183.s1555
3771,AIMed.d183,False,"In the baculovirus coexpression system, Raf-1 was activated by JAK2 in the presence of p21ras.",AIMed.d183.s1555
3772,AIMed.d183,True,"Under these conditions, a ternary complex of p21ras, JAK2, and Raf-1 was observed.",AIMed.d183.s1556
3773,AIMed.d183,False,"Under these conditions, a ternary complex of p21ras, JAK2, and Raf-1 was observed.",AIMed.d183.s1556
3774,AIMed.d183,False,"Under these conditions, a ternary complex of p21ras, JAK2, and Raf-1 was observed.",AIMed.d183.s1556
3775,AIMed.d183,False,"In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.",AIMed.d183.s1557
3776,AIMed.d183,False,"In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.",AIMed.d183.s1557
3777,AIMed.d183,False,"In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.",AIMed.d183.s1557
3778,AIMed.d183,False,"In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.",AIMed.d183.s1557
3779,AIMed.d183,False,"In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.",AIMed.d183.s1557
3780,AIMed.d183,False,"In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.",AIMed.d183.s1557
3781,AIMed.d183,False,"In addition, JAK2 phosphorylated Raf-1 at sites different from those phosphorylated by pp60v-src.",AIMed.d183.s1558
3782,AIMed.d183,True,"In addition, JAK2 phosphorylated Raf-1 at sites different from those phosphorylated by pp60v-src.",AIMed.d183.s1558
3783,AIMed.d183,True,"In addition, JAK2 phosphorylated Raf-1 at sites different from those phosphorylated by pp60v-src.",AIMed.d183.s1558
3784,AIMed.d183,True,"In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.",AIMed.d183.s1559
3785,AIMed.d183,False,"In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.",AIMed.d183.s1559
3786,AIMed.d183,False,"In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.",AIMed.d183.s1559
3787,AIMed.d183,True,"Taken together, these data suggest that JAK2 and p21ras cooperate to activate Raf-1.",AIMed.d183.s1560
3788,AIMed.d183,False,"Taken together, these data suggest that JAK2 and p21ras cooperate to activate Raf-1.",AIMed.d183.s1560
3789,AIMed.d183,False,"Taken together, these data suggest that JAK2 and p21ras cooperate to activate Raf-1.",AIMed.d183.s1560
3790,AIMed.d184,False,CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.,AIMed.d184.s1561
3791,AIMed.d184,False,CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.,AIMed.d184.s1561
3792,AIMed.d184,True,CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.,AIMed.d184.s1561
3793,AIMed.d184,False,"For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).",AIMed.d184.s1562
3794,AIMed.d184,False,"For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).",AIMed.d184.s1562
3795,AIMed.d184,False,"For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).",AIMed.d184.s1562
3796,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3797,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3798,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3799,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3800,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3801,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3802,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3803,AIMed.d184,True,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3804,AIMed.d184,True,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3805,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3806,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3807,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3808,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3809,AIMed.d184,False,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3810,AIMed.d184,True,"Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).",AIMed.d184.s1563
3811,AIMed.d184,True,The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.,AIMed.d184.s1564
3812,AIMed.d184,False,The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.,AIMed.d184.s1564
3813,AIMed.d184,False,The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.,AIMed.d184.s1564
3814,AIMed.d184,True,"Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.",AIMed.d184.s1565
3815,AIMed.d184,False,"Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.",AIMed.d184.s1565
3816,AIMed.d184,False,"Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.",AIMed.d184.s1565
3817,AIMed.d184,True,"A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.",AIMed.d184.s1566
3818,AIMed.d184,False,"A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.",AIMed.d184.s1566
3819,AIMed.d184,True,"A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.",AIMed.d184.s1566
3820,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3821,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3822,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3823,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3824,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3825,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3826,AIMed.d184,False,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3827,AIMed.d184,True,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3828,AIMed.d184,True,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3829,AIMed.d184,True,Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.,AIMed.d184.s1567
3830,AIMed.d184,False,"These results suggest that HIV-1 attachment to CD4 creates a high-affinity binding site for CCR-5, leading to membrane fusion and virus entry.",AIMed.d184.s1568
3831,AIMed.d185,False,"Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.",AIMed.d185.s1569
3832,AIMed.d185,True,"Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.",AIMed.d185.s1569
3833,AIMed.d185,False,"Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.",AIMed.d185.s1569
3834,AIMed.d185,False,"To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.",AIMed.d185.s1571
3835,AIMed.d185,False,"To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.",AIMed.d185.s1571
3836,AIMed.d185,False,"To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.",AIMed.d185.s1571
3837,AIMed.d185,False,"To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.",AIMed.d185.s1571
3838,AIMed.d185,False,"To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.",AIMed.d185.s1571
3839,AIMed.d185,False,"To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.",AIMed.d185.s1571
3840,AIMed.d185,False,"In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.",AIMed.d185.s1572
3841,AIMed.d185,True,"In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.",AIMed.d185.s1572
3842,AIMed.d185,True,"In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.",AIMed.d185.s1572
3843,AIMed.d185,False,IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.,AIMed.d185.s1573
3844,AIMed.d185,False,IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.,AIMed.d185.s1573
3845,AIMed.d185,False,IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.,AIMed.d185.s1573
3846,AIMed.d185,True,IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.,AIMed.d185.s1573
3847,AIMed.d185,False,IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.,AIMed.d185.s1573
3848,AIMed.d185,False,IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.,AIMed.d185.s1573
3849,AIMed.d185,False,"Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.",AIMed.d185.s1574
3850,AIMed.d185,False,"Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.",AIMed.d185.s1574
3851,AIMed.d185,True,"Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.",AIMed.d185.s1574
3852,AIMed.d185,False,"Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.",AIMed.d185.s1574
3853,AIMed.d185,False,"Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.",AIMed.d185.s1574
3854,AIMed.d185,False,"Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.",AIMed.d185.s1574
3855,AIMed.d185,False,Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.,AIMed.d185.s1575
3856,AIMed.d185,False,Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.,AIMed.d185.s1575
3857,AIMed.d185,False,Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.,AIMed.d185.s1575
3858,AIMed.d185,False,Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.,AIMed.d185.s1575
3859,AIMed.d185,False,Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.,AIMed.d185.s1575
3860,AIMed.d185,False,Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.,AIMed.d185.s1575
3861,AIMed.d185,False,"In contrast, tyrosine-phosphorylated peptides containing Tyr374 or Tyr396 did not interact with Stat3 or block Stat3 activation.",AIMed.d185.s1576
3862,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3863,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3864,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3865,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3866,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3867,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3868,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3869,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3870,AIMed.d185,False,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3871,AIMed.d185,True,These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.,AIMed.d185.s1577
3872,AIMed.d187,True,Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation.,AIMed.d187.s1585
3873,AIMed.d187,False,Aggregated amyloid beta-protein (A beta) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.,AIMed.d187.s1586
3874,AIMed.d187,False,The analysis of complexes of A beta with CSF proteins in a KBr gradient revealed an association of A beta only with free proteins and not with lipoprotein particles.,AIMed.d187.s1588
3875,AIMed.d187,False,"Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.",AIMed.d187.s1589
3876,AIMed.d187,False,"Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.",AIMed.d187.s1589
3877,AIMed.d187,True,"Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.",AIMed.d187.s1589
3878,AIMed.d187,False,"Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.",AIMed.d187.s1589
3879,AIMed.d187,False,"Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.",AIMed.d187.s1589
3880,AIMed.d187,True,"Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.",AIMed.d187.s1589
3881,AIMed.d187,False,"In physiological buffers and CSF, TTR exclusively decreased the level of A beta pentamers.",AIMed.d187.s1590
3882,AIMed.d187,True,Endogenous TTR-A beta complexes were detected in human CSF by immunoprecipitation.,AIMed.d187.s1591
3883,AIMed.d187,True,"Using site-directed mutagenesis and computer-assisted modelling, we identified amino acid residues on the surface of the TTR monomer that interact with A beta.",AIMed.d187.s1592
3884,AIMed.d187,False,We propose that A beta binding proteins play a key role in the modulation of A beta aggregation and normally prevent amyloid formation in biological fluids and in the brain.,AIMed.d187.s1594
3885,AIMed.d190,True,Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.,AIMed.d190.s1610
3886,AIMed.d190,False,Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.,AIMed.d190.s1610
3887,AIMed.d190,False,Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.,AIMed.d190.s1610
3888,AIMed.d190,False,Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.,AIMed.d190.s1610
3889,AIMed.d190,False,Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.,AIMed.d190.s1610
3890,AIMed.d190,False,Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.,AIMed.d190.s1610
3891,AIMed.d190,False,Hemopoietic cell proliferation is mediated by non-tyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the Grb2/c-Cbl.,AIMed.d190.s1611
3892,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3893,AIMed.d190,True,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3894,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3895,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3896,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3897,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3898,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3899,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3900,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3901,AIMed.d190,False,In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.,AIMed.d190.s1612
3902,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3903,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3904,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3905,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3906,AIMed.d190,True,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3907,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3908,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3909,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3910,AIMed.d190,True,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3911,AIMed.d190,False,"By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.",AIMed.d190.s1613
3912,AIMed.d190,True,In these cells the adaptor protein Grb2 constitutively binds a substantial fraction of c-Cbl through the N-terminal SH3 domain.,AIMed.d190.s1614
3913,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3914,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3915,AIMed.d190,True,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3916,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3917,AIMed.d190,True,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3918,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3919,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3920,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3921,AIMed.d190,True,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3922,AIMed.d190,False,"In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.",AIMed.d190.s1615
3923,AIMed.d190,False,By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2.,AIMed.d190.s1616
3924,AIMed.d190,False,By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2.,AIMed.d190.s1616
3925,AIMed.d190,True,By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2.,AIMed.d190.s1616
3926,AIMed.d190,False,In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl.,AIMed.d190.s1617
3927,AIMed.d190,True,In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl.,AIMed.d190.s1617
3928,AIMed.d190,False,In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl.,AIMed.d190.s1617
3929,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3930,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3931,AIMed.d190,True,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3932,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3933,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3934,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3935,AIMed.d190,True,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3936,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3937,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3938,AIMed.d190,False,"Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.",AIMed.d190.s1618
3939,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3940,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3941,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3942,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3943,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3944,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3945,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3946,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3947,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3948,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3949,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3950,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3951,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3952,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3953,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3954,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3955,AIMed.d190,True,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3956,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3957,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3958,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3959,AIMed.d190,False,By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.,AIMed.d190.s1619
3960,AIMed.d190,False,Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.,AIMed.d190.s1620
3961,AIMed.d190,True,Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.,AIMed.d190.s1620
3962,AIMed.d190,False,Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.,AIMed.d190.s1620
3963,AIMed.d192,False,Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.,AIMed.d192.s1635
3964,AIMed.d192,True,Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.,AIMed.d192.s1635
3965,AIMed.d192,False,Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.,AIMed.d192.s1635
3966,AIMed.d192,False,Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.,AIMed.d192.s1635
3967,AIMed.d192,False,Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.,AIMed.d192.s1635
3968,AIMed.d192,False,Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.,AIMed.d192.s1635
3969,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3970,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3971,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3972,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3973,AIMed.d192,True,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3974,AIMed.d192,True,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3975,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3976,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3977,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3978,AIMed.d192,False,The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.,AIMed.d192.s1636
3979,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3980,AIMed.d192,True,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3981,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3982,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3983,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3984,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3985,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3986,AIMed.d192,True,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3987,AIMed.d192,True,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3988,AIMed.d192,False,"ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.",AIMed.d192.s1637
3989,AIMed.d192,False,Lipopolysaccharide-activated ICE-deficient (ICE-/-) Kupffer cells synthesized the IGIF precursor but failed to process it into the active form.,AIMed.d192.s1638
3990,AIMed.d192,False,Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.,AIMed.d192.s1639
3991,AIMed.d192,False,Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.,AIMed.d192.s1639
3992,AIMed.d192,False,Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.,AIMed.d192.s1639
3993,AIMed.d193,True,Physical and functional interactions between the transcriptional inhibitors Id3 and ITF-2b. Evidence toward a novel mechanism regulating muscle-specific gene expression.,AIMed.d193.s1641
3994,AIMed.d193,False,"We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.",AIMed.d193.s1642
3995,AIMed.d193,False,"We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.",AIMed.d193.s1642
3996,AIMed.d193,False,"We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.",AIMed.d193.s1642
3997,AIMed.d193,True,"We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.",AIMed.d193.s1642
3998,AIMed.d193,True,"We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.",AIMed.d193.s1642
3999,AIMed.d193,False,"We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.",AIMed.d193.s1642
4000,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4001,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4002,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4003,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4004,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4005,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4006,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4007,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4008,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4009,AIMed.d193,False,"As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.",AIMed.d193.s1644
4010,AIMed.d193,False,"Moreover, while ITF-2b inhibited the creatine kinase promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site.",AIMed.d193.s1646
4011,AIMed.d193,False,"Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.",AIMed.d193.s1647
4012,AIMed.d193,False,"Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.",AIMed.d193.s1647
4013,AIMed.d193,False,"Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.",AIMed.d193.s1647
4014,AIMed.d193,True,"Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.",AIMed.d193.s1647
4015,AIMed.d193,False,"Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.",AIMed.d193.s1647
4016,AIMed.d193,False,"Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.",AIMed.d193.s1647
4017,AIMed.d193,False,"Additional analysis revealed the presence of transcripts for both the activating (ITF-2a) and inhibitory (ITF-2b) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process.",AIMed.d193.s1648
4018,AIMed.d195,True,Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.,AIMed.d195.s1660
4019,AIMed.d195,True,Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.,AIMed.d195.s1660
4020,AIMed.d195,False,Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.,AIMed.d195.s1660
4021,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4022,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4023,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4024,AIMed.d195,True,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4025,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4026,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4027,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4028,AIMed.d195,True,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4029,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4030,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4031,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4032,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4033,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4034,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4035,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4036,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4037,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4038,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4039,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4040,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4041,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4042,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4043,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4044,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4045,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4046,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4047,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4048,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4049,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4050,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4051,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4052,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4053,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4054,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4055,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4056,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4057,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4058,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4059,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4060,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4061,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4062,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4063,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4064,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4065,AIMed.d195,False,"The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.",AIMed.d195.s1662
4066,AIMed.d195,False,"Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin.",AIMed.d195.s1663
4067,AIMed.d195,False,"Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin.",AIMed.d195.s1663
4068,AIMed.d195,False,"Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin.",AIMed.d195.s1663
4069,AIMed.d196,True,HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.,AIMed.d196.s1665
4070,AIMed.d196,False,HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.,AIMed.d196.s1665
4071,AIMed.d196,True,HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.,AIMed.d196.s1665
4072,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4073,AIMed.d196,True,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4074,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4075,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4076,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4077,AIMed.d196,True,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4078,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4079,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4080,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4081,AIMed.d196,True,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4082,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4083,AIMed.d196,True,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4084,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4085,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4086,AIMed.d196,False,"We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.",AIMed.d196.s1669
4087,AIMed.d196,True,"Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.",AIMed.d196.s1673
4088,AIMed.d196,True,"Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.",AIMed.d196.s1673
4089,AIMed.d196,False,"Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.",AIMed.d196.s1673
4090,AIMed.d197,False,Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.,AIMed.d197.s1675
4091,AIMed.d197,True,Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.,AIMed.d197.s1675
4092,AIMed.d197,False,Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.,AIMed.d197.s1675
4093,AIMed.d197,True,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4094,AIMed.d197,True,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4095,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4096,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4097,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4098,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4099,AIMed.d197,True,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4100,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4101,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4102,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4103,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4104,AIMed.d197,True,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4105,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4106,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4107,AIMed.d197,False,The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.,AIMed.d197.s1676
4108,AIMed.d197,True,We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.,AIMed.d197.s1678
4109,AIMed.d197,True,We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.,AIMed.d197.s1678
4110,AIMed.d197,False,We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.,AIMed.d197.s1678
4111,AIMed.d197,True,"Following this hypothesis, we altered in hIL-6 and hIL-6R residues predicted to reside in the contact region and to interact with each other.",AIMed.d197.s1681
4112,AIMed.d197,True,We studied the capacity of these mutants to form an IL-6/IL-6R complex and their ability to transduce the signal.,AIMed.d197.s1682
4113,AIMed.d198,False,Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships.,AIMed.d198.s1686
4114,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4115,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4116,AIMed.d198,True,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4117,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4118,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4119,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4120,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4121,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4122,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4123,AIMed.d198,False,Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.,AIMed.d198.s1687
4124,AIMed.d198,False,"We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.",AIMed.d198.s1688
4125,AIMed.d198,True,"We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.",AIMed.d198.s1688
4126,AIMed.d198,False,"We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.",AIMed.d198.s1688
4127,AIMed.d198,False,"We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.",AIMed.d198.s1688
4128,AIMed.d198,False,"We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.",AIMed.d198.s1688
4129,AIMed.d198,False,"We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.",AIMed.d198.s1688
4130,AIMed.d198,False,Site-specific mutants were expressed in Escherichia coli as soluble EBP and analyzed for EPO binding in several different assay formats.,AIMed.d198.s1690
4131,AIMed.d198,False,"In addition, selected mutant proteins were expressed as full-length EPOR on the surface of COS cells and analyzed for 125I-EPO binding in receptor binding assays.",AIMed.d198.s1691
4132,AIMed.d198,False,"Using these methods, we have identified residues that appear to be involved in EPO binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the EPOR.",AIMed.d198.s1692
4133,AIMed.d199,False,"Stimulation of fibroblast growth factor receptor 3 (FGFR3) results in a variety of functional effects, including regulation of epithelial cell growth and differentiation.",AIMed.d199.s1695
4134,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4135,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4136,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4137,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4138,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4139,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4140,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4141,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4142,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4143,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4144,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4145,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4146,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4147,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4148,AIMed.d199,False,"In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.",AIMed.d199.s1696
4149,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4150,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4151,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4152,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4153,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4154,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4155,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4156,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4157,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4158,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4159,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4160,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4161,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4162,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4163,AIMed.d199,False,"Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.",AIMed.d199.s1697
4164,AIMed.d199,False,Activation of FGFR3 upon ligand binding resulted in activation of mitogen-activated protein kinase pathway.,AIMed.d199.s1698
4165,AIMed.d199,False,FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras.,AIMed.d199.s1699
4166,AIMed.d199,False,FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras.,AIMed.d199.s1699
4167,AIMed.d199,False,FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras.,AIMed.d199.s1699
4168,AIMed.d199,True,Activated FGFR3 predominantly interacts with GRB2.,AIMed.d199.s1700
4169,AIMed.d199,False,Sos in complex with a previously identified 90-kDa protein and designated protein 80K-H.,AIMed.d199.s1701
4170,AIMed.d199,False,"Tyrosine phophorylation of the 66-kDa protein was dependent on ligand activation of FGFR3, suggesting that the 66-kDa protein may play an important role in FGFR3-specific signaling.",AIMed.d199.s1705
4171,AIMed.d199,False,"In addition to this unique pathway, FGFR3 also links to GRB2.",AIMed.d199.s1706
4172,AIMed.d199,False,Sos complex via the adapter protein Shc.,AIMed.d199.s1707
4173,AIMed.d199,False,"Furthermore, activated FGFR3 was not able to induce dissociation of GRB2.",AIMed.d199.s1708
4174,AIMed.d199,False,Sos complex following Sos phosphorylation.,AIMed.d199.s1709
4175,AIMed.d199,False,"In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc.",AIMed.d199.s1710
4176,AIMed.d199,False,"In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc.",AIMed.d199.s1710
4177,AIMed.d199,False,"In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc.",AIMed.d199.s1710
4178,AIMed.d199,True,Sos and 80K-H.pp66.,AIMed.d199.s1712
4179,AIMed.d199,False,Sos and 80K-H.pp66.,AIMed.d199.s1712
4180,AIMed.d199,False,Sos and 80K-H.pp66.,AIMed.d199.s1712
4181,AIMed.d199,False,Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase.,AIMed.d199.s1714
4182,AIMed.d199,False,Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase.,AIMed.d199.s1714
4183,AIMed.d199,False,Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase.,AIMed.d199.s1714
4184,AIMed.d199,False,"Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.",AIMed.d199.s1715
4185,AIMed.d199,False,"Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.",AIMed.d199.s1715
4186,AIMed.d199,False,"Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.",AIMed.d199.s1715
4187,AIMed.d202,False,Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.,AIMed.d202.s1737
4188,AIMed.d202,False,Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.,AIMed.d202.s1737
4189,AIMed.d202,True,Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.,AIMed.d202.s1737
4190,AIMed.d202,False,Interleukin-1 (IL-1) is an important mediator of inflammatory disease.,AIMed.d202.s1738
4191,AIMed.d202,False,"The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.",AIMed.d202.s1739
4192,AIMed.d202,False,"The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.",AIMed.d202.s1739
4193,AIMed.d202,False,"The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.",AIMed.d202.s1739
4194,AIMed.d202,False,"The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.",AIMed.d202.s1739
4195,AIMed.d202,False,"The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.",AIMed.d202.s1739
4196,AIMed.d202,False,"The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.",AIMed.d202.s1739
4197,AIMed.d202,False,Each of these molecules binds to the type I IL-1 receptor (IL1R).,AIMed.d202.s1740
4198,AIMed.d202,False,Each of these molecules binds to the type I IL-1 receptor (IL1R).,AIMed.d202.s1740
4199,AIMed.d202,False,Each of these molecules binds to the type I IL-1 receptor (IL1R).,AIMed.d202.s1740
4200,AIMed.d202,True,The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.,AIMed.d202.s1741
4201,AIMed.d202,False,The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.,AIMed.d202.s1741
4202,AIMed.d202,False,The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.,AIMed.d202.s1741
4203,AIMed.d202,True,The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.,AIMed.d202.s1741
4204,AIMed.d202,False,The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.,AIMed.d202.s1741
4205,AIMed.d202,False,The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.,AIMed.d202.s1741
4206,AIMed.d202,True,Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 A resolution.,AIMed.d202.s1742
4207,AIMed.d202,False,Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 A resolution.,AIMed.d202.s1742
4208,AIMed.d202,True,Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 A resolution.,AIMed.d202.s1742
4209,AIMed.d202,True,IL-1beta binds to s-IL1R with a 1:1 stoichiometry.,AIMed.d202.s1743
4210,AIMed.d202,True,The crystal structure shows that s-IL1R consists of three immunoglobulin-like domains which wrap around IL-1beta in a manner distinct from the structures of previously described cytokine-receptor complexes.,AIMed.d202.s1744
4211,AIMed.d204,False,"The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).",AIMed.d204.s1756
4212,AIMed.d204,True,"The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).",AIMed.d204.s1756
4213,AIMed.d204,True,"The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).",AIMed.d204.s1756
4214,AIMed.d204,False,"The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).",AIMed.d204.s1756
4215,AIMed.d204,False,"The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).",AIMed.d204.s1756
4216,AIMed.d204,False,"The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1).",AIMed.d204.s1756
4217,AIMed.d204,False,"Here, we describe the production of recombinant human tissue inhibitor of metalloproteinases-1 (rTIMP-1) and wild-type and mutant human collagenase type I (rMMP-1) proteins in SF9 cells by the baculovirus expression system.",AIMed.d204.s1757
4218,AIMed.d204,False,"Here, we describe the production of recombinant human tissue inhibitor of metalloproteinases-1 (rTIMP-1) and wild-type and mutant human collagenase type I (rMMP-1) proteins in SF9 cells by the baculovirus expression system.",AIMed.d204.s1757
4219,AIMed.d204,False,"Here, we describe the production of recombinant human tissue inhibitor of metalloproteinases-1 (rTIMP-1) and wild-type and mutant human collagenase type I (rMMP-1) proteins in SF9 cells by the baculovirus expression system.",AIMed.d204.s1757
4220,AIMed.d204,False,"Here, we describe the production of recombinant human tissue inhibitor of metalloproteinases-1 (rTIMP-1) and wild-type and mutant human collagenase type I (rMMP-1) proteins in SF9 cells by the baculovirus expression system.",AIMed.d204.s1757
4221,AIMed.d204,False,"Here, we describe the production of recombinant human tissue inhibitor of metalloproteinases-1 (rTIMP-1) and wild-type and mutant human collagenase type I (rMMP-1) proteins in SF9 cells by the baculovirus expression system.",AIMed.d204.s1757
4222,AIMed.d204,False,"Here, we describe the production of recombinant human tissue inhibitor of metalloproteinases-1 (rTIMP-1) and wild-type and mutant human collagenase type I (rMMP-1) proteins in SF9 cells by the baculovirus expression system.",AIMed.d204.s1757
4223,AIMed.d204,False,"Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.",AIMed.d204.s1758
4224,AIMed.d204,False,"Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.",AIMed.d204.s1758
4225,AIMed.d204,False,"Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.",AIMed.d204.s1758
4226,AIMed.d204,False,"Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.",AIMed.d204.s1758
4227,AIMed.d204,False,"Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.",AIMed.d204.s1758
4228,AIMed.d204,False,"Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.",AIMed.d204.s1758
4229,AIMed.d204,False,"Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.",AIMed.d204.s1760
4230,AIMed.d204,False,"Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.",AIMed.d204.s1760
4231,AIMed.d204,False,"Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.",AIMed.d204.s1760
4232,AIMed.d204,False,"Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.",AIMed.d204.s1760
4233,AIMed.d204,False,"Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.",AIMed.d204.s1760
4234,AIMed.d204,False,"Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.",AIMed.d204.s1760
4235,AIMed.d204,False,"In addition to co-immunoprecipitation analysis, we have established a rapid and sensitive ELISA assay using immobilized rTIMP to determine the structural requirements of MMP-1 to form complexes with its inhibitor.",AIMed.d204.s1761
4236,AIMed.d204,True,Only the activated and not the latent forms of wild-type and C-terminal mutant des-(248-450)-MMP-1 proteins are able to form complexes with TIMP.,AIMed.d204.s1762
4237,AIMed.d204,False,"Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-MMP-1, interact with TIMP.",AIMed.d204.s1763
4238,AIMed.d204,False,"Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-MMP-1, interact with TIMP.",AIMed.d204.s1763
4239,AIMed.d204,False,"Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-MMP-1, interact with TIMP.",AIMed.d204.s1763
4240,AIMed.d204,False,"This demonstrates that the C-terminal hemopexin domain of MMP-1, in contrast to the corresponding regions of gelatinase A and gelatinase B, does not interact with TIMP-1.",AIMed.d204.s1764
4241,AIMed.d204,False,"This demonstrates that the C-terminal hemopexin domain of MMP-1, in contrast to the corresponding regions of gelatinase A and gelatinase B, does not interact with TIMP-1.",AIMed.d204.s1764
4242,AIMed.d204,False,"This demonstrates that the C-terminal hemopexin domain of MMP-1, in contrast to the corresponding regions of gelatinase A and gelatinase B, does not interact with TIMP-1.",AIMed.d204.s1764
4243,AIMed.d204,True,"This demonstrates that the C-terminal hemopexin domain of MMP-1, in contrast to the corresponding regions of gelatinase A and gelatinase B, does not interact with TIMP-1.",AIMed.d204.s1764
4244,AIMed.d204,False,"This demonstrates that the C-terminal hemopexin domain of MMP-1, in contrast to the corresponding regions of gelatinase A and gelatinase B, does not interact with TIMP-1.",AIMed.d204.s1764
4245,AIMed.d204,True,"This demonstrates that the C-terminal hemopexin domain of MMP-1, in contrast to the corresponding regions of gelatinase A and gelatinase B, does not interact with TIMP-1.",AIMed.d204.s1764
4246,AIMed.d204,False,"In summary, we have shown that the integrity of the catalytic domain of MMP-1 and its ability to bind Zn2+ is absolutely required for complex formation with TIMP-1, which further underlines the importance of this region for proper regulation of enzymatic activity of MMP-1.",AIMed.d204.s1765
4247,AIMed.d204,True,"In summary, we have shown that the integrity of the catalytic domain of MMP-1 and its ability to bind Zn2+ is absolutely required for complex formation with TIMP-1, which further underlines the importance of this region for proper regulation of enzymatic activity of MMP-1.",AIMed.d204.s1765
4248,AIMed.d204,False,"In summary, we have shown that the integrity of the catalytic domain of MMP-1 and its ability to bind Zn2+ is absolutely required for complex formation with TIMP-1, which further underlines the importance of this region for proper regulation of enzymatic activity of MMP-1.",AIMed.d204.s1765
4249,AIMed.d205,False,Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5.,AIMed.d205.s1766
4250,AIMed.d205,True,Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5.,AIMed.d205.s1766
4251,AIMed.d205,True,Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5.,AIMed.d205.s1766
4252,AIMed.d205,False,Antibody-mediated cross-linking studies or studies on CD5 knockout mice implicate CD5 as a co-stimulatory or negative regulatory molecule.,AIMed.d205.s1768
4253,AIMed.d205,False,Y429 and Y441 occur in an imperfect immunoreceptor tyrosine-based activation motif (ITAM)-like sequence.,AIMed.d205.s1770
4254,AIMed.d205,False,"We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated ITAM, interacts with CD5 following T cell activation.",AIMed.d205.s1771
4255,AIMed.d205,True,"We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated ITAM, interacts with CD5 following T cell activation.",AIMed.d205.s1771
4256,AIMed.d205,False,"We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated ITAM, interacts with CD5 following T cell activation.",AIMed.d205.s1771
4257,AIMed.d205,False,"PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.",AIMed.d205.s1772
4258,AIMed.d205,False,"PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.",AIMed.d205.s1772
4259,AIMed.d205,False,"PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.",AIMed.d205.s1772
4260,AIMed.d205,False,"PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.",AIMed.d205.s1772
4261,AIMed.d205,False,"PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.",AIMed.d205.s1772
4262,AIMed.d205,True,"PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.",AIMed.d205.s1772
4263,AIMed.d205,False,Cellular p85 as well as the recombinant Src homology 2 (SH2) domains of p85 bound a tyrosine-phosphorylated peptide encompassing Y463 with approximately threefold greater affinity than a doubly tyrosine-phosphorylated Y429-Y441 peptide.,AIMed.d205.s1773
4264,AIMed.d205,False,A 120-kDa phosphoprotein (pp120) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.,AIMed.d205.s1775
4265,AIMed.d205,True,A 120-kDa phosphoprotein (pp120) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.,AIMed.d205.s1775
4266,AIMed.d205,True,A 120-kDa phosphoprotein (pp120) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.,AIMed.d205.s1775
4267,AIMed.d205,False,We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and pp120 to CD5.,AIMed.d205.s1776
4268,AIMed.d205,True,We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and pp120 to CD5.,AIMed.d205.s1776
4269,AIMed.d205,True,We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and pp120 to CD5.,AIMed.d205.s1776
4270,AIMed.d206,False,"As CD9 forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour, we investigated CD9 expression and function in human epidermal keratinocytes.",AIMed.d206.s1779
4271,AIMed.d206,False,"There was extensive co-localisation of CD9 and beta 1 integrins on microvilli and at cell-cell borders of basal keratinocytes; however, in contrast to the integrins, CD9 was not found in focal adhesions.",AIMed.d206.s1781
4272,AIMed.d206,False,"CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan, but not of cadherins.",AIMed.d206.s1782
4273,AIMed.d206,False,"CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan, but not of cadherins.",AIMed.d206.s1782
4274,AIMed.d206,False,"CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan, but not of cadherins.",AIMed.d206.s1782
4275,AIMed.d206,False,CD9 was associated with alpha 3 beta 1 but not alpha 5 beta 1; small amounts of CD9 also co-immunoprecipitated with antibodies to alpha 2 beta 1 and alpha 6 beta 4.,AIMed.d206.s1783
4276,AIMed.d206,False,"Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.",AIMed.d206.s1784
4277,AIMed.d206,False,"Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.",AIMed.d206.s1784
4278,AIMed.d206,False,"Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.",AIMed.d206.s1784
4279,AIMed.d206,False,"Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.",AIMed.d206.s1784
4280,AIMed.d206,False,"Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.",AIMed.d206.s1784
4281,AIMed.d206,False,"Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.",AIMed.d206.s1784
4282,AIMed.d206,False,"Like antibodies to the beta 1 integrin subunit, anti-CD9 inhibited suspension-induced terminal differentiation.",AIMed.d206.s1785
4283,AIMed.d207,False,MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.,AIMed.d207.s1787
4284,AIMed.d207,False,MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.,AIMed.d207.s1787
4285,AIMed.d207,False,MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.,AIMed.d207.s1787
4286,AIMed.d207,True,MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.,AIMed.d207.s1787
4287,AIMed.d207,False,MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.,AIMed.d207.s1787
4288,AIMed.d207,False,MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.,AIMed.d207.s1787
4289,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4290,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4291,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4292,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4293,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4294,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4295,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4296,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4297,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4298,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4299,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4300,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4301,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4302,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4303,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4304,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4305,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4306,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4307,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4308,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4309,AIMed.d207,False,"Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.",AIMed.d207.s1788
4310,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4311,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4312,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4313,AIMed.d207,True,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4314,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4315,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4316,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4317,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4318,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4319,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4320,AIMed.d207,True,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4321,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4322,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4323,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4324,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4325,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4326,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4327,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4328,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4329,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4330,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4331,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4332,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4333,AIMed.d207,True,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4334,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4335,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4336,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4337,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4338,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4339,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4340,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4341,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4342,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4343,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4344,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4345,AIMed.d207,False,"An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).",AIMed.d207.s1791
4346,AIMed.d207,False,"In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.",AIMed.d207.s1793
4347,AIMed.d207,False,"In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.",AIMed.d207.s1793
4348,AIMed.d207,False,"In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.",AIMed.d207.s1793
4349,AIMed.d207,False,"In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.",AIMed.d207.s1793
4350,AIMed.d207,False,"In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.",AIMed.d207.s1793
4351,AIMed.d207,False,"In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.",AIMed.d207.s1793
4352,AIMed.d207,True,"Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.",AIMed.d207.s1794
4353,AIMed.d207,False,"Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.",AIMed.d207.s1794
4354,AIMed.d207,True,"Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.",AIMed.d207.s1794
4355,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4356,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4357,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4358,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4359,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4360,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4361,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4362,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4363,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4364,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4365,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4366,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4367,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4368,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4369,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4370,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4371,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4372,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4373,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4374,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4375,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4376,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4377,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4378,AIMed.d207,True,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4379,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4380,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4381,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4382,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4383,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4384,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4385,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4386,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4387,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4388,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4389,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4390,AIMed.d207,False,"Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.",AIMed.d207.s1795
4391,AIMed.d207,False,"Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.",AIMed.d207.s1796
4392,AIMed.d207,False,"Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.",AIMed.d207.s1796
4393,AIMed.d207,False,"Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.",AIMed.d207.s1796
4394,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4395,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4396,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4397,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4398,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4399,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4400,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4401,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4402,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4403,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4404,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4405,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4406,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4407,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4408,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4409,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4410,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4411,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4412,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4413,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4414,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4415,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4416,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4417,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4418,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4419,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4420,AIMed.d208,False,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4421,AIMed.d208,True,"The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.",AIMed.d208.s1803
4422,AIMed.d209,True,Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.,AIMed.d209.s1806
4423,AIMed.d209,False,Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.,AIMed.d209.s1806
4424,AIMed.d209,False,Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.,AIMed.d209.s1806
4425,AIMed.d209,True,We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.,AIMed.d209.s1807
4426,AIMed.d209,False,We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.,AIMed.d209.s1807
4427,AIMed.d209,False,We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.,AIMed.d209.s1807
4428,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4429,AIMed.d209,True,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4430,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4431,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4432,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4433,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4434,AIMed.d209,True,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4435,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4436,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4437,AIMed.d209,False,"RIN1 interacts with the ""effector domain"" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.",AIMed.d209.s1808
4438,AIMed.d209,False,"The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.",AIMed.d209.s1809
4439,AIMed.d209,False,"The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.",AIMed.d209.s1809
4440,AIMed.d209,False,"The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.",AIMed.d209.s1809
4441,AIMed.d209,False,"The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.",AIMed.d209.s1809
4442,AIMed.d209,True,"The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.",AIMed.d209.s1809
4443,AIMed.d209,False,"The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.",AIMed.d209.s1809
4444,AIMed.d209,True,"When expressed in mammalian cells, the RAS binding domain of RIN1 can act as a dominant negative signal transduction blocker.",AIMed.d209.s1810
4445,AIMed.d209,True,This RIN1 sequence shows preferential binding to the ABL-SH3 domain in vitro.,AIMed.d209.s1812
4446,AIMed.d209,True,"Moreover, the amino-terminal domain of RIN1 directly associates with, and is tyrosine phosphorylated by, c-ABL.",AIMed.d209.s1813
4447,AIMed.d211,False,"Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.",AIMed.d211.s1829
4448,AIMed.d211,False,"Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.",AIMed.d211.s1829
4449,AIMed.d211,False,"Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.",AIMed.d211.s1829
4450,AIMed.d211,False,The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta).,AIMed.d211.s1831
4451,AIMed.d211,False,The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta).,AIMed.d211.s1831
4452,AIMed.d211,False,The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta).,AIMed.d211.s1831
4453,AIMed.d211,False,"Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.",AIMed.d211.s1833
4454,AIMed.d211,False,"Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.",AIMed.d211.s1833
4455,AIMed.d211,True,"Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.",AIMed.d211.s1833
4456,AIMed.d211,False,"Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.",AIMed.d211.s1833
4457,AIMed.d211,True,"Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.",AIMed.d211.s1833
4458,AIMed.d211,True,"Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.",AIMed.d211.s1833
4459,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4460,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4461,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4462,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4463,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4464,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4465,AIMed.d211,True,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4466,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4467,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4468,AIMed.d211,True,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4469,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4470,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4471,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4472,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4473,AIMed.d211,False,"However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.",AIMed.d211.s1834
4474,AIMed.d213,False,"In addition, previous work indicated that p300 and CBP might be involved in YY1-mediated repression.",AIMed.d213.s1846
4475,AIMed.d213,False,"In addition, previous work indicated that p300 and CBP might be involved in YY1-mediated repression.",AIMed.d213.s1846
4476,AIMed.d213,False,"In addition, previous work indicated that p300 and CBP might be involved in YY1-mediated repression.",AIMed.d213.s1846
4477,AIMed.d213,False,"We show that the physical interaction between YY1 and p300, a coactivator for CREB, is not sufficient for repression of CREB-mediated transcription.",AIMed.d213.s1851
4478,AIMed.d213,False,"We show that the physical interaction between YY1 and p300, a coactivator for CREB, is not sufficient for repression of CREB-mediated transcription.",AIMed.d213.s1851
4479,AIMed.d213,True,"We show that the physical interaction between YY1 and p300, a coactivator for CREB, is not sufficient for repression of CREB-mediated transcription.",AIMed.d213.s1851
4480,AIMed.d213,False,"We show that the physical interaction between YY1 and p300, a coactivator for CREB, is not sufficient for repression of CREB-mediated transcription.",AIMed.d213.s1851
4481,AIMed.d213,False,"We show that the physical interaction between YY1 and p300, a coactivator for CREB, is not sufficient for repression of CREB-mediated transcription.",AIMed.d213.s1851
4482,AIMed.d213,True,"We show that the physical interaction between YY1 and p300, a coactivator for CREB, is not sufficient for repression of CREB-mediated transcription.",AIMed.d213.s1851
4483,AIMed.d213,False,Repression of CTF-1-directed transcription may be accomplished through direct physical interaction between YY1 and this activator.,AIMed.d213.s1853
4484,AIMed.d213,False,"In contrast, physical interaction is not necessary for YY1 to repress Sp1- and CREB-mediated transcription.",AIMed.d213.s1854
4485,AIMed.d213,False,"In contrast, physical interaction is not necessary for YY1 to repress Sp1- and CREB-mediated transcription.",AIMed.d213.s1854
4486,AIMed.d213,False,"In contrast, physical interaction is not necessary for YY1 to repress Sp1- and CREB-mediated transcription.",AIMed.d213.s1854
4487,AIMed.d214,True,Proto-oncoprotein Vav interacts with c-Cbl in activated thymocytes and peripheral T cells.,AIMed.d214.s1857
4488,AIMed.d214,True,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4489,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4490,AIMed.d214,True,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4491,AIMed.d214,True,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4492,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4493,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4494,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4495,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4496,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4497,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4498,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4499,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4500,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4501,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4502,AIMed.d214,False,"The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.",AIMed.d214.s1858
4503,AIMed.d214,False,This suggests that c-Cbl may link TCR activation to molecules that regulate GTP binding proteins.,AIMed.d214.s1859
4504,AIMed.d214,False,"The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.",AIMed.d214.s1860
4505,AIMed.d214,False,"The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.",AIMed.d214.s1860
4506,AIMed.d214,False,"The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.",AIMed.d214.s1860
4507,AIMed.d214,False,Here we show that Vav and c-Cbl form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.,AIMed.d214.s1861
4508,AIMed.d214,True,Here we show that Vav and c-Cbl form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.,AIMed.d214.s1861
4509,AIMed.d214,False,Here we show that Vav and c-Cbl form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.,AIMed.d214.s1861
4510,AIMed.d214,True,"Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.",AIMed.d214.s1862
4511,AIMed.d214,False,"Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.",AIMed.d214.s1862
4512,AIMed.d214,False,"Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.",AIMed.d214.s1862
4513,AIMed.d214,False,"Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.",AIMed.d214.s1862
4514,AIMed.d214,False,"Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.",AIMed.d214.s1862
4515,AIMed.d214,False,"Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.",AIMed.d214.s1862
4516,AIMed.d214,False,The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.,AIMed.d214.s1863
4517,AIMed.d214,True,The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.,AIMed.d214.s1863
4518,AIMed.d214,False,The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.,AIMed.d214.s1863
4519,AIMed.d214,False,The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.,AIMed.d214.s1863
4520,AIMed.d214,False,The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.,AIMed.d214.s1863
4521,AIMed.d214,False,The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.,AIMed.d214.s1863
4522,AIMed.d214,True,"In addition, we show that the conserved motif Y699 MTP present in c-Cbl is the binding site for the Vav SH2 domain in vitro.",AIMed.d214.s1864
4523,AIMed.d214,False,These data imply that c-Cbl is a molecular adapter that regulates the function of Vav in thymocytes and peripheral T cells.,AIMed.d214.s1865
4524,AIMed.d215,True,Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.,AIMed.d215.s1866
4525,AIMed.d215,True,Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.,AIMed.d215.s1868
4526,AIMed.d215,True,Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.,AIMed.d215.s1868
4527,AIMed.d215,False,Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.,AIMed.d215.s1868
4528,AIMed.d215,False,Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.,AIMed.d215.s1868
4529,AIMed.d215,True,Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.,AIMed.d215.s1868
4530,AIMed.d215,True,Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.,AIMed.d215.s1868
4531,AIMed.d215,False,"MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.",AIMed.d215.s1869
4532,AIMed.d215,False,"MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.",AIMed.d215.s1869
4533,AIMed.d215,True,"MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.",AIMed.d215.s1869
4534,AIMed.d215,False,"MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.",AIMed.d215.s1869
4535,AIMed.d215,False,"MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.",AIMed.d215.s1869
4536,AIMed.d215,False,"MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.",AIMed.d215.s1869
4537,AIMed.d215,True,Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.,AIMed.d215.s1871
4538,AIMed.d215,False,Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.,AIMed.d215.s1871
4539,AIMed.d215,False,Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.,AIMed.d215.s1871
4540,AIMed.d216,False,The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.,AIMed.d216.s1872
4541,AIMed.d216,True,The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.,AIMed.d216.s1872
4542,AIMed.d216,False,The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.,AIMed.d216.s1872
4543,AIMed.d216,False,The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.,AIMed.d216.s1873
4544,AIMed.d216,True,The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.,AIMed.d216.s1873
4545,AIMed.d216,False,The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.,AIMed.d216.s1873
4546,AIMed.d216,True,The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.,AIMed.d216.s1873
4547,AIMed.d216,False,The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.,AIMed.d216.s1873
4548,AIMed.d216,False,The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.,AIMed.d216.s1873
4549,AIMed.d216,False,An arginine side chain (arginine-789) of GAP-334 is supplied into the active site of Ras to neutralize developing charges in the transition state.,AIMed.d216.s1875
4550,AIMed.d216,True,"The switch II region of Ras is stabilized by GAP-334, thus allowing glutamine-61 of Ras, mutation of which activates the oncogenic potential, to participate in catalysis.",AIMed.d216.s1876
4551,AIMed.d216,False,"The switch II region of Ras is stabilized by GAP-334, thus allowing glutamine-61 of Ras, mutation of which activates the oncogenic potential, to participate in catalysis.",AIMed.d216.s1876
4552,AIMed.d216,False,"The switch II region of Ras is stabilized by GAP-334, thus allowing glutamine-61 of Ras, mutation of which activates the oncogenic potential, to participate in catalysis.",AIMed.d216.s1876
4553,AIMed.d216,False,"Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Ras, and even its mutation to alanine would disturb the arrangements of residues in the transition state.",AIMed.d216.s1878
4554,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4555,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4556,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4557,AIMed.d217,True,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4558,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4559,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4560,AIMed.d217,True,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4561,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4562,AIMed.d217,True,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4563,AIMed.d217,False,"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.",AIMed.d217.s1879
4564,AIMed.d217,False,The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).,AIMed.d217.s1880
4565,AIMed.d217,True,The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).,AIMed.d217.s1880
4566,AIMed.d217,True,The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).,AIMed.d217.s1880
4567,AIMed.d217,True,The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).,AIMed.d217.s1880
4568,AIMed.d217,False,The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).,AIMed.d217.s1880
4569,AIMed.d217,False,The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).,AIMed.d217.s1880
4570,AIMed.d217,False,"When human soluble FasL (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each FasL monomer were found to be essential for efficient secretion.",AIMed.d217.s1881
4571,AIMed.d217,False,"Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.",AIMed.d217.s1882
4572,AIMed.d217,False,"Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.",AIMed.d217.s1882
4573,AIMed.d217,True,"Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.",AIMed.d217.s1882
4574,AIMed.d217,True,"Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.",AIMed.d217.s1882
4575,AIMed.d217,False,"Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.",AIMed.d217.s1882
4576,AIMed.d217,False,"Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.",AIMed.d217.s1882
4577,AIMed.d217,False,"Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward Fas-positive cells with a concomitant decrease in the binding affinity for the recombinant Fas-immunoglobulin Fc fusion proteins.",AIMed.d217.s1885
4578,AIMed.d217,True,"Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of FasL interacts with a cluster of three basic amino acid side chains of Fas.",AIMed.d217.s1886
4579,AIMed.d218,False,Thrombopoietin (TPO) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets.,AIMed.d218.s1889
4580,AIMed.d218,True,"We sought to characterize how TPO binds and activates its receptor, myeloproliferative leukemia virus receptor.",AIMed.d218.s1890
4581,AIMed.d218,False,The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.,AIMed.d218.s1891
4582,AIMed.d218,False,The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.,AIMed.d218.s1891
4583,AIMed.d218,False,The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.,AIMed.d218.s1891
4584,AIMed.d218,False,Phage enzyme-linked immunosorbent assay was used to determine affinities for binding to both the TPO receptor and five anti-TPO1-153 monoclonal antibodies.,AIMed.d218.s1893
4585,AIMed.d218,False,"In contrast, the other three monoclonal antibodies, which were effective at blocking TPO activity but did not block initial binding of TPO to its receptor, had epitopes predominantly on helix or 3.",AIMed.d218.s1897
4586,AIMed.d218,False,These results suggest that TPO has two distinct receptor-binding sites that function to dimerize TPO receptors in a sequential fashion.,AIMed.d218.s1898
4587,AIMed.d219,False,14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain.,AIMed.d219.s1899
4588,AIMed.d219,True,14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain.,AIMed.d219.s1899
4589,AIMed.d219,True,14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain.,AIMed.d219.s1899
4590,AIMed.d219,False,"Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.",AIMed.d219.s1900
4591,AIMed.d219,False,"Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.",AIMed.d219.s1900
4592,AIMed.d219,False,"Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.",AIMed.d219.s1900
4593,AIMed.d219,False,"Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.",AIMed.d219.s1900
4594,AIMed.d219,False,"Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.",AIMed.d219.s1900
4595,AIMed.d219,False,"Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.",AIMed.d219.s1900
4596,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4597,AIMed.d219,True,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4598,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4599,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4600,AIMed.d219,True,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4601,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4602,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4603,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4604,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4605,AIMed.d219,False,"We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.",AIMed.d219.s1901
4606,AIMed.d219,False,The Raf-CRD is located in the NH2-terminal negative regulatory domain of Raf-1 and is highly homologous to cysteine-rich domains found in protein kinase C family members.,AIMed.d219.s1902
4607,AIMed.d219,False,Recent studies indicate that the structural integrity of the Raf-CRD is also critical for Raf-1 interaction with 14-3-3 proteins.,AIMed.d219.s1903
4608,AIMed.d219,False,"However, whether 14-3-3 proteins interact directly with the Raf-CRD and how this interaction may mediate Raf-1 function has not been determined.",AIMed.d219.s1904
4609,AIMed.d219,True,"In the present study, we demonstrate that 14-3-3 zeta binds directly to the isolated Raf-CRD.",AIMed.d219.s1905
4610,AIMed.d219,True,"Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not Ras, to the Raf-CRD.",AIMed.d219.s1906
4611,AIMed.d219,True,"Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not Ras, to the Raf-CRD.",AIMed.d219.s1906
4612,AIMed.d219,False,"Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not Ras, to the Raf-CRD.",AIMed.d219.s1906
4613,AIMed.d219,False,"Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.",AIMed.d219.s1908
4614,AIMed.d219,False,"Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.",AIMed.d219.s1908
4615,AIMed.d219,False,"Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.",AIMed.d219.s1908
4616,AIMed.d219,False,"Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.",AIMed.d219.s1908
4617,AIMed.d219,False,"Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.",AIMed.d219.s1908
4618,AIMed.d219,False,"Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.",AIMed.d219.s1908
4619,AIMed.d220,False,Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.,AIMed.d220.s1909
4620,AIMed.d220,False,Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.,AIMed.d220.s1909
4621,AIMed.d220,False,Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.,AIMed.d220.s1909
4622,AIMed.d220,True,Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.,AIMed.d220.s1909
4623,AIMed.d220,False,Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.,AIMed.d220.s1909
4624,AIMed.d220,False,Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.,AIMed.d220.s1909
4625,AIMed.d220,False,"The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).",AIMed.d220.s1910
4626,AIMed.d220,False,"The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).",AIMed.d220.s1910
4627,AIMed.d220,False,"The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).",AIMed.d220.s1910
4628,AIMed.d220,True,"The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).",AIMed.d220.s1910
4629,AIMed.d220,False,"The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).",AIMed.d220.s1910
4630,AIMed.d220,True,"The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).",AIMed.d220.s1910
4631,AIMed.d220,False,Two distinct ligand binding domains of TRKB were isolated from proteolytic digests of the receptor by affinity separation on immobilized BDNF.,AIMed.d220.s1911
4632,AIMed.d220,False,"These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.",AIMed.d220.s1920
4633,AIMed.d220,True,"These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.",AIMed.d220.s1920
4634,AIMed.d220,False,"These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.",AIMed.d220.s1920
4635,AIMed.d222,False,"The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.",AIMed.d222.s1928
4636,AIMed.d222,False,"The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.",AIMed.d222.s1928
4637,AIMed.d222,True,"The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.",AIMed.d222.s1928
4638,AIMed.d222,False,"The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.",AIMed.d222.s1928
4639,AIMed.d222,True,"The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.",AIMed.d222.s1928
4640,AIMed.d222,True,"The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.",AIMed.d222.s1928
4641,AIMed.d222,False,"The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.",AIMed.d222.s1929
4642,AIMed.d222,False,"The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.",AIMed.d222.s1929
4643,AIMed.d222,True,"The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.",AIMed.d222.s1929
4644,AIMed.d222,False,"The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.",AIMed.d222.s1929
4645,AIMed.d222,False,"The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.",AIMed.d222.s1929
4646,AIMed.d222,False,"The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.",AIMed.d222.s1929
4647,AIMed.d222,True,"The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.",AIMed.d222.s1931
4648,AIMed.d222,True,"The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.",AIMed.d222.s1931
4649,AIMed.d222,False,"The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.",AIMed.d222.s1931
4650,AIMed.d224,False,TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.,AIMed.d224.s1945
4651,AIMed.d224,False,TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.,AIMed.d224.s1945
4652,AIMed.d224,False,TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.,AIMed.d224.s1945
4653,AIMed.d224,False,We demonstrate that HLA-E surface expression is correlated with the presence of MHC class I molecules which provide suitable leader sequence peptides capable of binding to HLA-E.,AIMed.d224.s1949
4654,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4655,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4656,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4657,AIMed.d224,True,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4658,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4659,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4660,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4661,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4662,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4663,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4664,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4665,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4666,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4667,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4668,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4669,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4670,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4671,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4672,AIMed.d224,True,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4673,AIMed.d224,True,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4674,AIMed.d224,False,"Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.",AIMed.d224.s1950
4675,AIMed.d224,True,"In addition, HLA-E dissociates from TAP upon binding of MHC class I leader sequence peptides.",AIMed.d224.s1951
4676,AIMed.d224,False,The correlation between HLA-E and MHC class I surface expression might be relevant to the function of HLA-E.,AIMed.d224.s1953
4677,AIMed.d224,False,"Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA-E molecules.",AIMed.d224.s1954
4678,AIMed.d224,False,"Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA-E molecules.",AIMed.d224.s1954
4679,AIMed.d224,False,"Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA-E molecules.",AIMed.d224.s1954
